Control #,Recd Date,From,Subject
2024-2972,2024-04-01,LSU Law School,final response record for FOIA request 2023-10858
2024-2973,2024-04-01,LSU Law School,final response record for FOIA request 2024-2629
2024-2974,2024-04-01,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for ELEVIDYS (branded name / marketed by Sarepta Therapeutics, Inc.) or delandistrogene moxeparvovec-rokl (generic name) between March 20, 2024 and March 26, 2024    This request is similar to FDA FOIA Request Control # 2023-9783 which was recently fulfilled by your office.  Please provide the documents electronically if possible."
2024-2975,2024-04-01,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Syfovre (branded name / marketed by Apellis Pharmaceutical) or pegcetacoplan (generic name) between March 20, 2024 and March 26, 2024.  This request is similar to FDA FOIA Request Control # 2023-9306 which was recently fulfilled by your office.  Please provide the documents electronically if possible. "
2024-2976,2024-04-01,FOIA Professional Services,Drug Product: Diacomit (stiripentol) for suspension  NDA number/Supplement: 207223/S-003 Approved 14 July 2022  Requesting: Summary Basis of Approval  Please provide the documents electronically if possible.
2024-2977,2024-04-01,FOIA Professional Services,Drug Product: Epidiolex (cannabidiol) 100 mg/ml oral solution  NDA number/Supplements:210365/S-005 Approved 31 July 2020 and 210365/S-006 Approved 31 July 2020  Requesting: Summary Basis of Approval  Please provide the documents electronically if possible.
2024-2978,2024-04-01,Altria Client Services LLC,Reviewer notes related to STN: SE0016867.PD1.
2024-2979,2024-04-01,"Pyros Pharmaceuticals, Inc.",FAERS Individual Case Reports Suspect Drugs Vigabatrin Case Number Source: FAERS Public Dashboard Case IDs: 11042831; 11010097; 11007728; 11001791; 10954688; 10926945; 10923020; 10914180; 10892404; 10892370; 10873592; 10868114.
2024-2980,2024-04-01,Nuvama Institutional Equities,"Requesting form 483 issued by the United States Food and Drug Administration (USFDA) on Jubilant Generics Limited's solid dosage formulations facility located at Roorkee, India on February 2, 2024. Jubilant Generics Limited is a subsidiary Jubilant Pharma Limited. "
2024-2981,2024-04-01,Zennova LLC,"CycloSPORINE Ophthalmic Emulsion, 0.05% 1) Summary Basis of Approval for ANDA 207606 - Apotex 2) Summary Basis of Approval for ANDA 205894 "
2024-2982,2024-04-01,"Agarwal, Bhavish ","PLease share the copy of the Form 483 for the inspection conducted by the USFDA  at the SEZ Onco Injectable manufacturing plant at Ahmedabad. This cGMP USFDA inspection was conducted from March 18th to March 27th, 2024. The inspection was related to Human Drugs"
2024-2983,2024-04-01,NDTV Profit," USFDA had conducted an inspection at the Alkem Laboratories manufacturing facility located at Baddi, India from 19th March, 2024 to 27th March, 2024. At the end of the inspection, the Company has received Form 483 with ten (10) observations. we seek those records"
2024-2984,2024-04-01,AltaThera Pharmaceuticals," I would like to obtain the sNDA/NDA submitted by AltaThera Pharmaceuticals, Sotalol Hydrochloride NDA #022306."
2024-2985,2024-04-01,FINANCIAL TIMES,"Form 483 with 10 observations from GMP and pre-approval inspection of Alkem Laboratories Limited's manufacturing facility in Baddi, India, between 19th March, 2024 to 27th March, 2024."
2024-2986,2024-04-01,FINANCIAL TIMES,"Form 483 with 4 observations following inspection of Zydus Lifesciences Limited's SEZ Onco Injectable manufacturing plant at Ahmedabad, India, between March 18 2024 and March 27 2024."
2024-2987,2024-04-01,Abbott Diabetes Care,"We are requesting an Establishment Inspection Report (EIR) for the audit of Abbott Diabetes Care that was conducted in Alameda, California under eNSpect Operation ID: 222429. The audit was conducted from 04/11/2022 to 04/21/2022.  etc"
2024-2988,2024-04-01,PFIZER,"1. REMS Modification Rationale Review associated with REMS modification letter that resulted in supplement 60 for NDA 021752_x000D_
2. REMS Modification Review associated with supplement 60 for NDA 021752"
2024-2989,2024-04-01,Redica Systems,CDER/Human Drugs 483 Request (US-based inspection)
2024-2990,2024-04-01,Redica Systems,CDER/Human Drugs 483 Request (International inspection)
2024-2991,2024-04-01,Epic Pharma LLC,"As the current ANDA holder of ANDA 076615, we would like to request: 1. Copy of initial submission and subsequent amendments of the original ANDA 076615.  2. Copy of initial submission and subsequent amendments (if applicable) of ANDA 076615/Supplement-001.  3. Copy of FDA's Approval Letter for ANDA 076615/Supplement-001. 4. Copy of annual reports for ANDA 076615 submitted between 2004 to 2014."
2024-2992,2024-04-01,Thomson Reuters (Reuters news agency),"I’m writing to request the Form 483 related to the FDA’s inspection in March 2024 of Novo Nordisk’s factory in Kalundborg, Denmark. "
2024-2993,2024-04-01,Nomura,Form 483 issued to Alkem Labs following USFDA inspection at Baddi site between 19-27 Mar 2024.
2024-2994,2024-04-01,HSBC Securities and Capital Markets (India) Private Limited,Please share Form 483 issued to Alkem Labs for Baddi plant after FDA inspection in March 2024
2024-2995,2024-04-01,HSBC Securities and Capital Markets (India) Private Limited,Please share Form 483 issued to Zydus for a plant at Ahmedabad inspected by FDA in March 2024
2024-2996,2024-04-01,Clarivate Analytics (France) SAS,"As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483:  Monarch PCM, LLC 7333 Jack Newell Blvd N Ste 100 Fort Worth, TX 76118-7151 United States End Dates of inspection: 20 Aug 2021 FEI: 3012816585 PRODUCT TYPE: Drugs PROJECT AREA: Drug Quality Assurance Classification: OAI   "
2024-2997,2024-04-01,Lassman Law+Policy,"I am hereby requesting a copy of the most recent Tentative Approval letter issued to the sponsor of Abbreviated New Drug Application (ANDA) 213713 for Rifaximin Tablets, 550 mg. The Tentative Approval letter was issued to Sandoz, Inc. on or about March 8, 2024."
2024-2998,2024-04-01,Lassman Law+Policy,"I am hereby requesting a copy of the Tentative Approval letter issued to the sponsor of Abbreviated New Drug Application (ANDA) 214369 for Rifaximin Tablets, 550 mg. The Tentative Approval letter was issued to Norwich Pharmaceuticals Inc. on or about March 14, 2024."
2024-2999,2024-04-01,Indivior Inc,"Please provide complete NDA package (containing clinical, non-clinical, and CMC sections) of REVEX NDA #020459. "
2024-3000,2024-04-01,Manasa Rayanki,"I am requesting access to records regarding FDA submission K233227, specifically the Substantial Equivalence Record associated with it.  "
2024-3001,2024-04-01,"Agarwal, Bhavish ","Please share the Form 483 for the inspection that the USFDA had conducted  at the Alkem Laboratories manufacturing facility located at Baddi from 19th March 2024 to 27th March 2024. At the end of the inspection, the company has received Form 483 with ten (10) observations. The inspection was related to Human Drugs."
2024-3002,2024-04-01,Encube Ethicals Inc.,Please provide us with a Bioequivelence review document along with approval letter(s) and Summary Basis of Approval for the drug  Estradiol 0.01% vaginal cream (ANDA 209767 Alvogen) 
2024-3003,2024-04-01,Gland Pharma Limited,"LIDOCAINE HYDROCHLORIDE TOPICAL SOLUTION USP, 4% (ANDA # 086364) held by International Medication Systems is approved by Agency on Prior to Jan 1, 1982. Requesting Agency to provide the below documents as we are unable to find these documents at FDA website i.e. Drugs@FDA.         • ANDA Approval letter  •Summary Review   •Medical Review   •Chemistry Review   •Pharmacology Review "
2024-3004,2024-04-01,IPD Analytics,Please consider this a request for a copy of the 08/15/2023 Effective Approval letter for ANDA No. 216278 for Tiopronin (generic drug).  
2024-3005,2024-04-01,"Ripley, Teresa ",VAERS Report.
2024-3006,2024-04-01,Functional Government Initiative," 1. All calendar items, including invitees, responses, notes, attachments, and full details, related to travel to and preparation for attendance to The Tenth Conference of the Parties (COP10), February 5-10, 2024, in Panama City, Panama. 2. All travel records related to Dr. King’s attendance to COP10. ETC"
2024-3007,2024-04-01,"Burkavage, Brook ","Tentative approval letter, final approval letter, final approval routing sheet, and complete response letter(s) (CRL) for ANDA No. 211287."
2024-3008,2024-04-01,"CryoSurgery, Inc.","All Verruca-Freeze Cryosurgical System 510(k)s, including: K881349, K944221, K955083, K982506. Cool Renewal 510(k) - K161296 Nuance Medical 510(k)s - K130995, K210310"
2024-3009,2024-04-01,"BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.","I am requesting the FDA Approval Packages for VRAYLAR for the following 2 indications: (1) ""treatment of depressive episodes associated with bipolar I disorder (bipolar depression)"" (NDA 204370/S-006) and (2) ""adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults"" (NDA 204370/S-009). These new indications were approved on 05/24/2019 and 12/16/2022, respectively."
2024-3010,2024-04-01,Matthew Zorn,All records evidencing “increasing public interest” in sublingual and oral dosage forms of compounded ketamine for the treatment of psychiatric disorders described in the October 2023 Notice (https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine).
2024-3011,2024-04-01,University of Texas Health Science Center,"Need all adverse drug reaction reports on epoetin alfa-epbx since approval for human use, please"
2024-3012,2024-04-01,"Faruqi & Faruqi, LLP","Dear FOIA Officer:  I am seeking:  (1)  The meeting minutes related to the FDA's decision to issue the Complete Response Letter regarding Revance Therapeutics Inc.'s Biologics License Application (""BLA"") for DaxibotulinumtoxinA (""DAXI"" or ""Daxxify"") that was issued on or about October 15, 2021.    (2) The Summary Basis of Approval for Daxi.  Thank you."
2024-3014,2024-04-01,Neoma Business School,"I am requesting electronic versions of the Orange Book Data Files contain current Orange Book data for approved drug products and related patents (including expired patents), we found that Orange Book Data Files ZIP file online, but this file deletes expired patents. Besides, whether it is possible to ask for one electronic file of FDA-approved drugs and related all patents during the period 1996-2006 or other periods. "
2024-3015,2024-04-01,Servier Pharmaceuticals LLC,"FDA Case ID:  23213623, 23279997, 23063247, 23039325, 23321980, 23258742, 23292312, 23288376, 23282588,  23282587, 23282586, 23278134 "
2024-3016,2024-04-01,Ascension macomb oakland warren michigan,Vonoprazan-associated clostridium difficle  Cases IDs: 16823437 17161901 17554306 19997886 23273438 15835904 23284492 20307333 15486152 16718492
2024-3017,2024-04-01,"Oobli, Inc.","We request correspondence post- or pre-submission between FDA and MycoTechnology, Inc. regarding mycodulcein or honey truffle sweet protein."
2024-3018,2024-04-01,Yetter Coleman LLP,Documents produced in response to FOIA Request 2022-8583 re: “adverse event reports including the case narrative associated with the following case numbers involving Ketamine and Esketamine:   21081890 20583158 20220211 20215663 etc.”
2024-3019,2024-04-01,United Safety Agents LLC,"Dear FDA FOIA Request Team,  We respectfully request all entry-line records that contain any of the following data points in reference to any entry-line’s FSVP Importer, Importer of Record, or Consignee; for entry-lines with submission or arrival dates from March 01 to March 31, 2024:   1) DUNS Number / Unique Facility Identifier (UFI) of  080801169  etc"
2024-3021,2024-04-01,Michael Havert,  EA documents from Imlygic to Instiladrin  
2024-3022,2024-04-01,"Becker, David C","I would like a list by title of any documents the fda has on supervision of food safety inspections in NYS from January 1 2020 to March 1, 2024."
2024-3023,2024-04-01,THE NEW YORK TIMES,"1. FDA Guidance issued to clinical trial sponsors conducting clinical trials with amyloid-lowering agents for the treatment of Alzheimer’s Disease, which was issued around July 2010 (This guidance has also been referred to as a cautionary letter, advice, and guidelines).  2. Any responses received by the FDA from the Alzheimer’s Association Research Roundtable (AARR) in response to the 2010 guidance, including the official report sent by the AARR to the FDA for review and consideration.  "
2024-3024,2024-04-01,Foley & Mansfield PLLP,Please provide any and all documents related to petitioner’s petition to FDA in 1983 regarding warnings on cosmetic talcum powder products and FDA’s response dated in 1986. Please provide a certification (red ribbon) of authentication/business records admissibility. 
2024-3025,2024-04-01,Foley & Mansfield PLLP,"Please send any and all documents associated with the results from testing referenced in this FDA Summary attached herein, and please provide a certification of authentication/business records admissibility. "
2024-3026,2024-04-01,"Clark, Milt ","Provide Q/A Q/C and relevant laboratory test results showing active ingredient and purity as well as internal FDA memorandums regarding Abiraterone manufactured by:  The Arab Pharmaceuticals Manufacturing Company Sahab, Jordon Distributed by Civicascript Lehi, Utah  "
2024-3028,2024-04-01,Humphrey Farrington and McClain, 1.	All consumer complaints about adverse events potentially caused by Brazilian Blowout products or any other hair-straightening product brought to the FDA’s attention from 2007 to the present; and  2.	All correspondence between FDA staff and cosmetics manufacturers regarding health concerns about hair-straightening products such as Brazilian Blowout from 2007 to the present. 
2024-3029,2024-04-01,ALSTON & BIRD LLP,"All documents or communications between Luciano Escobedo or his agent Christine Humphrey of Humphrey & Associates and the FDA that contain the terms “Electrolit,” “Electrolyte,” “PiSA,” or “Laboratorios PiSA.” The documents requested include, but are not limited to: - Any documents or communications related to inclusion of Luciano Escobedo as an FSVP participant. - Any documents or communications associated with Luciano Escobedo or Christine Humphrey acting as an FSVP Importer for ELECTROLIT® beverage products."
2024-3030,2024-04-01,Redica Systems,CVM/Animal Drugs & Feed 483 Request (US-based inspection)
2024-3031,2024-04-01,Redica Systems,CBER/Biologics 483 Request (US-based inspection)
2024-3032,2024-04-01,Redica Systems,CFSAN/Food & Cosmetics 483 Request (US-based inspection)
2024-3033,2024-04-01,Millicent U.S. Inc.,"I would like a copy of the tentative approval letter for ANDA 203113 Lo-Blisovi Fe, Action Date 05/12/2014"
2024-3034,2024-04-01,POINT72,"FDA FAERS reports on the drug Ogsiveo (nirogacestat), from 11/27/23 to 4/1/24 (or the latest date available). "
2024-3035,2024-04-01,Cohen Milstein Sellers & Toll PLLC,Documents pertaining to Abbott Laboratories and certain executives and officers regarding infant formula manufacturing and safety (further details in the letter attached).
2024-3036,2024-04-01,"Camacho, Diana ","Good afternoon, could you send me information about Damiana leaves- turnera difusa. It is an herb, where it says that its use for tea is permitted. thank you"
2024-3037,2024-04-01,PHIBRO ANIMAL HEALTH,"Requesting the Establishment Inspection Report (EIR) for the Phibro Saude e Nutricao Animal Ltda site for an FDA inspection concluding October 19, 2023. As the US Agent for this site, I am requesting an unredacted version of the EIR."
2024-3038,2024-04-01,Heller Horowitz & Feit,"1. Documents showing the registration of Tropicosmeticos S.A. (Duns Number 814905154) with the FDA in 2020._x000D_
2. The certificate of Electronic Drug Listing for Britz Hand Sanitizer filed by Tropicosmeticos in 2020._x000D_
3. All documents concerning the placement of Urbane hand sanitizer manufactured by Tropicosmeticos, on its alert or warning lists in or about July 2020"
2024-3039,2024-04-02,U.S. Army Institute of Surgical Research,"FDA Data Integrity Inspection at US Army Institute of Surgical Research, Joint Base San Antonio, Fort Sam Houston, TX 78234, EIR, Booker T. King MD"
2024-3040,2024-04-02,POLITICO,"Please provide the following documents in electronic PDF format: All inspection-related documents obtained by Redica Systems and FDAZilla via a Freedom of Information Act requests during the period from January 1, 2019 - March 31, 2024. Please store documents in an accessible cloud-based Box folder and send a link to that folder via email."
2024-3041,2024-04-02,POLITICO,"Please provide a list of all closed FOIA requests, by month, from FOI Services in the period from January 1, 2008 to March 30, 2024. Please send this list in a Microsoft Excel format."
2024-3042,2024-04-02,Zydus Lifesciences Limited,"Online FOIA 483 request for: Most recent US FDA inspection observations (483s) of the FEI#3006370533 (Refer to detail mentioned below). Product Type- Human Drugs, Finished drug product manufacturer. Please send documents as email attachments.   "
2024-3043,2024-04-02,REUTERS,I would like to request a copy of the Form 483 that was issued to Zhejiang Peptites Biotech after the inspection of its facility that end on 09/08/2023. The FEI number is 3015685285
2024-3044,2024-04-02,HB Fuller,"FCN No. 1746 (Henkel, Inc.; 4/15/17) FCN No. 1692 (Henkel, Inc.; 12/17/16) FCN No. 1597 (Henkel, Inc.; 2/18/16) FCN No. 1596 (Henkel, Inc.; 2/18/16) FCN No. 1583 (Henkel, Inc.; 1/15/16) FCN No. 1991 (COIM; 8/21/19) FCN No. 1858 (COIM; 3/16/18) FCN No. 733 (Dainippon Ink and Chemicals, Inc.; 10/3/07) FCN No. 1718 (DIC Corporation; 2/22/17)"
2024-3045,2024-04-02,HB Fuller,"FCN No. 766 (Nippon Polyurethane Industry Co., Ltd.; 4/4/08) FCN No. 1531 (Mitsui Chemicals, Inc.; 7/2/15)"
2024-3046,2024-04-02,"Deep Track Capital, LP","Please send all adverse event reports for OGSIVEO (USAN name: nirogacestat), manufactured by SpringWorks Therapeutics, Inc., from 1/1/2023 through 4/1/2024.  Please include results under search term ""nirogacestat"" prior to FDA approval on 11/27/23, in addition to results under both OGSIVEO and nirogacestat subsequent to 11/27/23.  Please email results in excel if possible, or PDF if not.  Thank you."
2024-3047,2024-04-02,"Freiman, Sharon K","Copy of current janitorial services contract between Didlake, Inc. and FDA for janitorial services at White Oak facility in Silver Spring Maryland and any amendments to the contract. "
2024-3048,2024-04-02,Pharmamed USA,"We are looking for the approval letter for pharmaceutical products ANDA207739 that is not posted on Drugs@FDA:FDA-Approved Drugs, this product are correctly listed on the electronic Orange Book, but we need a copy of the approval letter."
2024-3049,2024-04-02,Jazz Pharmaceuticals,A copy of the Complete Response Letter ('CRL') issued by US FDA in November 2021 or December 2021 to Porton Biopharma Limited ('PBL') regarding PBL's Biologics License Application ('BLA') for Erwinaze® (asparaginase Erwinia chrysanthemi). 
2024-3050,2024-04-02,Barr & Gulyas,"All summary reviews and memoranda, OSE reviews and memoranda, clinical reviews and memoranda, adverse event and other analyses related to FDA's August 2021 Newly Identified Safety Signal for gallbladder-related disorders with GLP-1 RA medicines as described in FDA's posting for ""July - September 2021 Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)"" prepared between January 1, 2021 and April 1, 2024.   "
2024-3051,2024-04-02,Cogency Global Inc," investigational new drug application (IND) for X0002, ibuprofenamine hydrochloride spray"
2024-3052,2024-04-02,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/media/119312/download, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs. We request a spreadsheet which includes the 23 publicly available data points for all entries that led to Pacific Trellis Fruit's inclusion in this list for the last 2 years (March 1, 2022 - March 31, 2024). See attached Waiver. "
2024-3053,2024-04-02,"Hyman, Phelps & McNamara, P.C.","Copies of any correspondence between FDA and WoundVision LLC, including any memoranda of any phone conversations, related to advertising and/or promotion of its Scout Multi-Modal Imaging Technology product."
2024-3054,2024-04-02,The Detroit Free Press,"Any and all documents, including electronic correspondence, which reference Dr. Jeffrey W. Taub and a clinical trial involving the use of vincristine in pediatric patients with cancer written between Jan. 1, 2020 and today. • The inspection report and any related documents following an FDA inspection of Dr. Taub’s clinical site written between Sept. 23, 2022 and today. • Correspondence, including emails, between Dr. Taub and any employee of the FDA between Jan. 1, 2020, and today. • Internal documents, including email correspondence among FDA employees and contractors, referencing this clinical trial and/or Dr. Taub written between Jan. 1, 2020 and today. etc"
2024-3055,2024-04-02,Redica Systems,CDER/Human Drugs 483 Request (US-based inspection)
2024-3056,2024-04-02,Registrar Corp,"Ahold Delhaize requests a spreadsheet of the 23 publicly available data fields for imports of any FDA regulated product entering the United States where the firm has been transmitted as FSVP importer during the period of March 1, 2022 - March 31, 2024. Please include FEI numbers and DUNS numbers if available. This request is for shipments of all FDA-regulated products (not specifically for shipments designating an FSVP importer).  "
2024-3057,2024-04-02,Registrar Corp,"  We request a spreadsheet which includes the 23 publicly available data points for all entries that led to the inclusion of the following companies in this list: Nestle USA, Inc (DUNS number 00-825-6224), Nestle Professional (DUNS number 07-678-0409), Dreyer's Grand Ice Cream Holdings, Inc. (DUNS number 06-656-3859), Nestle Puerto Rico (DUNS number 09-014-5707), Payco Foods Corp (DUNS number 36-295-4588), Gerber Products Company (DUNS number 00-601-9780), Nestle Healthcare Nutrition (DUNS number 00-624-7332), Nestle Nutrition Gerber (DUNS number 10-939-2637).   "
2024-3058,2024-04-02,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/media/119312/download, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs. We request a spreadsheet which includes the 23 publicly available data points for all entries that led to Mclane Global, Inc.'s inclusion in this list for the last 2 years (March 1, 2022 - March 31, 2024). See attached Waiver. "
2024-3059,2024-04-02,Registrar Corp,"Lipari Foods Operating Company, LLC requests a spreadsheet of the 23 publicly available data fields for imports of any FDA regulated product entering the United States where the firm has been transmitted as FSVP importer during the period of March 1, 2022 - March 31, 2024.  "
2024-3060,2024-04-02,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/media/119312/download, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs. We request a spreadsheet which includes the 23 publicly available data points for all entries that led to San-J International's inclusion in this list for the last 2 years (March 1, 2022 - March 31, 2024).  "
2024-3061,2024-04-02,REUTERS,I would like to request all Form 483s issued for inspections carried out of any facilities belonging to Eli Lilly between January 1 2024 and March 31 2024. 
2024-3062,2024-04-02,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/media/119312/download, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs. We request a spreadsheet which includes the 23 publicly available data points for all entries that led to Associated Wholesale Grocers, Inc's inclusion in this list for the last 2 years (March 1, 2022 - March 31, 2024).  "
2024-3063,2024-04-02,Registrar Corp,"Dollar Tree requests a spreadsheet of the 23 publicly available data fields for imports of any FDA regulated product entering the United States where the firm has been transmitted FSVP importer during the period of March 1, 2022 - March 31, 2024.   "
2024-3064,2024-04-02,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/media/119312/download, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs. We request a spreadsheet which includes the 23 publicly available data points for all entries that led to Daiso California, Llc.'s inclusion in this list for the last 2 years (March 1, 2022 - March 31, 2024). See attached Waiver."
2024-3065,2024-04-02,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/media/119312/download, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs. We request a spreadsheet which includes the 23 publicly available data points for all entries that led to Jasper Wyman & Son's inclusion in this list for the last 2 years (March 1, 2022 - March 31, 2024). See attached Waiver. "
2024-3066,2024-04-02,Registrar Corp,"We request a spreadsheet identifying the firms that received FDA Warning Letters between October 1, 2011 and March 31, 2024 or the most recently available date, to include the following: Company FEI; Company Name; Company Address Line 1; Company Address Line 2; Company City; etc"
2024-3067,2024-04-02,Registrar Corp,FDA publishes weekly Enforcement Reports on its website (http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm) identifying all recalls monitored by FDA once they are classified according to the level of hazard involved. These reports are available as a downloadable CSV file which includes the following data fields: 1. Product Type 2. Event ID 3. Status 4. Recalling Firm 5. City 6. State 7. Country 8. Voluntary/Mandated etc
2024-3068,2024-04-02,Registrar Corp,"  We request a list of companies found in violation found during FSVP inspections, as well as the various types of violation and the frequency in which they were observed between December 20, 2017 and March 31, 2024 (or the most recently available date for 2024).  "
2024-3069,2024-04-02,Registrar Corp,"We request a modified version of FDA's publicly available Inspection Classifications spreadsheet to include the FEI, Address (Line 1), and Address (Line 2) for each inspection that occurred between October 1, 2011 and March 31, 2023 (or the most recent available date in 2023). "
2024-3070,2024-04-02,Registrar Corp,We request a spreadsheet which includes the 23 publicly available data points for all entries that led to our company's inclusion in this list as of March 31 or the most recently available date. 
2024-3071,2024-04-02,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/food/importing-food-products-united-states/foreign-suppliers-verification-programs-fsvp-list-participants, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs.  "
2024-3072,2024-04-02,"Faruqi & Faruqi, LLP","Dear FOIA Officer:   I am seeking the meeting minutes of the ""Type A"" meeting the FDA held on or around December 15, 2021 with Revance Therapeutics Inc. regarding its Biologics License Application (""BLA"") for DaxibotulinumtoxinA (""DAXI"" or ""Daxxify"").  Thank you."
2024-3073,2024-04-02,"J.E. Dice Regulatory Solutions, LLC","Please provide the TPMF job aid document referenced on page 24 and the TPMF review template document, both referenced on page 24 of the EX and SE Scientific review job aid dated February 18, 2021."
2024-3074,2024-04-02,Alliance for Benzodiazepine Best Practices,"We would like to get the background report and references providing the evidence for the FDA Boxed Warning on Benzodiazepine Use During Pregnancy, issued around 08/03/22. We would be happy to receive this as a PDF to the email: bernie@benzoreform.org. If there is another way to obtain this information, please let us know."
2024-3075,2024-04-02,Taxpayers Protection Alliance Foundation,"I am requesting internal email correspondence from July 25, 2022 through February 29, 2024 between staff members of the Food and Drug Administration referencing Brix levels in pasteurized orange juice in relation to the Standard of Identity for pasteurized orange juice (as defined under 21 C.F.R. § 146.140).  "
2024-3076,2024-04-02,Inside Climate News,"I request that a copy of the following documents be provided to me: MedWatch adverse event reports related to Formaldehyde, Formalin, Methylene glycol in hair straighteners and hair smoothers from July 1, 2023 until March 31, 2024 as well as communications related to Formaldehyde, Formalin, Methylene glycol in hair straighteners and hair smoothers from July 1, 2023 until March 31, 2024. etc"
2024-3077,2024-04-02,ARZNEI-TELEGRAMM," Abraham D, Mosholder AD, Leishear White K, Sandhu SK. Functional neurobehavioral outcomes and urogenital outcomes associated with prenatal acetaminophen exposure. July 15, 2022. Silver Spring (MD), U.S. Food and Drug Administration. Available in Lifecycle Signal Tracker (LiST) under NISS ID: 1001355.1_x000D_
_x000D_
 "
2024-3078,2024-04-02,Matthew Zorn,"All records concerning comparisons of safety and/or efficacy between ketamine and esketamine as treatments for psychiatric disorders from January 1, 2000 to the present  "
2024-3079,2024-04-02,Matthew Zorn,"All e-mails, documents, and other records, concerning or relating to FDA’s decision to issue (1) the February 2022 Notice (“https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray” ) and (2) the October 2023 Notice (“https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine”)."
2024-3080,2024-04-02,Matt,"All documents previously produced in response to the FOIA request by UC Santa Cruz: ""Any communications, memos or reports relating to the FDA warning issued on February 16, 2022, alerting healthcare professionals to the potential risks associated with compounded ketamine nasal spray AND/OR the warning issued on October 10, 2023, etc"
2024-3081,2024-04-02,Matthew Zorn,"Any record currently kept in FDA’s FOIA Office that has been previously produced to a FOIA requestor and contains the word “ketamine” from January 1, 2020 to the present."
2024-3082,2024-04-02,Sorenson Law LLC,INVESTIGATIONS AGAINST PROFESSORS ETC
2024-3083,2024-04-03,Murata Manufacturing Co. Ltd,"510(k) Premarket Notification Submission Document, 510(k) Number: K142364, Device Name: Barrx RFA Self Sizing Balloon Catheter, Applicant: Covidien Llc"
2024-3084,2024-04-03,Sovish,"Please share the Form 483 for Human Drug related inspection for QPS Netherlands B.V. that ended on Feb 24, 2017 for the site Groningen, Netherlands and FEI id 3008548421"
2024-3085,2024-04-03,Sovish,"Please share the copy of the Form 483 for QPS Netherlands B.V. Inspection that ended on Dec 06, 2019 for the site Groningen, Netherlands and fei id 3008548421. The inspection was related to Human Drugs."
2024-3086,2024-04-03,REUTERS,I would like to request all Form 483s issued from inspections of Corden Pharma Colorado's facilities in 2023 and 2024 so far
2024-3087,2024-04-03,REUTERS,I would like to request all Form 483s issued to BSP Pharmaceuticals between August 1 2023 and March 31 2024
2024-3088,2024-04-03,REUTERS,I would like to request the records provided under FOIA number 2023-11501
2024-3089,2024-04-03,REUTERS,I would like to request copies of the records handed over under FOIA request 2022-6475
2024-3090,2024-04-03,REUTERS,I would like to request copies of the records already provided to another party under FOIA number 2024-1540
2024-3091,2024-04-03,Marisa Panella," Inferno Smoke Shop previously located at 6560 n Sheridan Rd, Chicago, Illinois 60626. I am hoping to gain access to the inspection report for the inspection of the store done on June 22, 2023 in relation to any violations done surrounding tobacco sale and misuse. I am also seeking access to any complaints filed against the establishment and any information on the closure of the business on   "
2024-3092,2024-04-03,Redica Systems,CBER/Biologics 483 Request (US-based inspection)
2024-3093,2024-04-03,Zydus Pharmaceuticals USA Inc,Please provide Summary Basis of Approval of RESMETIROM TABLET (REZDIFFRA) ORAL 60MG;	80MG;	100MG for the Applicant MADRIGAL PHARMACEUTICALS INC-N217785
2024-3094,2024-04-03,FOIA Professional Services,I would like to obtain a copy of the two FDA Summary Reviews listed below for Rinvoq (upadacitinib) NDA supplements.   NDA 211675/S-015- Treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers.  NDA 211675 S-017  
2024-3095,2024-04-03,The University of Tampa,"To the Department of Health and Human Services I am requesting for access to any investigative information pertaining to the foods that may be food fraud, economically driven adulteration, or counterfeit products.  "
2024-3096,2024-04-03,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Syfovre (branded name / marketed by Apellis Pharmaceutical) or pegcetacoplan (generic name) between March 27, 2024 and April 2, 2024.  Please provide the documents electronically if possible."
2024-3097,2024-04-03,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for ELEVIDYS (branded name / marketed by Sarepta Therapeutics, Inc.) or delandistrogene moxeparvovec-rokl (generic name) between March 27, 2024 and April 2, 2024.   Please provide the documents electronically if possible.        "
2024-3098,2024-04-03,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Wegovy (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between March 25, 2024 and April 2, 2024.  Please provide the documents electronically if possible."
2024-3099,2024-04-03,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Ozempic  (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between March 25, 2024 and April 2, 2024.  Please provide the documents electronically if possible."
2024-3100,2024-04-03,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Zepbound (branded name / marketed by Lilly) or tirzepatide (generic name) between March 25, 2024 and April 2, 2024.  Please provide the documents electronically if possible."
2024-3101,2024-04-03,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Mounjaro (branded name / marketed by  Lilly) or tirzepatide (generic name) between March 25, 2024 and April 2, 2024  Please provide the documents electronically if possible."
2024-3102,2024-04-03,Redica Systems,"Please provide the results for the following CV/Resumes from 01-01-2013 to current, in electronic pdf format as email attachments delivered to support@fdazilla.com."
2024-3103,2024-04-03,"Amore, Teal L","  I'm wanting to get any reports where the company name includes (not case sensitive) ""enchroma"" where the initial report was submitted between 8/1/23-4/1/23.  I understand the investigations may not be complete, but any documents that are currently available are ok with me. "
2024-3104,2024-04-03,Boston Analytical dba BA Sciences,would like an unredacted copy of the 90-day Classification letter and FMD-145 for the Feb-Mar 2023 inspection of our facilities at 12 and 14 Manor Parkway Salem NH conducted by Inspector Lori M Newman-S
2024-3105,2024-04-03,"PETERSON, REBECCA ","• any and all records, reports, and/or communications related to Import Alert “IA-99-42,” Description Text “Detention Without Physical Examination of Foods Due to Heavy Metal (Toxic Element) Contamination,” and URL “None” (“IA-99-42”),  whether generated by, sent to, or received by the FDA from March 1, 2016 to the present for any ingredients, firms, and/or infant formula or baby food products.   • any and all records, reports, and/or communications related to the FDA’s determination of products, ingredients, firms, and/or countries designated on the Red List of IA-99-42, whether generated by, sent to, or received by the FDA from March 1, 2016 to the present. "
2024-3106,2024-04-03,Traditional Medicinals,"  Dynamic 3PL a United States of America company, for their headquarters at   30610 S Kavanaugh Rd. Wilmington, IL 60481  and/or any associated manufacturing locations or offices.  has a webpage located at: https://www.dynamic3pl.com 1)	Any and all noted observations, objections, and comments during such facility inspections such as a Form-483 or otherwise, as well as any responses thereto; 2)	A list of all ingredients and/or products packed, handled or stored by Dynamic 3PL that have been subject to, implicated in, or impetus for a recall from 2 April 2020 to present; 3)	A list of all reports by, or related to, Dynamic 3PL to the Reportable Food Registry from 2 April 2020 to present. "
2024-3107,2024-04-03,Pharm1,"Wittman Pharma, Inc.  FDA Form 483 Inspection Observations   Wittman Pharma, Inc. 15431 Flight Path Drive Brooksville, FL 34604"
2024-3108,2024-04-03,The Capitol Forum,"lease provide me with the following: Professional calendar of FDA Commissioner Robert M. Califf for the months of January, February and March 2024 (1/01/2024 – 3/31/2024). Fo"
2024-3109,2024-04-03,Decof Barry Mega & Quinn,"1.  The Establishment Inspection Report  (FEI:  3004170064; inspection # 1205514), regarding the FDA's inspection, from 3/1/23 - 5/17/23, of Integra LifeSciences Corporation's TEI Biosciences, Inc.'s manufacturing facility in Boston, MA.  2.  Correspondence with Medtronic, Inc., TEI Biosciences, Inc., or Integra LifeSciences Corporation regarding:  (a) inspection # 1205514; and/or (b) the June 2023 medical device recall of Durepair products manufactured at the TEI/Integra facility in Boston, MA. "
2024-3110,2024-04-03,The Capitol Forum,"Professional calendars of Patrizia Cavazzoni, director of the FDA Center for Drug Evaluation and Research (CDER); Jacqueline Corrigan-Curay, principal deputy center director of CDER; Iilun Murphy, director of the FDA Office of Generic Drugs; Peter Stein, director of the FDA Office of New Drugs; and Carol Bennett, acting director of CDER’s Office of Regulatory Policy for the months of January, February and March 2024 (1/01/2024 – 3/31/2024). "
2024-3111,2024-04-03,JUUL Labs Inc.,"Please provide a copy of the disclosable portions of all CTP guidances, memorandum, scientific reviewer guides or other reviewer documents created, updated, or used for evaluating MRTPAs from the date range 1/1/2022-4/3/2024."
2024-3112,2024-04-03,JUUL Labs Inc.,"Please provide a copy of the disclosable portions of all periodic postmarketing reports submitted by Philip Morris Products S.A. as required in the Agency’s modified risk granted orders for numbers MR0000059, MR0000060, MR0000061, and MR0000133 issued by FDA under section 911 of the Family Smoking Prevention and Tobacco Control Act (“FSPTCA”) from the date range 1/1/2022-4/3/2024."
2024-3113,2024-04-03,POINT72,"I am an investment professional requesting information under the Freedom of Information Act.  Can we please check for FDA FAERS reports on the drug Veozah (fezolinetant), from 5/1/23 to 4/3/24 (or the latest date available). Please look for events under both the brand and generic names. Where possible, please include full narrative of events, and email the results in a PDF or Excel file._x000D_
_x000D_
Thank you!"
2024-3114,2024-04-03,INTERTEK,FCN No. 2281 
2024-3115,2024-04-04,FORTUNE MAGAZINE,"A copy of the response to FOIA request 2022-8418, submitted November 30, 2022, that requested ""any emails, call logs or other communications between Neuralink, Elon Musk representing Neuralink or other's representing Neuralink, specifically as it related to animal testing or human trials of their brain implantation device.'"
2024-3116,2024-04-04,FORTUNE MAGAZINE,"I am requesting copies of all records and responses provided in response to FOIA requests 2023-1070 and 2023-1071, filed 3/08/2023, requesting ""all Forms 483 (notice of inspectional observations) at laboratories operated by Neuralink Corp. in Austin or Del Valle, Texas and Fremont, California, since Jan. 1, 2021."" "
2024-3117,2024-04-04,STAT,I seek the release of the following records in the custody or control of the United States Food and Drug Administration:  All records produced pursuant to FOIA request 2024-1540.  
2024-3118,2024-04-04,FORTUNE MAGAZINE,"I am seeking all documents provided in response to FOIA request 2023-631, filed 2/23/2023, which requested ""information about any interactions between the Federal Drug Administration and Neuralink, a California-based company founded by entrepreneur Elon Musk. Other key personnel include Shivon Zilis and Max Hodak. I believe there is also communication outside of device approval that occurred with FDA leaders.""   "
2024-3119,2024-04-04,TSG Consulting,FCN 476 
2024-3120,2024-04-04,FORTUNE MAGAZINE,"I am requesting any documents or responses produced regarding FOIA request 2023-1294, requested 3/15/2023, that requested ""Emails dated between Jan. 1, 2019 and present day, including attachments, between @neuralink.com addresses and Jeff Shuren (jeff.shuren@fda.hhs.gov), Paul Norris (Paul.Norris@fda.hhs.gov), David McMullen (David.McMullen@fda.hhs.gov), John Marler (John.Marler@fda.hhs.gov), Capt. Nina Mezu-Nwaba (CAPTNina.Mezu-Nwaba@fda.hhs/gov),  etc"""
2024-3121,2024-04-04,Redica Systems,CDRH/Medical Devices & Rad Health 483 Request (US-based inspection)
2024-3122,2024-04-04,The Capitol Forum,A log of all form 483 inspection reports generated by the FDA for the month of March 2024. 
2024-3123,2024-04-04,Redica Systems,CDRH/Medical Devices & Rad Health 483 Request (International inspection)
2024-3124,2024-04-04,The Capitol Forum,"Inspection reports for the following facilities for inspections on the associated dates:  Fresenius Kabi USA, LLC, 5200 Corporate Pkwy, Wilson, NC, 27893-9412 (2/8/2024) Repligen Corporation, 3400 Royalty Row, Irving, TX, 75062-4946 (2/8/2024) Medtronic Navigation, Inc., 200 Medtronic Drive, Lafayette, CO, 80026 (2/9/2024)"
2024-3125,2024-04-04,The Capitol Forum,"Inspection reports for the following facilities at the associated address for inspections on the associated  date:  Novocure, Inc,195 Commerce Way, Portsmouth, NH, 03801-3251 (2/9/2024) Stericycle Inc, 2355 Waukegan Rd, Bannockburn, IL, 60015-1586 (2/12/2024) Zoetis LLC, 2605 E Kilgore Rd, Kalamazoo, MI, 49001-5505 (2/13/2024)"
2024-3126,2024-04-04,EXPONENT,"We kindly request documents in CFSAN files pertaining to the use of bacteriophages (phages) as a functional ingredient (e.g., nutritional or prebiotic effects rather than effects as an antimicrobial) in food, including but not limited to the use of bacteriophages discussed with FDA at a consultation on December 3, 2018, and any other consultations FDA may have had on the use of bacteriophages as an ingredient in food. "
2024-3127,2024-04-04,UNIVERSITY OF MARYLAND,I am requesting access to a dataset for drug products containing the following info from 2009 to 2023: 1. product name; 2. substance name; 3. dosage form; 4. strength; 5. labeler name; 6. manufacturing plant FEI; 7. manufacturing plant address; 8. marketing date of the product; 9. operations performed at the manufacturing plant. 
2024-3128,2024-04-04,Spotlight PA," - All 40 exhibits collected by the FDA during its March 2019 inspection of the Penn State Health Milton S. Hershey Medical Center (FEI: 3003940926). These exhibits are detailed on pages 15 and 16 of the FDA’s Establishment Inspection Report.  - The exhibits collected #1, #5, and #8 by the FDA during its July 2023 inspection of the Pennsylvania State University IRB (FEI: 3009798188).  ETC"
2024-3129,2024-04-04,TSG Consulting,"To Whom It Concerns, Technology Sciences Group Inc. (TSG) hereby submits this FOIA request to obtain all physically and electronically releasable copies of the documentation submitted by Ishizuka Glass Co., LTD in support of Food Contact Notifications FCN 1981. "
2024-3130,2024-04-04,"Willner, Neil ","I am seeking all records, reports, findings and written communications (whether via e-mail, letter, or otherwise) regarding inspections of ""Drink Brez, LLC"" and/or ""Formula Wonders LLC""'s facility conducted by FDA over the past year.  "
2024-3131,2024-04-04,Tyler Kwack,"I am requesting the 2021 Establishment Inspection Report (EIR) for Eastman Chemical Company. The EI start date was 11/29/2021 and EI end date was 12/1/2021. The location is 200 S Wilcox Dr Kingsport, TN 37660-5147."
2024-3133,2024-04-04,"Grim, Christopher E",I am seeking the FDA's results/conclusions into their investigation of Black Lion Research's supplement called Follidrone. I wanted all the information the FDA has gathered in their investigation of the Follidrone supplement produced by Black Lion Research.
2024-3135,2024-04-04,"Rainypixels, LLC","On Nov 20, 2023, Linda Walter-Grimm, Director, Division of Pharmacovigilance and Surveillance addressed an Untitled Letter (NADA 141-562) to Dr. Cleaver, Zoetis Inc. requesting a written response within 15 days in the ""Conclusion and Requested Action"" section. I am requesting written response from Zoetis, Inc. to be released."
2024-3136,2024-04-04,"Applaud Medical, Inc.","I would like a copy of the most recent Establishment Inspection Report (EIR) and any FDA Form 483’s for the following company:_x000D_
Avanti Polar Lipids_x000D_
700 Industrial Park Drive_x000D_
Alabaster, Alabama 35007-9105_x000D_
Est. #: 1036868_x000D_
DUNS: 075473496"
2024-3137,2024-04-04,"Applaud Medical, Inc.","I would like a copy of the most recent Establishment Inspection Report (EIR) and any FDA Form 483’s for the following company:_x000D_
FlouroMed Products, L.P._x000D_
2350 Double Creek Dr., _x000D_
Round Rock, TX 78664_x000D_
Est. ID: 3001237276_x000D_
DUNS: 016219128_x000D_
Date: from 2017 to date"
2024-3138,2024-04-04,"Applaud Medical, Inc.","I would like a copy of the most recent Establishment Inspection Report (EIR) and any FDA Form 483’s for the following company:_x000D_
Berkshire Sterile Manufacturing_x000D_
480 Pleasant Street_x000D_
Lee, MA 01238_x000D_
FEI: 3012144557_x000D_
Date: from 2022 to date"
2024-3139,2024-04-04,"Applaud Medical, Inc.","I would like a copy of the most recent Establishment Inspection Report (EIR) and any FDA Form 483’s for the following company:_x000D_
Polymun Scientific Immunbiologische Forchung GmbH_x000D_
Donaustrasse 99, 3400 Klosterneuburg, _x000D_
Austria_x000D_
Date: from Jan 2023 to date"
2024-3140,2024-04-04,LSU Law School,"I am requesting the final document for the CVM Key Initiave Plan 2019-2020. This record would be located at FDA-CVM. Employees who could possibly maintain the final version or at least point to where the final document's location at CVM would be Steven Solomon, Shera Moxley, Roxanne Schweitzer, Almas Azeem."
2024-3141,2024-04-04,"Orca1 Digital Intelligence, LLC","2024-1344, 2024-169, 2023-10799, 2023-10675, 2023-8862 "
2024-3142,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-8864, 2023-8988, 2023-9139, 2023-9178, 2023-9221 "
2024-3143,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-10068, 2023-9511, 2023-7840, 2023-11436, 2023-6722 "
2024-3144,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-9624, 2023-8227, 2023-6004, 2023-5043, 2023-5974 "
2024-3145,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-7517, 2023-4332, 2023-6450, 2023-5442, 2023-5849 "
2024-3146,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-5482, 2023-3713, 2023-6255, 2023-3328, 2023-3327 "
2024-3147,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-3019, 2023-2965, 2023-2961, 2024-71, 2023-2959 "
2024-3148,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-7815, 2023-2921, 2023-2918, 2023-2914, 2023-2821 "
2024-3149,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-2822, 2023-2818, 2023-5729, 2023-1803, 2023-2811 "
2024-3150,2024-04-04,"Orca1 Digital Intelligence, LLC","2023-11440, 2023-2807, 2023-2808, 2023-2771, 2023-2635 "
2024-3151,2024-04-04,COVINGTON & BURLING LLP,  All documentation in FDA’s files regarding the GRAS status of Thaumatin derived from the West African Katemfe fruit and marketed under the brand name Talin® 
2024-3152,2024-04-04,PROPUBLICA,"USTR-FY23-23 Referral: Records since January 20, 2017 regarding the U.S. Government position on infant formula in the WTO, WHA, WHO, Malaysia, Vietnam, Thailand, Philippines or Indonesia "
2024-3153,2024-04-05,Ekta Batra,Form 483 for  Cipla Patalganga Plant 
2024-3154,2024-04-05,"Stimlabs, LLC","I am requesting a letter provided by the Tissue Reference Group (TRG) to Musculoskeletal Transplant Foundation d/b/a/ MTF Biologics (FEI# 3001236616),  located at 125 May St. Suite 300 Edison, New Jersey, 08837, describing_x000D_
the recommendation of the specific product ""Salera Mini Membrane"" for regulation as a Section 361 Human Cell, Tissue, and Cellular and Tissue-Based Product."
2024-3155,2024-04-05,The Daily Signal," :  All communications: (1) between the agency and  any of the following email domains: @demos.org, @electionexcellence.org,@sentencingproject.org, @aclu.org, @campaignlegal.org, @advancingjustice-aajc.org,@fairfight.com, @techandciviclife.org, @electioninnovation.org. @ndrn.com, @aapd.com, @narf.org, @lwv.org, @maldef.org, @fairelectionscenter.org,@civilrights.org, @opensocietyfoundations.org, @taketheplej.org,@modernelections.org, @funderscommittee.org, @newventurefund.org,@faircount.org, @brennancenter.org, @democracyfund.org, @democracyfundvoice.org,@rockthevote.org, @northfund.org, @triggerthevote.com etc"
2024-3156,2024-04-05,Cogency Global Inc,"Pursuant to the Freedom of Information Act (FOIA), as amended, 5 U.S.C. § 552, et seq., and 21 C.F.R. Part 20, COGENCY GLOBAL INC., hereby requests all publicly available records from January 1, 2023 to the present (unless another date range is specified below) related to the Class 2 Device Recall for the LIFEPAK 15 (“LIFEPAK 15”); Recall Posting Date: 11/14/2023; Recall Event ID 93233; PMA Number P160026; Recalling Firm/Manufacturer Physio-Control, Inc. (the “Recall”)."
2024-3158,2024-04-05,MCGUIREWOODS LLP,"All test reports for any testing FDA laboratories have performed on skin creams for the presence of mercury in the creams, including but not limited to the test reports for the testing referenced at: https://www.fda.gov/consumers/health-fraud-scams/skin-products-containing-mercury-andor-hydroquinone"
2024-3159,2024-04-05,THE WALL STREET JOURNAL,"I am requesting all adverse event reports made to the FDA regarding Librela, from 2023 through present day, as well as adverse event reports made to the FDA for Solensia from 2022 through present day. These drugs are both monoclonal antibodies approved by the FDA to manage osteoarthritis in dogs and cats."
2024-3160,2024-04-05,Rad Turkin," the data collected related to the DCM cases in dogs, I am a student and do not know the name of the data is, if someone would be able to help. I would love all the raw data available on this."
2024-3161,2024-04-05,"Hyman Phelps & McNamara, P.C.","Any and all statistical information concerning the number of Formal Dispute Resolution Requests (FDRR) relating to drug approvals reviewed by FDA between 2004 to present day, and any statistical quantification of the specific procedural disposition of the respective FDRRs considered during this timeframe.  "
2024-3162,2024-04-05,Ballard Spahr LLP on behalf of Partnership for Safe Medicines,"The records you produced in response to a FOIA request by FOI Services, Inc. (No. 2020-1991) for “correspondence between Office of the Commissioner and state of Florida, regarding FDA’s proposed rule on ‘Importation of Prescription Drugs,’ Florida’s ‘Canadian Prescription Drug Importation Concept Paper,’ or Florida’s ‘Act Relating to Prescription Drug Importation Programs’ (Florida HB 19).”"
2024-3163,2024-04-05,The University of Michigan Law School,"1/01/2010-5/25/2024: I am requesting information on ads reported through the Bad Ad Program through the Office of Prescription of Drug Promotion. The information will be the number of ads reported per year and then for reports with at least one of any of the keywords (ghostwriting, ghostwrite, ghostwritten, journal, conflict of interest), ETC"
2024-3164,2024-04-05,The University of Michigan Law School,"I am requesting any internal memoranda from the OPDP relating to the promulgation of the FDA's draft guidance entitled ""Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers Guidance for Industry"" with the keyword ghostwriting or ghostwrite from 1/01/2023 to 5/25/2024. "
2024-3165,2024-04-05,The University of Michigan Law School,"I am requesting any internal memoranda relating to the promulgation of the guidance document entitled ""Guidance for Industry: Industry-Supported Scientific and Educational Activity"" that includes the keywords ghostwrite, ghostwriting, thought leader or opinion leader or conflict of interest. Time period: 1/01/1996-12/3/1997. "
2024-3166,2024-04-05,AMERICAN HERBAL PRODUCTS ASSOCIATION,"All records pertaining to a targeted survey for PFAS analytes in seafood product samples conducted in 2022, as referenced in the description of Import Alert 99-48. Any records interpreting the results of the above survey for the purpose of establishing Import Alert 99-48."
2024-3167,2024-04-05,STAT,"All daily calendars / schedules from September 1, 2022 to June 30, 2023  and October 1, 2023 to April 4, 2024 for CBER Director Peter Marks  All official cell phone bills, including call logs, from September 1, 2022 to June 30, 2023  and October 1, 2023 to April 4, 2024 for CBER Director Peter Marks   "
2024-3168,2024-04-05,Redica Systems,CDER/Human Drugs 483 Request (US-based inspection)
2024-3169,2024-04-05,Redica Systems,CBER/Biologics 483 Request (US-based inspection)
2024-3170,2024-04-05,Pharmobedient Consulting,"Please see the attached request for tablet size, shape, weight and volume information of RLD Kemstro ODT (Baclofen), 10 mg and 20 mg. The Controlled Correspondence was kicked back to us and requested to get the info through FOI."
2024-3171,2024-04-05,Meitheal Pharamaceuticals Inc,"The BLA approval package for BLA 761362, Jubbonti (denosumab-bbdz) injection 60 mg/mL and  Wyost (denosumab-bbdz) injection 120 mg/1.7 mL (70 mg/mL), interchangeability, dated 3/5/2024, including  but not limited to; Product Quality Review(s), Multi-discipline Review(s), Other Review(s), and Administrative and Correspondence Documents. "
2024-3172,2024-04-05,Itempnews.org,"Any annual report, oversight report, presentation, memorandum, or communication that the Food and Drug Administration, through the Center for Biologics Evaluation and Research (CBER), on the National Donor Deferral Registry (NDDR®).  "
2024-3173,2024-04-05,CNBC,Please send form 483 of Cipla's Patalganga (Maharashtra) plant 
2024-3174,2024-04-05,Giseob Kim,"I am writing to request access to records under the provisions of the Freedom of Information Act from the U.S Food and Drug Administration (FDA). Specifically, I am seeking access to the New Drug Application (NDA) 01854 for LONITEN.  Please provide all relevant documents, including but not limited to: 1. Any FDA review documents, approval letters, or PMS reports related to Loniten. 2. Clinical trial data, efficacy studies, safety reports, and labeling information associated with Loniten.  Detailed request is in the attachment."
2024-3175,2024-04-05,"Agarwal, Bhavish ","The U.S. Food and Drug Administration (USFDA) conducted  a routine current Good Manufacturing Practices (cGMP) inspection at Cipla's facility in Patalganga, Maharashtra, India from from 28 March 2024 to 4 April 2024. I request you please share the copy of the Form483 of this Human Drug inspection.  "
2024-3176,2024-04-05,Nephron Research,"Under FOIA, I'm requesting any materials delivered responding to closed FOIA control # 2024-2789. The FOIA relates to the closeout letter and EIR for Catalent's Maryland Harmans facility (BWI) from 18-24 January 2023. If possible, could I please get response via email? Thanks "
2024-3177,2024-04-05,Tom Chen,All inspection and investigative documents regarding the FDA's 2018 inspection of BioTE Medical's compounded hormone pellets. Date range of search: 01/01/2018 - 12/31/2018.
2024-3178,2024-04-05,EOS Optical Inc., We would like to get a record report showing that EOS is the original owner of the FEI# 3022988037 registration. Cler Vision Inc. 
2024-3179,2024-04-08,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Cloud 9 Vapor Products LLC dated September 08, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3180,2024-04-08,"Kleinfeld, Kaplan & Becker LLP","•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Cloud House LLC dated September 08, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3181,2024-04-08,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Diamond Vapor LLC dated September 01, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3182,2024-04-08,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to ECS Global LLC dated September 10, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). _x000D_
_x000D_
"
2024-3183,2024-04-08,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Electric Clouds Inc. dated September 08, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3184,2024-04-08,CBS NEWS,"Records provided in response to the following FOIA requests: 2023-667, 2024-792, 2024-1540, 2024-2175, 2024-2227, 2024-2645 "
2024-3185,2024-04-08,"Fisher Diagnostics, Part of Thermo Fisher Scientific","Request a copy of the available records for the 2017 FDA inspection that occurred at the facility listed above.  _x000D_
Registration Number: 1181121_x000D_
FEI Number: 1181121"
2024-3186,2024-04-08,NEW YORK TIMES,"All records produced in response to FOIA request #2020-8296 filed on 11/25/2020 by Levin, Rojas, Camassar & Reck."
2024-3187,2024-04-08,NEW YORK TIMES,"All records produced in response to FOIA request #2023-7963 filed by THE ASSOCIATED PRESS In addition, I am seeking all records produced in response to the related FOIA request #2024-845 filed by THE ASSOCIATED PRESS."
2024-3188,2024-04-08,NEW YORK TIMES,"All records produced in response to FOIA requests #2024-428, #2024-429 and #2024-430 filed by Helaina Inc.."
2024-3189,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2024-1929 filed by Arla Foods Ingredients Group P/S.
2024-3190,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2023-794 filed by BLBG LLP.
2024-3191,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2023-7776 filed by KIRKLAND & ELLIS LLP.
2024-3192,2024-04-08,NEW YORK TIMES,"All records produced in response to FOIA request #2023-7381 filed by Brown & Crouppen, PC / Attn: Jim Lemonds/M Broughman."
2024-3193,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2023-4271 filed by ByHeart.
2024-3194,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2023-3680 filed by PROPUBLICA.
2024-3195,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2023-216 filed by MINNEAPOLIS STAR TRIBUNE.
2024-3196,2024-04-08,NEW YORK TIMES,"All records produced in response to FOIA request #2023-1369 filed by ANDERSON, BLANDA & SALTZMAN."
2024-3197,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2023-11416 filed by Claudia Guerrero.
2024-3198,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2023-11128 filed by Infinant Health.
2024-3199,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-8584 filed by Jason Sager & Associates.
2024-3200,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-7223 filed by Preuss Foster Law.
2024-3201,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-7054 filed by eFoodAlert.
2024-3202,2024-04-08,NEW YORK TIMES,"All records produced in response to FOIA request #2022-6845 filed by Webster Law Office, PLLC."
2024-3203,2024-04-08,NEW YORK TIMES,"All records produced in response to FOIA request #2022-6061 filed by PETERSON, REBECCA."
2024-3204,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-5793 filed by FDAZILLA.
2024-3205,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-4750 filed by Bernstein Litowitz Berger & Grossmann LLP.
2024-3206,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-4701 filed by Moms Across America.
2024-3207,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-4490 filed by BLOOMBERG NEWS. All records produced in response to FOIA request #2022-4492 filed by BLOOMBERG NEWS. All records produced in response to FOIA request #2022-4604 filed by BLOOMBERG NEWS.
2024-3208,2024-04-08,NEW YORK TIMES,"All records produced in response to FOIA request #2022-4334 filed by ABC News, Sasha Pezenik."
2024-3209,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-4240 filed by Scherer Construction.
2024-3210,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-3734 filed by Claudia Guerrero.
2024-3211,2024-04-08,NEW YORK TIMES,All records produced in response to FOIA request #2022-3064 filed by BROWN & CROUPPEN PC.
2024-3212,2024-04-08,TORRENT PHARMA INC,"Fidaxomicin Tablets 200 mg, ANDA 208443 is approved dated January 16, 2024 however the approval package is not available on FDA site. We request Agency to provide the approval package for ANDA 208443. Thank you. "
2024-3213,2024-04-08,GCU,I would like to receive the premarket notification for K171120 Senhance Surgical System.
2024-3214,2024-04-08,Yale University,"A dataset that contains all FDA approved pharmaceuticals (NDAs, ANDAs, NMEs, Biologics) since 1938, including these drugs' application type, application number, product number, drug name, active ingredients, approval date, and sponsor name.   "
2024-3215,2024-04-08,INTERTEK,"Please share all files for NOL No. 329 - Dated 23 Feb 2024 - Shanghai SmartLoop Industrial Co., Ltd. - High-density polyethylene (HDPE) or Polypropylene (PP) - Provided the feedstock complies with all applicable authorizations: Articles (e.g., single layer trays, containers, crates, and clamshells) intended to contact raw fruits, vegetables, and shell eggs under Conditions of Use (COU) E through G. Articles (e.g., containers) etc"
2024-3216,2024-04-08,GCU,I would like to receive the premarket notification for K171294 	da Vinci X Surgical System.
2024-3217,2024-04-08,INTERTEK,"Please share all files for NOL No. 332 - Dated 05 March 2024 - Pashupati Group of Industries - Polypropylene (PP) - Provided the feedstock complies with all applicable authorizations: Articles (e.g., single layer trays, containers, crates, and clamshells) intended to contact raw fruits, vegetables, and shell eggs under Conditions of Use (COU) E through G. Articles (e.g., containers) intended for use with dry dietary supplements etc"
2024-3218,2024-04-08,GCU,I would like to receive the premarket notification for K131861 	DA VINCI SURGICAL SYSTEM.
2024-3219,2024-04-08,The International Companies,"Please let us know which companies are stating that IFPC is their FSVP importer and using our DUNS numbers: 04-350-4356, 07-941-1610, 08-137-3935, 11-900-2630, 08-000-0102, 61-885-3899, 04-825-7935, 36-116-0583, Thank you."
2024-3220,2024-04-08,"Mikart, LLC","Any Form 483 and EIR issued in association with any CDER inspection of Curia New York (33 Riverside Ave., Rensselaer, NY).  "
2024-3221,2024-04-08,Steptoe LLP,"A copy of the U.S. Food and Drug Administration’s (FDA) no objection letter (NOL) 90, along with supporting information and Agency correspondence regarding same, to include the original filing.  "
2024-3222,2024-04-08,KING & SPALDING,"via electronic delivery; copies of all 483s or other inspection-related documents involving the LGM Pharma Solutions, LLC Facility; FDA Establishment Number:  3017140477; DUNS 117549200 located at 17802 Gillette Avenue, Irvine California (CA) 92614, United States."
2024-3223,2024-04-08,DEERFIELD INSTITUTE,I am requesting copies of the complete detailed reports for the following individual case reports listed on the FAERS Public Dashboard:   23189672 22790143 23169117 22953188 23201938 22654649 20687150 22777080 22784310 23141420 23050277 23304244 22633700 23189729 23112127 22973606 22774028 23277969 23060886 23196516 21946502 23180940 23230179  etc
2024-3224,2024-04-08,Regenesis Biomedical,"I am looking for all records related to document number CPT230503, a report submitted to CDRH Office of Regulatory Programs, Division of Regulatory Programs 3 (Surveillance Support), Allegation of Regulatory Misconduct Team."
2024-3225,2024-04-08,"Sheehan & Associates, PC",Docket No. 82P-0030 and all comments or submissions in response to this petition.  
2024-3226,2024-04-08,COOLEY LLP,"Dear Records Manager:  Pursuant to the Freedom of Information Act, on behalf of our client Acadia Pharmaceuticals, Inc. (“Acadia”), we respectfully request copies of the following records related to Acadia’s supplemental new drug application for the treatment of hallucinations and delusions associated with dementia-related psychosis, submitted on June 3, 2020 under NDA 210793, Sequence 0043, and NDA 207318, Sequence 0111  etc"
2024-3227,2024-04-08,"Dishaw, Diane ",core/clinical study of Mentor Memory Gel Xtra Breast Implants. Mentor Worldwide LLC
2024-3228,2024-04-08,University of Pennsylvania Carey Law School,"I seek inspection records pertaining to an FDA Warning Letter (attached) dated April 20, 2017 (MARCS-CMS 523832) for:   Adolfo E. Kaplan, M.D.  Ref.: 17-HFD-45-04-01  Pulmonary and Sleep Center of the Valley 5300 North McColl Road, Suite 100 McAllen, Texas 78504  Additionally, can you provide any documented responses by Dr. Kaplan (Form 483 Response)? Specifically, I am looking for any documents related to Dr. Kaplan's failure to properly supervise and oversee the clinical trial.  I am a law student conducting research, for processing fee purposes.  "
2024-3229,2024-04-08,"Hockett, Jessica ","Pursuant to FOIA, please provide the following record:  1) A list of all participants (in person and via Zoom/phone call) at the February 3, 2020 MDIC - FDA Workshop: Advancing EUA IVD Products Toward Full Marketing Status "
2024-3230,2024-04-08,CNBC TV18,Form 483 for  1. Aurobindo - Eugia Steriles facility 2. Strides Pharma Chennai Facility 
2024-3231,2024-04-08,CNBC TV18,Form 483 for  Alkem Baddi facility  Issued 10 observations 
2024-3232,2024-04-08,Boehringer Ingelheim International Limited Liability Company Vietnam    Vietnam,"Please provide an unredacted version of the following documents issued during the review of the original NDA 206111 (SYNJARDY Tablets), which was submitted on August 4, 2014 and approved on August 26, 2015  "
2024-3233,2024-04-08,Shaun Mehra,"I am seeking the monthly tally adverse event reports for the period Jan 2023 to Mar 2024 for the following branded drugs: Ayvakit, Caryvkti, Casgevy, Daybue, Filspari, Lumryz, Ogsiveo, Orladeyo, Pombiliti/Opfolda, Syfovre, Vyjuvek, and Wakix. I would like to receive this in the .CSV format as soon as possible. Please also include also the events that have been reported to-date within April, as well. Thank you!"
2024-3234,2024-04-08,Sovish,"2024-2031, 2024-2121, 2024-2221, 2024-2242, 2024-2293, 2024-2344"
2024-3235,2024-04-08,Sovish,"2024-2345, 2024-2600, 2024-2660, 2024-2661, 2024-2813"
2024-3236,2024-04-08,Sovish,"Please share the Form 483 for Eugia Steriles (a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the company), situated at Parawada Mandal, Anakapalli District, Andhra Pradesh for the Human Drug inspection that happened from 28 March 2024 to 5 April 2024."
2024-3237,2024-04-08,Redica Systems,CVM/Animal Drugs & Feed 483 Request (US-based inspection)
2024-3238,2024-04-08,Redica Systems,CFSAN/Food & Cosmetics 483 Request (US-based inspection)
2024-3239,2024-04-08,Redica Systems,CVM/Animal Drugs & Feed 483 Request (International inspection)
2024-3240,2024-04-08,Siena college," I am requesting any and all records, documents, emails, correspondence, text messages, and material that includes, discusses, or mentions anything related to inspections of the Sturgis, MI Abbott Laboratories infant formula plant from January 1, 2020 to March 1, 2022. Also, I am requesting any and all records, documents, emails, correspondence, text messages, consumer complaints, and material that includes, discusses, or mentions anything related to illness or death of infants who consumed formula produced in this factory from January 1, 2020 to March 1, 2022 in the month prior to their deaths."
2024-3241,2024-04-08,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Marketing Denial Order and Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Fontem US, LLC dated April 8, 2022, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3242,2024-04-08,KING & SPALDING,"via electronic delivery; copies of all 483s or other inspection-related documents involving the LGM Pharma Solutions, LLC Facility; FDA Establishment Number: 3017140477; DUNS 117549200 located at 17802 Gillette Avenue, Irvine California (CA) 92614, United States."
2024-3243,2024-04-08,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to GRIPUM LLC dated September 08, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3244,2024-04-08,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Johnny Copper LLC dated September 07, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3245,2024-04-08,Kleinfeld Kaplan & Becker LLP," •	Copies of the Marketing Denial Order and Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to JUUL Labs, Inc. dated June 23, 2022, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3246,2024-04-08,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Logic Technology Development LLC dated October 26, 2022, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3247,2024-04-09,FDA NEWS,"Copies of Form 483s issued to the following CLINICAL INVESTIGATOR from December 1-31, 2023: "
2024-3248,2024-04-09,FDA NEWS,"(Rq#1) Copies of Form 483s issued to the following DEVICE companies from December 1-31, 2023"
2024-3249,2024-04-09,FDA NEWS,"(Rq#2) Copies of Form 483s issued to the following DEVICE companies from December 1-31, 2023"
2024-3250,2024-04-09,FDA NEWS,"(Rq#3) Copies of Form 483s issued to the following DEVICE companies from December 1-31, 2023"
2024-3251,2024-04-09,FDA NEWS,"(Rq#4) Copies of Form 483s issued to the following DEVICE companies from December 1-31, 2023"
2024-3252,2024-04-09,FDA NEWS,"(Rq#1) Copies of Form 483s issued to the following DRUG companies from December 1-31, 2023: "
2024-3253,2024-04-09,FDA NEWS,"(Rq#2) Copies of Form 483s issued to the following DRUG companies from December 1-31, 2023: "
2024-3254,2024-04-09,FDA NEWS,"(Rq#3) Copies of Form 483s issued to the following DRUG companies from December 1-31, 2023: "
2024-3255,2024-04-09,FDA NEWS,"Copies of Form 483s issued by the CBER Office in December 1-31, 2023."
2024-3256,2024-04-09,FDA NEWS,"Copies of Form 483s issued by the CDER Office in December 1-31, 2023."
2024-3257,2024-04-09,FDA NEWS,"Copies of Form 483s issued by the CDER Office in December 1-31, 2023."
2024-3258,2024-04-09,FDA NEWS,"Copies of Form 483s issued by the CDRH Office in December 1-31, 2023."
2024-3259,2024-04-09,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Paradigm Distribution dated September 15, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3260,2024-04-09,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Pop Vapor Co. LLC dated September 15, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3261,2024-04-09,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Pop Vapor Co., LLC dated September 16, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3262,2024-04-09,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to R.J. Reynolds Vapor Company dated January 24, 2023, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3263,2024-04-09,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to R.J. Reynolds Vapor Company dated March 17, 2023 related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3264,2024-04-09,Jonathan Good,"IMPELLA PUMP ADVERSE EVENTS, RECALLS, ETC"
2024-3265,2024-04-09,Regunalys LLC," FDA Inspections list, information request under Freedom of Information Act (FOIA). "
2024-3266,2024-04-09,Regunalys LLC,Freedom of Information (FOIA) request for FDA Inspection listing BIMO
2024-3267,2024-04-09,Regunalys LLC,Freedom of Information (FOIA) request for FDA Inspections OCP
2024-3268,2024-04-09,THE NEW YORK TIMES,"  483s from the last three inspections of the Abraham J. and Phyllis Katz Cord Blood Foundation (FEI 3006718574) located at 25001 Emery Road, Suite 150, Warrensville Heights, OH 44128. I am looking for the following three inspections: 1. Inspection #1217939, dated 9/15/2023 2. Inspection #1115313, dated 1/17/2020 3. Inspection #1051259, dated 3/22/2018"
2024-3269,2024-04-09,The State Newspaper,"We are seeking any compliance or inspection reports the FDA has for the Nephron Pharmaceuticals facilities at 4500 12th St. Extension, West Columbia, S.C., during the prescribed time period."
2024-3270,2024-04-09,Teva Pharmaceuticals Inc,Request for FDA Review of Supplement 3 (Efficacy - New Indication) for NDA 022315 (OZURDEX)
2024-3271,2024-04-09,Biocon Biologics Limited,"Requesting Agency to provide for BLA 761118/S-007 below listed documents from the FDA approval package 1) Chemistry Review(s) 2) Pharmacology Review(s) 3) Clinical Pharmacology Biopharmaceutics Review(s) 5) Device & Other Review(s) 6) Administrative Document(s) & Correspondence 7) summary review, as applicable."
2024-3272,2024-04-09,HOGAN LOVELLS US LLP,"Pursuant to the Freedom of Information Act, 5 U.S.C. Section 552, and the implementing regulations under 21 C.F.R. Part 20, I respectfully request a copy of the original request letter and all responsive information for File Number 2024-2143."
2024-3273,2024-04-09,FINANCIAL TIMES,"Form 483 with three observations following inspection at Eugia Steriles Private Limited injectable facility  in Parawada Mandal, Anakapalli District, Andhra Pradesh, India between March 28 2024 and 12 April 2024. "
2024-3274,2024-04-09,"Dragon's Mouth, LLC","Please provide the Form 483 associated with the FDA’s inspection of LGM Pharma Solutions, LLC's (FEI #: 3017140477) Irvine, CA facility that concluded on 3/1/2024. Facility address: 17802 Gillette Ave, Irvine, CA, 92614-6502."
2024-3275,2024-04-09,RGRD LLP,"Establishment Inspection Report (EIR) pertaining to the FDA's June-July 2021 inspection of Medtronic's Northridge, California facility and relating to Medtronic's MiniMed diabetes pump products.  "
2024-3276,2024-04-09,Redica Systems,CDER/Human Drugs 483 Request (US-based inspection)
2024-3277,2024-04-09,"Mize Law Firm, PLLC",Please provide all reports and testing related to Consumer Complaint #175421.   
2024-3278,2024-04-09,BLOOMBERG,"  Emails, text messages, letters, memos, mentioning or referring to GLP-1 drugs received from or sent to Kellogg Co., Kellanova, PepsiCo, Coca-Cola Co., Mondelez International, Kraft Heinz Co., JM Smucker Co., Campbell Soup Co., Tyson Foods Inc., Nestle SA, Hormel Foods Corp, General Mills, Conagra Brands (“the Companies”); or the Consumer Brand Association, the North American Meat Institute, the National Milk Producers Federation, or the International Dairy Foods Association (“the Interest Groups”)  ETC"
2024-3279,2024-04-09,Registrar Corp,"We request a spreadsheet detailing the number of foreign food facilities registered in each country as of April 2024 in which at least one facility is registered, to include the name of the country and the number of food facilities registered in that country."
2024-3280,2024-04-09,Globizz Corp.,"510(k) number: K223882_x000D_
Trade/Device Name: Narrowband UV Phototherapy Light Lamp (Model: HB-UPLL-01, HB-UPLL-02)_x000D_
Applicant: 	Shenzhen Honpal Optoelectronic Technology Co., Ltd. Room 505, Shenghui Building A,Xixiang Street,Baoan District Shenzhen,  CN 518126"
2024-3281,2024-04-09,Globizz Corp.,"510(k) Number	: K103540_x000D_
Device Name: PSORIA-LIGHT_x000D_
Applicant: PSORIA-SHIELD INC. 19404 PINE VALLEY DR._x000D_
ODESSA,  FL  33556"
2024-3282,2024-04-09,Globizz Corp.,"510(k) Number	K230076_x000D_
Device Name	Enhanced AURORA™ Medical Diode System, and related accessories_x000D_
Applicant: Psoria-Shield, Inc. 409 Mandeville St Utica,  NY  13502"
2024-3283,2024-04-09,Globizz Corp.,"510(k) Number: K181451_x000D_
Device Name: URETERO-RENO VIDEOSCOPE OLYMPUS URF-V3/V3R, URETERO-RENO FIBERSCOPE OLYMPUS URF-P7/P7R_x000D_
Applicant: Olympus Medical Systems Corp._x000D_
2951 Ishikawa-Cho Hachioji-Shi,  JP 192-8507"
2024-3284,2024-04-09,Globizz Corp.,"510(k) Number: K221683_x000D_
Device Name: CYSTO-NEPHRO VIDEOSCOPE (OLYMPUS CYF-V2), CYSTO-NEPHRO VIDEOSCOPE (OLYMPUS CYF-V2R), CYSTO-NEPHRO VIDEOSCOPE (OLYMPUS CYF-VH) and CYSTO-NEPHRO VIDEOSCOPE (OLYMPUS CYF-VHR)_x000D_
Applicant: Olympus Medical Systems Corporation"
2024-3285,2024-04-09,Mentor Worldwide LLC,"May I have materials related to any FDA inspections including any Form 483s over the past 4 years for Establishment Labs Holdings two plants in Costa Rica, Building B15 and 25 Coyol Free Zone, Alajuela Costa Rica"
2024-3286,2024-04-09,HOGAN LOVELLS US LLP,2024-1180
2024-3287,2024-04-09,"Deportation Research Clinic, Northwestern University",I write under the Freedom of Information Act to request all records indicating annual expenditures on the Public Affairs office of the Food and Drug Administration.  
2024-3288,2024-04-09,LUPIN PHARMACEUTICALS INC,"On behalf of Lupin Pharmaceutical Inc, I would like to request FDA Auditor Jolanna A Nortons's recent (2022-2024) FDA 483 observations."
2024-3289,2024-04-09,"McCarter & English, LLP","Disclosable portions of any and all documents and records concerning the Hickman Subcutaneous Port with Pre-Attached Catheter (K863305), including but not limited to memoranda, reports, summaries, briefing documents, presentations, slide decks, reviews, analyses, meeting minutes, notes, letters, emails, facsimiles, telephone logs, etc., from January 1, 1984 to present."
2024-3290,2024-04-09,"McCarter & English, LLP","Disclosable portions of any and all documents and records concerning the Power-Injectable Implantable Ports with ChronoFlex® Polyurethane Catheters (K150514) and the related pre-submission (Q150965), including but not limited to memoranda, reports, summaries, briefing documents, presentations, slide decks, reviews, analyses, meeting minutes, notes, letters, emails, facsimiles, telephone logs, etc., from January 1, 2013 to present."
2024-3291,2024-04-09,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to R.J. Reynolds Vapor Company dated October 12, 2023, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3292,2024-04-09,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Shenzhen Goldreams Technology Co., Ltd / New World Wholesale Inc. dated September 10, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3293,2024-04-09,"Kleinfeld, Kaplan & Becker LLP","•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to SV Packaging LLC dated September 10, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3294,2024-04-09,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to SWT Global Supply Inc. dated August 31, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3295,2024-04-10,"Kleinfeld, Kaplan & Becker LLP","•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to SWT Global Supply Inc. dated September 07, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3296,2024-04-10,"Kleinfeld, Kaplan & Becker LLP","•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Union Street Brands LLC dated September 15, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). _x000D_
_x000D_
"
2024-3297,2024-04-10,"Kleinfeld, Kaplan & Becker LLP","•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Vapetasia LLC dated September 16, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3298,2024-04-10,"Kleinfeld, Kaplan & Becker LLP"," •	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Vapor Unlimited LLC dated September 10, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3299,2024-04-10,"Kleinfeld, Kaplan & Becker LLP"," •	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Vaporized Inc. dated September 08, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3300,2024-04-10,"Kleinfeld, Kaplan & Becker LLP"," •	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Wages & White Lion Investments LLC dba Triton Distribution dated September 14, 2021, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3301,2024-04-10,"Kleinfeld, Kaplan & Becker LLP","•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to SWT Global Supply Inc. dated May 12, 2023, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3303,2024-04-10,Leucine Inc.,"Dear Madam/Sir,   I am the Head of Strategy at Leucine, an AI platform to help pharmaceutical manufacturers stay compliant with the cGMP guidelines. I am writing this on behalf of my company, Leucine,Inc. to access Form 483 issued by Center for Drug Evaluation and Research (CDER) to Purisys LLC with FEI number 3012286613 at its facility located in 1550 Olympic Dr, Athens, GA 30601-1602, United States   "
2024-3304,2024-04-10,QYOBO GmbH,"Please provide the following 1 inspection-related document in electronic PDF format: The 483 (in electronic format) for: FEI: 3004134577 Inspection date: 09/12/2023 Firm Name: Fournier Laboratories Ireland, Ltd. (Abbvie Cork)"
2024-3305,2024-04-10,Jeffrey Brownlee," All communications, documents, emails, and memos that were used in the planning of and creation of a recent study by the National Academies of Sciences, Engineering, and Medicine titled “The Role of Seafood Consumption in Child Growth and Development.” "
2024-3306,2024-04-10,"Lewis & Harrison, LLC",All available documentation related to Food Contact Notification (FCN) No. 111 including but not limited to the Environmental Assessment. 
2024-3307,2024-04-10,"Gianaris Trial Lawyers, LLC","1.	Any records, reports, or correspondence related to Genetic Design, Inc. 2.	Any studies, research papers, or findings conducted by or submitted to the FDA concerning Genetic Design, Inc. 3.	Any regulatory documents, guidelines, or policies relevant to Genetic Design, Inc. 4.	Any communications, memos, or directives issued internally or externally regarding Genetic Design, Inc. 5.	Any documents or information relating to the testing and laboratory procedures of Genetic Design, Inc. 6.	Any inspections or reports relating to Genetic Design, Inc.  "
2024-3308,2024-04-10,PLEXUS CORP,"Inspection records, including the 483 and EIR for the following facilities and dates: - Hologic Inc 10210 Genetic Center Drive, San Diego California 92121; Date of Inspection conclusion: October 14, 2022 - Avacen Inc 2365 Camino Vida Roble Ste C, Carlsbad CA 92011;  ETC"
2024-3309,2024-04-10,Jennifer Sexsmith,"Seeking Freedom of Information Summary for NADA 132-338, GENTOCIN Topical Spray, which was approved by the FDA CVM on January 7, 1985. Company was Schering-Plough Animal Health. "
2024-3310,2024-04-10,Sovish,"PLease share the copy of the Form 483 for Crown Laboratories, Inc. Inspection ended on Apr 08, 2016 for the site Johnson City, United States and fei id 1019820. The inspection was related to Human Drugs."
2024-3311,2024-04-10,GE Healthcare,"BLA 761139,  clinical review in regard to NCT03529110 Enhertu (fam-trastuzumab deruxtecan-nxki) 100 mg lyophilized powder for solution for intravenous injection.  Please provide the Clinical Review."
2024-3312,2024-04-10,Smith & Schwartzstein LLC,"Please provide records relate to health inspections including dates, times, inspector name and findings for the business Kontos Foods Inc. and any related food processing facilities of Kontos Foods Inc. with the primary business headquarters located at  100 6th Ave, Paterson, NJ 07524. "
2024-3313,2024-04-10,Smith & Schwartzstein LLC,"Please provide records related to any and all health inspections, the dates of such inspections, time, name of inspector and any findings or related complaints for KB Foods Enterprises Inc. located at 43 E 6th St, Paterson, NJ 07524.  Please provide any inspection records that relate to food preparation, food handling or cleanliness of the facility and any violations. "
2024-3314,2024-04-10,SIRI & GLIMSTAD LLP,"All clinical trial documents relied upon by FDA to approve the use of Pfizer/ Octapharma’s Immune Globulin Intravenous (Human)-ifas 10% (Panzyga) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP), including but not limited to:_x000D_
(1)	BLA Efficacy Supplement_x000D_
(2)	Final Clinical Study Report (CSR) for Study NGAM-08 (NCT02638207) ETC_x000D_
 "
2024-3315,2024-04-10,Jakob and Partners,We are requesting the feedback to control number 2024-931 concerning the ANDA 210317 for Octreotide Acetate.
2024-3316,2024-04-10,Redica Systems,CBER/Biologics 483 Request (US-based inspection)
2024-3317,2024-04-10,"Corbin Clinical Resources, LLC","I am writing to request a complete, non-redacted copy of the original Premarket Notification K160414 for the Corbin Clinical Resources, LLC PrecisionPoint Biopsy Needle Guide.  "
2024-3318,2024-04-10,"Corbin Clinical Resources, LLC","I am writing to request a complete, non-redacted copy of the original Premarket Notification K160423 for the Corbin Clinical Resources, LLC Perineologic Access Needle.  Corbin Clinical has misplaced their copy of the original submission for K160423, which was logged in by FDA in February 2016.  "
2024-3319,2024-04-10,BEVERIDGE & DIAMOND,"Pursuant to the Freedom of Information Act (FOIA), 5 U.S.C. § 552, as amended, and the regulations promulgated by the U.S. Food and Drug Administration (“FDA”) in 21 C.F.R. Part 20, I hereby request a report of all FOIA requests filed with FDA’s Center for Food Safety and Applied Nutrition (“CFSAN”), including related offices, from January 1, 2024 through March 31, 2024.  "
2024-3320,2024-04-10,13782247 Canada Inc.,"Requested to provide PMA dossier of P210025 as redacted copy, if allowable under certain provisions."
2024-3321,2024-04-10,13782247 Canada Inc.,"   I therefore request to provide name of all Indian Labs submitted unreliable data  OR  If providing all lab name is not possible, kindly clarify that whether GLR Laboratories Private Limited, Chennai INDIA is in the list or not as unreliable data submitter."
2024-3322,2024-04-10,FOIA Professional Services,"Please provide copies of the disclosable portions of the Center for Tobacco Products (CTP), Office of Science, reviewer’s summaries, TPLs, and any associated supporting CTP memoranda or reviewer guides for the following STNs: SE0018473-SE0018476, SE0018478-SE00018479, SE0018482-SE0018484, SE0018486  Please provide the documents electronically if possible."
2024-3323,2024-04-10,FOIA Professional Services,"Please provide copies of the disclosable portions of the Center for Tobacco Products (CTP), Office of Science, reviewer’s summaries, TPLs, and any associated supporting CTP memoranda or reviewer guides for the following STNs: EX0002486, EX0002847, EX0003019-EX0003022, EX0003025-EX0003027, EX0003029  Please provide the documents electronically if possible."
2024-3324,2024-04-10,FOIA Professional Services,"Please provide copies of the disclosable portions of the Center for Tobacco Products (CTP), Office of Science, reviewer’s summaries, TPLs, and any associated supporting CTP memoranda or reviewer guides for the following STNs: EX0002668  Please provide the documents electronically if possible."
2024-3325,2024-04-10,FOIA Professional Services,"Please provide copies of the disclosable portions of the Center for Tobacco Products (CTP), Office of Science, reviewer’s summaries, TPLs, and any associated supporting CTP memoranda or reviewer guides for the following STNs: EX0002987  Please provide the documents electronically if possible."
2024-3326,2024-04-10,FOIA Professional Services,"Please provide copies of the disclosable portions of the Center for Tobacco Products (CTP), Office of Science, reviewer’s summaries, TPLs, and any associated supporting CTP memoranda or reviewer guides for the following STNs: EX0002816  Please provide the documents electronically if possible."
2024-3327,2024-04-10,FOIA Professional Services,"Please provide the disclosable portions of any correspondence or letters between FDA and Outlaw Dip Co. during the period 1/1/23 – 3/31/24 regarding the use of Nic-safe™, Nixamide, or Zero Nicotine Nixamide in products etc"
2024-3328,2024-04-10,FOIA Professional Services,"Please provide a list in Microsoft Excel format of all exemption from substantial equivalence (SE) market orders issued from 11/29/23 to 4/9/24. Specifically, for each market order included in this list provide the manufacturer name, product name(s), FDA receipt date, STN number(s), product category, and date issued.  Please provide the documents electronically if possible"
2024-3329,2024-04-10,FOIA Professional Services,"Please provide a list in Microsoft Excel format of all substantial equivalence (SE) market orders issued from 11/29/23 to 4/9/24. Specifically, for each market order included in this list provide the manufacturer name, product name(s), FDA receipt date, STN number(s), product category, and date issued.  "
2024-3330,2024-04-10,FOIA Professional Services,"I am requesting copies of the supplemental BLA Acceptance letter/memo for the following:  onasemnogene abeparvovec-xioi sBLA, submitted on 09/11/20  STN = BL 125694/129  Axicabtagene ciloleucel sBLA, submitted on 09/30/21  STN = BL 125643/394   Please provide the documents electronically if possible."
2024-3331,2024-04-10,Will Bekker,"I am seeking Premarket Tobacco Product Application materials, including the initial application filing, together with any supplements or amendments thereto, and any notices or approvals issued in respect thereof, for the following companies: (i) Pixotine Products, Inc. and (ii) Zippix Nicotine Toothpicks.     I am seeking the PMTA materials for such companies granted in respect of certain nicotine toothpick products."
2024-3332,2024-04-10,"Majmudar, Maulik ",Looking for Post-Marketing Real World Study Results/ Submissions for: Cologuard Stool DNA-Based Colorectal Cancer Screening Test.  Details of the various Reports are on this FDA link:  https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?t_id=664987&c_id=5693   
2024-3333,2024-04-10,"Aylstock, Witkin, Kreis & Overhotlz, PLLC","Copies of all written communications, including all attachments, relating to the citizen petition submitted to the U.S. Food & Drug Administration (“FDA”) in February 2007, requesting that phenylephrine bitartrate in effervescent dosage form be generally recognized as safe and effective etc"
2024-3334,2024-04-10,Pertento Partners,Please could I get details on the number of Investigational New Drug (IND) applications there have been by month for the requested periods. Please could this be split for human drug products and biologics by month. Please do not include animal drugs or any drugs/biologics that are not intended for use on humans. Thank you
2024-3335,2024-04-10,"Waters, Kraus, Paul, & Siegel","Dear FOIA Officer,  I am requesting copies (if available) of The Rose Sheet - Toiletries, Fragrances, and Skin Care newsletter. Specifically, I am requesting copies of this newsletter published between 01/01/1990 and 12/31/1999."
2024-3336,2024-04-10,Cogency Global Inc,"  2024-1204, 2024-1623, 2024-1624, 2024-1628, and 2024-2003 "
2024-3337,2024-04-10,Cogency Global Inc,2024-1362
2024-3338,2024-04-10,Cogency Global Inc,2024-1361
2024-3339,2024-04-10,"Dr. Reddy's Laboratories, Inc.","Dear Sir/Madam,  We would like to request the Approval Letter for ERIBULIN MESYLATE 1MG/2ML (0.5mg/mL) approved on April 5, 2024"
2024-3340,2024-04-10,RBC CAPITAL MARKETS,I am looking for documents related to Applied Therapeutics' NDA filing on govorestat (AT-007).  
2024-3341,2024-04-10,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Syfovre (branded name / marketed by Apellis Pharmaceutical) or pegcetacoplan (generic name) between April 3, 2024 and April 10, 2024.  Please provide the documents electronically if possible."
2024-3342,2024-04-10,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for ELEVIDYS (branded name / marketed by Sarepta Therapeutics, Inc.) or delandistrogene moxeparvovec-rokl (generic name) between April 3, 2024 and April 10, 2024.   Please provide the documents electronically if possible."
2024-3343,2024-04-10,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Wegovy (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between April 3, 2024 and April 10, 2024.  Please provide the documents electronically if possible."
2024-3344,2024-04-10,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Ozempic  (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between April 3, 2024 and April 10, 2024.  Please provide the documents electronically if possible."
2024-3345,2024-04-10,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Zepbound (branded name / marketed by Lilly) or tirzepatide (generic name) between April 3, 2024 and April 10, 2024.  Please provide the documents electronically if possible."
2024-3346,2024-04-10,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Mounjaro (branded name / marketed by  Lilly) or tirzepatide (generic name) between April 3, 2024 and April 10, 2024.  Please provide the documents electronically if possible."
2024-3347,2024-04-10,FOIA Professional Services,"Please provide a copy of the disclosable portions of the orphan drug exclusivity memorandum(a) (or equivalent decisional documents if no exclusivity memoranda exist) for Radicava ORS (edaraone) oral suspension (NDA 215446, held by Mitsubishi Tanabe Pharma Corporation) approved May 12, 2022, for the treatment of amyotrophic lateral sclerosis (ALS).  Please provide the documents electronically if possible."
2024-3348,2024-04-10,FOIA Professional Services," Please provide copies of the disclosable portions of the Orphan Drug Designation request(s), reviews, exclusivity documents, and related internal and external correspondence for Radicava ORS (edaraone) oral suspension (NDA 215446, held by Mitsubishi Tanabe Pharma Corporation) approved May 12, 2022, for the treatment of amyotrophic lateral sclerosis (ALS).  Please provide the documents electronically if possible."
2024-3350,2024-04-11,COGENCY GLOBAL INC., Case ID Suspect Product Names Manufacturer Control Number 14266705 14842969 14844458 14895883 14974758 15335776 15473032 15491085 15606329 15683560 15736432 15920746 Keytruda;Naproxen etc
2024-3351,2024-04-11,"Zymergi, Inc.",Please provide the pdfs of Drug & Device 483s previously released to FDA News for the above 2 month time period 11.01.2023 thru 12.31.2023.
2024-3352,2024-04-11,"Parcus Medical, L.L.C.",Requesting the 510(k) Summary and clearance letter for K091018 for the Arthrex Biowire. 
2024-3353,2024-04-11,Arnold & Porter Kaye Scholer LLP,"Pursuant to the Freedom of Information Act (FOIA), 5 U.S.C. § 522 and the Food and Drug Administration’s Freedom of Information Regulations, 21 C.F.R. Part 20, I hereby request a copy of all labeling submitted to or otherwise shared with FDA for the Eroxon non-medicated topical formulation for treatment of erectile dysfunction (i.e., the product related to classification order DEN220078).  "
2024-3354,2024-04-11,ICON Clinical Research UK,Adverse event reports (MedWatch forms) in electronic format e.g. pdf for the following FAERS Case IDs: 21791563; 21199418; 20858694; 20645838; 14982227; 14958293; 14304766; 11770236; 10381884; 7664646 
2024-3355,2024-04-11,Nupharm Regulatory Services,"Requesting Arizona Nutritional Supplements Softgel manufacturing facility 483 and/or EIR reports for location 14700 NW 60th Ave, Miami Lakes, FL 33014.  Address may also be listed as 14620 NW 60th Ave, Hialeah, FL 33014.   "
2024-3356,2024-04-11,Andrew Sheinfeld,"I am an investment professional requesting information under the Freedom of Information Act.  I am making a request for copies of any form 483s, warning letters, import alerts issued to Cipla ltd. From 3/1/2024 to 4/10/2024 (or the latest date available). _x000D_
_x000D_
Thank you!"
2024-3357,2024-04-11,"Dr. Reddy's Laboratories, Inc.","Dear Sir/Madam,  I would like to request the complete Summary Basis of Approval of Supplement 9 (NDA 209637/S-009) Efficacy-New Dosing Regimen of OZEMPIC (Semaglutide Injection, 2 mg/1.5 mL (1.34 mg/mL) and 4 mg/3 mL (1.34 mg/mL), 8mg/3mL (2.68mg/mL)) approved on March 28, 2022, detailed information of application is as below,  Active Ingredient: SEMAGLUTIDE Proprietary Name: OZEMPIC Dosage Form;  etc "
2024-3358,2024-04-11,THE WASHINGTON POST,"Dear FOIA officer:  This is a request under the U.S. Freedom of Information Act for a record of all employees of the FDA at the end of each calendar year from 2014 through 2023, including but not limited to first name, last name, middle initial, division (i.e. CDER, CTP, etc.) and job title as published online here: https://directory.psc.gov/hhsdir/eeQ.asp.   "
2024-3359,2024-04-11,"Orca1 Digital Intelligence, LLC","2024-2721, 2024-2723, 2024-2729, 2023-3268, 2023-3273 "
2024-3360,2024-04-11,"Orca1 Digital Intelligence, LLC","2023-3274, 2023-3367, 2023-3366, 2023-3370, 2023-3375 "
2024-3361,2024-04-11,"Orca1 Digital Intelligence, LLC","2023-3372, 2023-3381, 2023-3364, 2023-5232, 2023-5237 "
2024-3362,2024-04-11,"Orca1 Digital Intelligence, LLC","2023-3090, 2023-3758, 2023-3763, 2023-5776, 2023-5806 "
2024-3363,2024-04-11,"Orca1 Digital Intelligence, LLC","2023-5807, 2023-5539, 2023-5541, 2023-5387, 2023-5441 "
2024-3364,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and the National Association of Boards of Pharmacy mentioning “semaglutide” or “tirzepatide” from January 1, 2022 – April 5, 2024. "
2024-3365,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and any State Board of Pharmacy mentioning “semaglutide” or “tirzepatide” from January 1, 2022 – April 5, 2024. "
2024-3366,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and Novo Nordisk mentioning compounding and “semaglutide” from January 1, 2022 – April 5, 2024. "
2024-3367,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and Eli Lilly mentioning compounding and “tirzepatide” from January 1, 2022 – April 5, 2024. "
2024-3368,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and Eli Lilly mentioning compounding and “retatrutide” from January 1, 2022 – April 1, 2024. "
2024-3369,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and any third-party mentioning “FarmaKeio” from January 1, 2022 – April 5, 2024."
2024-3370,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and the National Association of Boards of Pharmacy mentioning the bulk drug substance “AOD-9604” from January 1, 2022 – April 5, 2024."
2024-3371,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and any State Board of Pharmacy mentioning the bulk drug substance “AOD-9604” from January 1, 2022 – April 5, 2024."
2024-3372,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and the National Association of Boards of Pharmacy mentioning the bulk drug substance “CJC-1295” from January 1, 2022 – April 5, 2024. "
2024-3373,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and any State Board of Pharmacy mentioning the bulk drug substance “CJC-1295” from January 1, 2022 – April 5, 2024."
2024-3374,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and any State Board of Pharmacy mentioning the bulk drug substance “ipamorelin acetate (“ipamorelin”)” from January 1, 2022 – April 5, 2024."
2024-3375,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and the National Association of Boards of Pharmacy mentioning the bulk drug substance “ipamorelin acetate (“ipamorelin”)” from January 1, 2022 – April 5, 2024."
2024-3376,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and the National Association of Boards of Pharmacy mentioning the bulk drug substance Thymosin Alpha-1 (“Ta1”) from January 1, 2022 – April 5, 2024.   "
2024-3377,2024-04-11,Baker & Hostetler LLP,"Any and all communications between the Agency and any State Board of Pharmacy mentioning the bulk drug substance Thymosin Alpha-1 (“Ta1”) from January 1, 2022 – April 5, 2024.  "
2024-3378,2024-04-11,"Hyman, Phelps & McNamara, P.C.","A copy of the clinical superiority memo for purposes of Orphan Drug Exclusivity for RADICAVA ORS, approved on May 12, 2022, under NDA 215446 for the treatment of amyotrophic lateral sclerosis."
2024-3379,2024-04-11,"Hyman, Phelps & McNamara, P.C.","A copy of the letter dated February 23, 2024, from Sandra S. Retzky, D.O., J.D., M.P.H., Director, Office of Orphan Products Development, to Rare Disease Therapeutics, Inc. concerning Xromi (hydroxyurea) oral solution, NDA 216593."
2024-3380,2024-04-11,Jordi Zamarreño,"Available toxicological data on following susbtances:  MK-2866 (Ostarine, Enobosarm); CAS: 841205-47-8 RU-58841 (PSK-3841, HMR 3841)); CAS: 154992-24-2 MK-677 (Ibutamoren); CAS: 159634-47-6"
2024-3381,2024-04-11,FFM,"Request for the following documents from Tepezza (teprotumumab-trbw) IND 112952, BLA 761143 and BLA 761143/S-023: Protocol submitted for PMR 3780-8 (Aug 2020) and any subsequent amendments, materials documenting communications regarding the inclusion of language to describe hearing loss and/or tinnitus in patients treated with Tepezza, FDA Adverse Event Reporting System (FAERS) reports on Tepezza and FDA Adverse Event Reporting System (FAERS) reports on Tepezza."
2024-3382,2024-04-11,Jessica James,"Phenergan by the IV-push (Wyeth) - all versions of updates to labeling and any FDA requirements for post approval studies, recalls, dear doctor letters, label changes, warnings of the IV use.   List of reported sides affects and dates. "
2024-3383,2024-04-12,"Kuhnil Pharmaceuticals Co., LTD","Dear Sir/Madam,  We, Kuhnil Pharmaceuticals Co. Ltd, hereby solemnly and sincerely request redacted FDA’s review documents for the following ANDA covering the Bioequivalence disciplines via email.   Please see the attached request letter for more detailed description of the requested records.   Sincerely,  Jo Eun Chung  Business Development Division / Global RA Team  Kuhnil Pharmaceuticals Co., Ltd.  "
2024-3384,2024-04-12,"Kuhnil Pharmaceuticals Co., LTD","Dear Sir/Madam,  We, Kuhnil Pharmaceuticals Co. Ltd, hereby solemnly and sincerely request redacted FDA’s review documents for the following ANDA covering the Bioequivalence disciplines via email.   Please see the attached request letter for more detailed description of the requested records.   Sincerely,  Jo Eun Chung  Business Development Division / Global RA Team  Kuhnil Pharmaceuticals Co., Ltd.  "
2024-3385,2024-04-12,Encube Ethicals,"Please provide us with complete assessment report pertaining to ANDA number 212387 for the drug product ""Tacrolimus Ointment 0.1%"""
2024-3386,2024-04-12,Encube Ethicals,"Please provide us with complete assessment report pertaining ANDA number 212984 for the drug product ""Testosterone Gel, 1%"""
2024-3387,2024-04-12,Solve Consulting International Pty Ltd,A copy of Supplement 43 dated 1998 for the N0020216
2024-3388,2024-04-12,"Schreiber Foods, Inc.","Would like data pertaining to all instances in which a Schreiber Foods entity was identified on the FSMA Foreign Supplier Verification Program (FSVP) transmission as the ""FSVP Importer."" Please see the attached request letter. Thank you."
2024-3389,2024-04-12,Industry Dive,"I am looking for records on FDA inspection reports related to Philips Respironics, or Respironics LLC between 2020 and the present. The documents I am looking for include Form 483s, warning letters, and Philips' responses to the 483s and warning letters.  The documents include:  -A warning letter sent to Philips Respironics from an inspection of its Murrysville, Penn. facility in 2021. etc"
2024-3390,2024-04-12,Lachman Consultants Inc.,Drug summary basis of approval for SUPPL-38 to NDA 007513 w 
2024-3391,2024-04-12,Zydus Pharmaceuticals USA Inc,Please provide Summary Basis of Approval of ATORVASTATIN CALCIUM TABLET ORAL	EQ 10MG BASE; EQ 20MG BASE;  ETC
2024-3392,2024-04-12,Zydus Pharmaceuticals USA Inc,Please provide Summary Basis of Approval of CARVEDILOL TABLET	ORAL 3.125MG;6.25MG;12.5MG;25MG for the followimg mentioned Applicant Holders:  1. AUROBINDO PHARMA LTD- A078332 2. BEXIMCO PHARMACEUTICALS USA INC- A078384 3.CHARTWELL MOLECULAR HOLDINGS LLC-A077474 4.DR REDDYS LABORATORIES LTD-	 ETC
2024-3393,2024-04-12,Chorus,I would like to request a copy of the DEN230007 De Novo request for classification of the LightStrike+ and the Decision Summary for DEN230007.
2024-3394,2024-04-12,Keller and Heckman LLP,"Freedom of Information Act (FOIA) Request for Premarket Tobacco Product Application (PMTA) Marketing Denial Orders (MDO) Related to SMOK, Suorin, and blu PLUS+ E-Cigarette Products. "
2024-3395,2024-04-12,Regulatory,"FDA review of BLA 761139/S-028, approved April 5, 2024."
2024-3396,2024-04-12,Cogency Global Inc,2024-2898
2024-3397,2024-04-12,Cogency Global Inc,2024-2644
2024-3398,2024-04-12,"MERCK & CO., INC.",Medwatch Reports for 12 cases:  22588774 22596080 22601729 22606186 22625624 22637227 22646481 22691592 22917172 22677216 22677512 22692084 
2024-3399,2024-04-12,Cooper Surgical,"De Novo Fetal Pillow (DEN150053). FP-010.  CooperSurgical is submitting a formal request for records related to the De Novo for Fetal Pillow DEN150053. CooperSurgical is requesting any and all documents, correspondence, and communications related to the De Novo for Fetal Pillow. "
2024-3400,2024-04-12,"Dr. Reddy's Laboratories, Inc.","  We would like to request the Drug Substance Eribulin Mesylate DMF review Summary Basis of DMF adequacy for the drug substance used for ERIBULIN MESYLATE 1MG/2ML (0.5mg/mL) approved on April 5, 2024 "
2024-3401,2024-04-12,Gregory Stevens,I am seeking an electronic file in CVS (or XLS nessesary) format that contains the entire `Establishment Registration & Device Listing´ with the following search criteria:  Establishment or Trade Name:  ALL Owner/Operator Name:  ALL Proprietary Name:  ALL Product Code:  ALL Establishment State (U.S.):  ALL Registration or FEI Number:  ALL Owner/Operator Number:  ALL Classification Device Name: ETC
2024-3402,2024-04-12,"Dr. Reddy's Laboratories, Inc."," We would like to request the Summary Basis of Approval of CMC (Chemistry, Manufacture and Control) section for ERIBULIN MESYLATE 1MG/2ML (0.5mg/mL) approved on April 5, 2024, detailed information of application is as below,  Active Ingredient: ERIBULIN MESYLATE Proprietary Name: ERIBULIN MESYLATE  Dosage Form; Route of Administration: SOLUTION; INTRAVENOUS ETC"
2024-3403,2024-04-12,TSG Consulting,  US FDA Food Contact Notifications – FCN 972   
2024-3404,2024-04-12,TSG Consulting, US FDA Food Contact Notifications – FCN 16   
2024-3405,2024-04-12,TSG Consulting,Re: FOIA Request – US FDA Food Contact Notifications – FCN 24   
2024-3406,2024-04-12,"Tusa, Nicolas ","Patheon Biologics St. Louis, MO site FDA Warning Letter"
2024-3407,2024-04-12,Lighthouse Reports,"Please provide documents released for all previous FOIAs that included the word or “V-Fluence” OR ""Jay Byrne"" OR ""White House Writers Group"" OR ""Bonus Eventus"" OR ""Joshua Gilder"".  "
2024-3408,2024-04-12,Hogan Lovells,"Pursuant to the Freedom of Information Act, 5 U.S.C. § 552, and the implementing regulations under 21 CFR Part 20, I hereby request a copy of all documents related to the color additive petition submitted by Phytolon Ltd., proposing that the color additive regulations be amended to provide for the safe use of beetroot red in various foods (Docket No. FDA-2024-C-1085), including but not limited to all internal agency memoranda, correspondence, and memoranda of meetings regarding this petition. "
2024-3409,2024-04-12,Functional Government Initiative,"FGI requests from the Food and Drug Administration, Center for Tobacco Products, the following records related to Kathy Crosby, former Director of the Office of Health Communication and Education: •	Any requests for recusal and notifications of future employment discussion filed by Ms. Crosby prior to departing CTP. •	Any post-government memos related to Ms. Crosby’s departure from CTP. _x000D_
_x000D_
Please see the request letter for more details."
2024-3410,2024-04-12,BLOOMBERG NEWS,"I am requesting the FDA form 483 from the agency's inspection of Sun Pharmaceutical's Dadra facility that ended Dec. 15, 2023. Thank you "
2024-3411,2024-04-12,"Rodriguez, David ","Hello,  I am writing to request copies any inspection reports, any filed complaints or violations, and any recalls regarding the company LSG Sky Chefs Inc. Their addresses include:  1. 3500 NW 24th St, Miami, FL 33142 2. 650 SW 34th St. Fort Lauderdale, FL 33315   "
2024-3412,2024-04-12,Yale University,"I am requesting a dataset that contains all FDA approved pharmaceutical products (INDs, NDAs, ANDAs, Biologics, OTC, etc.) since 1938,"
2024-3413,2024-04-12,BLOOMBERG NEWS,"All Form 483s issued between January 1, 2015 and April 11, 2024, for the facility with_x000D_
FDA Establishment Number 3007162768, with a Firm Name of Johnson and Johnson_x000D_
(Pty) Ltd, with an address of approximately 241 Main Rd, Cape Town, Western Cape_x000D_
7945, South Africa."
2024-3414,2024-04-12,"Stewart, Kristen M","The FDA audit report for Integra Lifesciences Holdings Corporation that was submitted by the company on/before March 31, 2024. "
2024-3415,2024-04-12,Redica Systems,CDER/Human Drugs 483 Request (US-based inspection)
2024-3416,2024-04-12,Redica Systems,CBER/Biologics 483 Request (US-based inspection)
2024-3417,2024-04-12,Redica Systems,CDRH/Medical Devices & Rad Health 483 Request (US-based inspection)
2024-3418,2024-04-12,Redica Systems,CDER/Human Drugs 483 Request (International inspection)
2024-3419,2024-04-12,Redica Systems,CDRH/Medical Devices & Rad Health 483 Request (International inspection)
2024-3420,2024-04-12,"CSL Plasma, Inc.","Requesting a copy of the FDA EIR from an FDA Inspection that was conducted in our CSL Plasma, Inc. -Tempe 048, AZ location (2077744). January 30, 2018-February 2, 2018."
2024-3421,2024-04-12,Point72 Asset Management,I am an investment professional and this is a request under the Freedom of Information Act. I am looking for records related to up to date information on the Adverse Event Reporting related to Xdemvy (Lotilaner .25% produced by Tarsus). Thank you in advance!
2024-3422,2024-04-12,COGENCY GLOBAL INC.,2024-2042 2024-2043
2024-3423,2024-04-12,"magoc, timothy ",inspection records from the audit of: Greco Gas Inc  450 Grantham St Tarentum Pa 15084
2024-3424,2024-04-12,"OnderLaw, LLC","1.	All adverse event reports, supporting documentation, and investigative findings involving Mead Johnson and/or Reckitt brand powdered infant or baby formulas and bacterial contamination, including but not limited to Cronobacter Sakazakii or Enterobacter Cloacae, from 1994 to present;  2.	All consumer complaints, supporting documentation, and investigative findings involving Mead Johnson and/or Reckitt brand powdered infant or baby formulas and bacterial contamination, including but not limited to Cronobacter Sakazakii or Enterobacter Cloacae, from 1994 to present; etc"
2024-3425,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Abdoo, Mark A  (Mark.Abdoo@FDA.HHS.GOV), ASSOC COMM FOR GLOBAL PLCY. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  etc"
2024-3426,2024-04-12,The Daily Signal,"From the month of March 2024, all of the following records from Akbari, Asim A (Asim.Akbari@FDA.HHS.GOV), DIR, DIV OF ETHICS & INTEGR. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3427,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Cassens, Barbara J (Barbara.Cassens@FDA.HHS.GOV), DIR, OFFICE OF PARTNERSHIPS. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3428,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Ibarra Pratt, Elenita Y (Elenita.IbarraPratt@FDA.HHS.GOV), DEPUTY DIRECTOR FOR REGULAT. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3429,2024-04-12,The Daily Signal,"From the month of March 2024, all of the following records from Mital, Michele (Michele.Mital@FDA.HHS.GOV), DEPUTY DIRECTOR, CTP. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3430,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Raza, Mark J (Mark.Raza@FDA.HHS.GOV), DEP GEN COUN & CHIEF COUN. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts etc"
2024-3431,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Roth, Lauren K (Lauren.Roth@FDA.HHS.GOV), ASSOC COMMISSIONER FOR POLICY. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3432,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Trzeciak, Kimberlee R (Kimberlee.Trzeciak@FDA.HHS.GOV), ASSOCIATE COMMISSIONER. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3433,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Velez, Megan (Megan.Velez@FDA.HHS.GOV DIR), OFC OF REGS & PLCY. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3434,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Alexander, Nicholas D  (Nicholas.Alexander@FDA.HHS.GOV), SPV. INTERGOVERNMENTAL AFFA. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3435,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Beardsley, Sara E (Sara.Beardsley@FDA.HHS.GOV), ATTORNEY-ADVISER. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. etc"
2024-3436,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Benton, Sandra J (Sandra.Benton@FDA.HHS.GOV), SENIOR POLICY COORDINATOR. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3437,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Desta, Abiy B  (Abiy.Desta@FDA.HHS.GOV), OFC OF POLICY. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3438,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Dewitt, Susan J (Susan.Dewitt@FDA.HHS.GOV), SUPERVISORY POLICY ANALYST. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3439,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Farizo, Karen M (Karen.Farizo@FDA.HHS.GOV), MEDICAL OFFICER. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts etc"
2024-3440,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Finn, Theresa M (Theresa.Finn@FDA.HHS.GOV), OFFICE OF VACCINES RESEARCH AND REVIEW. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts etc"
2024-3441,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Goldberg, Rebecca L (Rebecca.Goldberg@FDA.HHS.GOV), ATTORNEY-ADVISER. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3442,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Kim, Sylvia Y (Sylvia.Kim@FDA.HHS.GOV), SENIOR ADVISOR FOR POLICY. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts."
2024-3443,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Minor, Travis J (Travis.Minor@FDA.HHS.GOV), SENIOR POLICY ADVISOR. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3444,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Nalubola, Padmashri  (Ritu.Nalubola@FDA.HHS.GOV), DEP DIR, OPLIA. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3445,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Paulos, Aubrie L (Lauren.Paulos@FDA.HHS.GOV), SUPERVISORY CONGRESSIONAL A. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3446,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Pratt, Robert D (Douglas.Pratt@FDA.HHS.GOV), SUPERVISORY MEDICAL OFFICER All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts etc"
2024-3447,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Rawson, Uta O (Uta.Rawson@FDA.HHS.GOV), ATTORNEY-ADVISER. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3448,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Sundlof, Thomas M (Thomas.Sundlof@FDA.HHS.GOV), ATTORNEY-ADVISER. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3449,2024-04-12,The Daily Signal," From the month of March 2024, all of the following records from Thanhauser, William (William.Thanhauser@FDA.HHS.GOV), ATTORNEY-ADVISER. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts. "
2024-3450,2024-04-12,The Daily Signal,"  From the month of March 2024, all of the following records from Yeatts, Andrew B (Andrew.Yeatts@FDA.HHS.GOV), REGULATORY COUNSEL. All congressional correspondence and communications to/from Congressional Offices or Committees for the previous month including responses or document productions to outstanding, extant, or previous congressional inquiries or oversight efforts.  "
2024-3451,2024-04-15,HSBC Securities and Capital Markets (India) Private Limited,Please provide form 483 issued by USFDA to Sun Pharma for its facility located at Dadra
2024-3452,2024-04-15,The Epoch Times,"Hello,  Please provide all emails, texts, and instant chat messages to and from Tracey Forfa mentioning one or more of the following word combinations: bird + flu + cattle bird + flu + dairy bird + flu + cow avian + influenza + cattle avian + influenza + dairy avian + influenza + cow H5n1 + cattle H5n1 + dairy H5n1 + cow  Thank you"
2024-3453,2024-04-15,AccuLine,"Full 510(k) Request (Number - K232686) of the CorVista Health, Inc. (“CorVista Health”), for the CorVista® System under the Common name of ""Cardiovascular machine learning-based notification software"", Classification: Class II, Regulation number: 21 CFR 870.2380, Classification Panel: Cardiovascular, Product Code: QXX, Subsequent Product Code: DQK."
2024-3454,2024-04-15,Clarivate Analytics (France) SAS,"As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483:  Celltrion Inc. 23 Akademi-Ro Yeonsu, Incheon 22014 Korea South End Dates of inspection: 27 Feb 2024 FEI: 3005241015 PRODUCT AREA: Human Drugs District: ORA   I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3455,2024-04-15,Clarivate Analytics (France) SAS,"As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483:  Abraxis Bioscience, LLC 620 N 51st Ave Phoenix, AZ 85043-2702 United States End Dates of inspection: 06 Oct 2023 FEI: 3006441852 PRODUCT AREA: Human Drugs Project Area: Drug Quality Assurance Classification: VAI    I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3456,2024-04-15,Clarivate Analytics (France) SAS,"As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483:  Abraxis Bioscience, LLC 620 N 51st Ave Phoenix, AZ 85043-2702 United States End Dates of inspection: 06 Apr 2022 FEI: 3006441852 PRODUCT AREA: Human Drugs Project Area: Drug Quality Assurance Classification: OAI    I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3457,2024-04-15,"ALLEN-HALL, TERRI ",I am requesting ALL maude adverse event reports for Medtronic VIVA XT CRT-D (ICD) model DTBA1D1.  I would prefer to receive them on a flash drive(s) or cd(s).  Thank you.
2024-3458,2024-04-15,,2023-9410; RECORDS RE LAST WEEK TONIGHT
2024-3459,2024-04-15,Jon Gilbert,Copy of PMN K832621 for TOP Disposable Plastic Syringes for TOP Corporation.   
2024-3460,2024-04-15,Strides Pharma Inc.,"Summary Based Approval (SBA) package for BLA 101995, Santyl Topical Ointment, 250 units/gram held by Smith and Nephew Inc. which was approved on June 4, 1965."
2024-3461,2024-04-15,REGENXBIO Inc.,"Request for the Establishment Inspection Report (EIR) from the manufacturing facility Pre-License Inspection (PLI) for BioMarin located in Novato, CA.  The inspection took place in the May-August timeframe in 2020."
2024-3462,2024-04-15,"Comprehensive Sleep Medicine Associates, PA",FDA package submission for 510(k) Number K182618 (SleepImage System)
2024-3463,2024-04-15,Vontobel Asset Management,FDA corr with Zoetis re Librela (Bedinvetmab) on insufficient or new warning labels or any failures in veterinary and clinical support etc
2024-3464,2024-04-15,PHILIPS RESPIRONICS,K230476 
2024-3465,2024-04-15,"MARKETSHIELD, INC","I would like an import report for Market Shield, Inc. with DUNS Number 12-189-0620, for period between October 2nd 2023 to April 12 2024. "
2024-3466,2024-04-15,Sovish,2021-4703
2024-3467,2024-04-15,FOIA Information,"Please provide the full reports of any and all adverse events reported to the FAERS database for Syfovre (pegcetacoplan) since March 1, 2024 up until today. In an Excel format, if possible."
2024-3468,2024-04-15,FOIA Information,"Please provide the full reports of any and all adverse events reported to the FAERS database for Izervay (avacincaptad pegol) since March 1, 2024 up until today. In an Excel format, if possible."
2024-3469,2024-04-15,Redica Systems,CVM/Animal Drugs & Feed 483 Request (US-based inspection)
2024-3470,2024-04-15,Pistevo Law LLC,"On April 11, 2024, Commissioner Califf appeared before Congress. In his testimony, he mentioned that FDA had transmitted a reorganization package to Congress on March 8, 2024.  I am requesting a copy of that reorganization package. "
2024-3471,2024-04-15,Redica Systems,CDRH/Medical Devices & Rad Health 483 Request (US-based inspection)
2024-3472,2024-04-15,Redica Systems,CVM/Animal Drugs & Feed 483 Request (International inspection)
2024-3473,2024-04-15,PAUL HASTINGS LLP,"Expedited Processing - Request for Internal FDA Decision Memorandum on Copaxone (glatiramer acetate), Vitrase (hyaluronidase), and Creon (pancrelipase) concerning whether to transition these products to CBER under the BPCIA."
2024-3475,2024-04-15,COGENCY GLOBAL INC., 2024-1738  
2024-3476,2024-04-15,LEXINGTON LAW GROUP,"I am seeking records of or relating to applications to and approvals from the Food and Drug Administration (“FDA”) related to two nicotine pouch products: (1) “Zyn” brand nicotine pouches and (2) “On!” brand nicotine pouches. This includes, without limitation, all communications between the manufacturers of Zyn and On! and FDA related to the sale of such products pending review of the premarket tobacco product applications (""PMTAs"") ETC"
2024-3477,2024-04-15,Advocate Lutheran General Hospital,  The case ID (obtained from FAERS) for reports requested are listed below:  20449284 19873908 19782878 19497669 19359726 14176087 16990374 18625187
2024-3478,2024-04-15,CEDARS-SINAI MEDICAL CENTER,"Request copy(ies) for Forms 483 (Notice of Inspectional Observations) issued on December 14, 2023 to Janssen Pharmaceuticals Inc. 1000 US Route 202 South Raritan, NJ 08869-1425 FEI # 2211100  "
2024-3479,2024-04-15,"Taro Pharmaceuticals U.S.A., Inc.","The Summary Basis of Approval, the Medical Officer’s Review, Chemistry Review, approved labeling and all information concerning the studies performed by or for the Application Holder concerning the effectiveness of the product: ZORYVE (ROFLUMILAST) FOAM; TOPICAL; 0.3% N217242 / Dec 15, 2023 -  ARCUTIS BIOTHERAPEUTICS INC"
2024-3480,2024-04-15,Septodont,Please provide all information regarding Adverse Drug Reactions above and beyond what is listed in the FAERS database report numbers:  1) Primary ID - 230768982.23076898 - Product involved - Lidocaine 2) Primary ID - 230549792.23054979 - Product involved - Lidocaine 3) Primary ID - 230504791.23050479 - - Product involved - Lidocaine
2024-3481,2024-04-15,MEDTRONIC,Please provide the K231850 - Quartex Occipto-Cervico-Thoracic Spinal System ExcelsiusGPS Instruments 510(k) submission and corresponding documents.
2024-3482,2024-04-15,Independent,Summary Basis of Approval or New Drug Application for NDA 012122 (Glucagon Hydrochloride) 1mg base / vial and 10mg base / vial
2024-3483,2024-04-15,"Endure Industries,Inc.",Need 510k records of the following :                                                                                                K973827 K803293 K953776 
2024-3484,2024-04-15,GAP Regulatory Consulting,"Requesting- 483 for Wittman Pharma, Inc.,3005350897, 830980947,ANALYSIS; LABEL;MANUFACTURE 15431 Flight Path Drive, Brooksville, Florida (FL) 34604, United States Have concerned clients that use them to manufacture their products. "
2024-3485,2024-04-15,Learn About Pharma,"Please provide the following in CSV file:  1) Listing of all INSPECTIONS since Friday, October 1, 2021 (in CSV format) with the following fields:   FEI Number, Inspection Start Date, Inspection End Date, Legal Name, Address, City Name, State Code, Zip Code, Country Name, FDA483, Full Name, District, Center, Inspection reason etc.TC"
2024-3486,2024-04-15,Sovish,Inspection and Citation Records
2024-3487,2024-04-15,Sovish,"Request for 483s and EIRs RELEASED TO REDICA, FDAZILLA, CLARICATE, FDANEWS"
2024-3488,2024-04-15,Anthony Roberts,"I am seeking records concerning and containing the email address ""CompoundingIncidents@fda.hhs.gov."" Specifically, I would like communications that reflect the setting up procedure of this email (e.g., for what purpose it was created, to which state, local, and federal agencies it has been distributed, any communications that accompany distribution of the email address, and any memorandum that reference the email address).  The purpose of this request is to ascertain the function of this email address and what information those who have received this email address have been given. "
2024-3489,2024-04-15,Taxpayers Protection Alliance Foundation,"Records and documents from January 1, 2024 through January 10, 2024 relating to the FDA’s issuance of a complete response letter regarding the biologics license application seeking the approval of zolbetuximab for the treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin18.2 (CLDN18.2) positive. "
2024-3490,2024-04-15,University of Missouri - Kansas City,FOI for NADA 065-122 Tetracyn ointment
2024-3491,2024-04-15,CHILDREN'S HEALTH DEFENSE,"All electronic mail (e-mail) communications (in text or attached file contents) between and including the dates of May 15, 2020 and February 24, 2021 that contain the word “codon” and involves an FDA e-mail address and at least one key member of Operation Warp Speed (Moncef Slaoui; Gustave Perna; Peter Marks; Janet Woodcock; Bruce Tromberg; Lee Payne; Sean Biggerstaff; Matt Hepburn; Stacy Cummings; etc"
2024-3492,2024-04-15,Beehive Botanicals Inc.,Inspection Report from site inspection June 2023
2024-3493,2024-04-15,Julianne Basabe," I am requesting any and all records, documents, emails, correspondence, text messages, and material that includes, discusses, or mentions anything related to the approval process for the SARS-CoV-2 vaccine from January 1st, 2020, in either hard copy or electronic form. This can include background and historical documents, or any materials being utilized in current discussions. "
2024-3494,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-5443, 2023-5812, 2023-9143, 2023-11439, 2023-5848 "
2024-3495,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-7413, 2023-4487, 2023-4486, 2023-4490, 2023-4976 "
2024-3496,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-7413, 2023-4487, 2023-4486, 2023-4490, 2023-4976 "
2024-3497,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-4488, 2023-4482, 2023-5858, 2023-4491, 2023-5928 "
2024-3498,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-4483, 2023-4329, 2023-4328, 2023-4249, 2023-4327 "
2024-3499,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-4407, 2023-11432, 2023-11564, 2023-4485, 2023-4620 "
2024-3500,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-5600, 2023-5936, 2023-5937, 2023-5602, 2023-5046 "
2024-3501,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-5976, 2023-5710, 2023-5044, 2023-4624, 2023-5973 "
2024-3502,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-5040, 2023-5777, 2023-5972, 2023-5042, 2023-6209 "
2024-3503,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-4849, 2023-6002, 2023-5717, 2023-6204, 2023-6335 "
2024-3504,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-6336, 2023-6899, 2023-6769, 2023-6725, 2023-6285 "
2024-3505,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-9181, 2023-9266, 2023-9177, 2023-9218, 2023-9137 "
2024-3506,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-9060, 2023-9051, 2023-11549, 2023-9049, 2023-9264 "
2024-3507,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-9062, 2023-10210, 2023-8867, 2023-9043, 2023-8989 "
2024-3508,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-9534, 2023-11258, 2023-8769, 2023-8863, 2023-9065 "
2024-3509,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-9400, 2024-902, 2023-11392, 2023-8860, 2024-529 "
2024-3510,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-10037, 2024-2146, 2021-6888, 2023-6262, 2023-9068 "
2024-3511,2024-04-15,"Orca1 Digital Intelligence, LLC","2023-4634, 2023-10895, 2023-3863, 2023-7849, 2024-2539 "
2024-3512,2024-04-16,Redica Systems,CDER/Human Drugs 483 Request (International inspection)
2024-3513,2024-04-16,Redica Systems,CDER/Human Drugs 483 Request (US-based inspection)
2024-3514,2024-04-16,Krensavage Asset Management LLC, 483's issued to LGM Pharma post inspections of Boca Raton FL and Erlanger KY facilities. 
2024-3515,2024-04-16,INTERNATIONAL ASSOCIATION OF COLOR MANUFACTURERS,"I request a copy of the abandonment petition submitted by SIRC referenced in the Notice of Petition filed on June 15, 2016 (81 FR 38984).  "
2024-3516,2024-04-16,"FOIA Request Services, LLC","Requesting a copy of Pre-Notification Consultation (PNC) No. 002616 and all FDA internal review memoranda associated with it. This PNC relates to the Agency’s letter of no objection (LNO) 246, which confirms the capability of Fresh Pak’s secondary recycling process for producing post- consumer recycled high-density polyethylene (PCR-HDPE) material that is suitable for food-contact applications."
2024-3517,2024-04-16,Hometown Food Company,"Hello, I am looking for a copy of routine testing results.  This is for reference sample # 1245268 Pillsbury Zero Sugar Moist Supreme Premium Cake Mix Classic Yellow (16 OZ). The Best If Used By date is: JUN 21 2025 3 355 501 01."
2024-3518,2024-04-16,Redica Systems,"Please provide disclosable, redacted 483s, 483 Responses, and EIRs in electronic format (.pdf) that have been released since February 1, 2024. Any documents previously sent to Redica Systems may be excluded. Please feel free to contact us (support@fdazilla.com) to discuss any questions or issues which may result prior to or during the processing of this request."
2024-3519,2024-04-16,Redica Systems,"Please provide the following two (2) CSV files: 1) Listing of all INSPECTIONS since Wednesday, February 1, 2023 (in CSV format) with the following fields: FEI Number, Inspection Start Date, Inspection End Date, Legal Name, Address, City Name, State Code, Zip Code, Country Name, FDA 483, Full Name, District, Center, INSPECTION REASON 2) Listing of releasable inspection CITATIONS ETC"
2024-3520,2024-04-16,Blazing Stars Foundation,information on all grants that have been approved under Grant Code 13.103 by the U.S. Department of Health and Human Services (HHS) over the last year with a 95% or better rating.  
2024-3521,2024-04-16,"Pritzker Hageman, PA",CFSAN SAMPLE RESULTS
2024-3522,2024-04-16,"Orca1 Digital Intelligence, LLC","2021-2086, 2021-3973, 2021-4458, 2024-1339, 2023-11565 "
2024-3523,2024-04-16,"Orca1 Digital Intelligence, LLC","2023-10205, 2023-8858, 2023-9547, 2023-9755, 2023-9561 "
2024-3524,2024-04-16,"Orca1 Digital Intelligence, LLC","2023-10681, 2023-10515, 2023-11399, 2023-10290, 2024-16 "
2024-3525,2024-04-16,"Orca1 Digital Intelligence, LLC","2023-10484, 2023-11429, 2023-10569, 2024-649, 2023-10784 "
2024-3526,2024-04-16,"Orca1 Digital Intelligence, LLC","2023-10150, 2024-455, 2023-10483, 2024-607, 2024-608 "
2024-3527,2024-04-16,"Orca1 Digital Intelligence, LLC","2023-11467, 2024-134, 2023-10679, 2023-10798, 2024-68 "
2024-3528,2024-04-16,"Orca1 Digital Intelligence, LLC","2024-377, 2024-401, 2023-10730, 2024-232, 2024-133 "
2024-3529,2024-04-16,"Orca1 Digital Intelligence, LLC","2023-11466, 2024-65, 2024-2004, 2024-229, 2023-11558 "
2024-3530,2024-04-16,"Orca1 Digital Intelligence, LLC","2024-128, 2024-231, 2024-226, 2024-1512, 2024-1993 "
2024-3531,2024-04-16,"Orca1 Digital Intelligence, LLC","2024-1568, 2022-6664, 2022-7043, 2022-7037, 2022-7044 "
2024-3532,2024-04-16,"PrimeVigilance USA, Inc.","Dear Agency,  We are seeking Individual Case reports for following Case IDs. Thank you in advance. 23286755 23286754 23286746 23286708 23286707 23286706 23286704 23286701 23286696 23286695 23286615 23088925 23088923 23022886 23022876 23022875 23022874 23022873 23022865 22970589 22970556 22970554 22970545 22970534 22712433 22712415 22712413 22712395 22712329 22712328 22712326 22710924 22710923 22710922 22280613 "
2024-3533,2024-04-16,Soterius Inc. on behalf of Graviton Biosciences Corporation,"Product at Issue: Belumosudil  Case ID 23099292: Request you to please share case reports (Complete case Narrative, details on Concomitant Medication, Medical History, Course of Hospitalization along with Treatment Details, Hospital Discharge Summary and Relevant Laboratory Tests). "
2024-3535,2024-04-16,Harrington Films,"All e-mails from Steven Allen (FDA-ORA /DHHS/FDA/ORA/ORA/OHAFO/OHAFOW/DHAFOWII) for January 01, 2024-March 31,2024 containing the keyword, AAFCO."
2024-3536,2024-04-16,Eskay Packaging,US FDA INSPECTION ON GALENTIC PHARMA INDIA PVT LTD  LOCATION : GANDHIDHAM & NAVI MUMBAI 
2024-3537,2024-04-16,bofa securities,Form 483 for SUN Pharma's Dadra facility that was inspected between 4th dec and 15th dec 2023 and was issued an OAI on 12th April 2024
2024-3538,2024-04-16,GBUK Group Ltd,"FOIA Request for the FDA Form 483 issued to Jiangsu Shenli Medical Production Co. Ltd (Registration Number 3003902757) following FDA inspection, in regard to the concerns raised by FDA as part of the FDAs ongoing evaluation of Plastic Syringes Made in China for Potential Device Failures. "
2024-3539,2024-04-16,Syngene International Limited,"Subject: Request for unredacted Establishment Inspection Report, including the narrative of the PAI conducted by USFDA (CVM) in Nov 2022 (Inspection ID 1193108)_x000D_
 "
2024-3540,2024-04-16,BD, K780130 BURETTE INTRAVENOUS ADMIN. SETS K790582 INTRAVASCULAR ADMINISTRATION SET K874564 MINIMED III INFUSION PUP & UNI-SET ADMIN SET K924718 SHROUDED NEEDLE DEVICES K931550 EZ ADMINISTRATION SET K934095 IVAC VENTED SYRINGE ADAPTER ADMINISTRATION SETS K951922 ADMINISTRATION SETS WITH BALL FLOAT
2024-3541,2024-04-16,Chemular Inc,"Requesting from the Center for Tobacco Products (CTP), Office of Science, the MDO letter and TPL review for Shenzhen Yibo Technology Co.LtD as referenced in the CTP announcement from April 15, 2024."
2024-3542,2024-04-16,Scott Savedow,"Under the Freedom of Information Act, 5 U.S.C. subsection 552, I am requesting access to any and all emails, text messages, and recorded teleconference meetings referencing the proposed assignment of a Criminal Investigator in India.  "
2024-3543,2024-04-16,PETA,"PETA requests all agency records, dated January 7, 2024 through the date of the fulfillment of this request, related in any way to:  •	The Veterinarians’ Blood Bank (also doing business as Professional Veterinary Research, Inc.), an animal-breeding facility and blood-banking operation managed by Debbie Sweany and owned by Dr. Darren D. Bryant and Dr. Ron E. Harrison, with sites at 1851 W. County Rd. 600 N., Brownstown, IN 47220, and at 3849 SR-135, Vallonia, IN, 47281.  •	Dr. Jodi Lovejoy, a veterinarian with the Indiana State Board of Animal Health. "
2024-3544,2024-04-16,PROCTER AND GAMBLE,"Requesting 1) Letter of No Objection (Recycle No. 322) dated January 24, 2024 issued to Borealis for their high-density polyethylene (HDPE). 2) The preceding post-consumer recycled plastics submission filed by Borealis for the HDPE process on which the LNO is based. 3) LNO (Recycle# 325) dated February 5, 2024 issued to Borealis for their polypropylene (PP). 4) The preceding post-consumer recycled plastics submission filed by Borealis for the PP process on which the LNO is based. "
2024-3545,2024-04-16,,I've been informed by Amazon's Regulatory team that the FDA has approached Amazon with a warning concerning the safety  / health impact of smokeable marshmallow leaf products (as opposed to Spice). I would like a copy of the correspondence and full details of any issues associated with such products.
2024-3546,2024-04-16,Hogan Lovells,"Pursuant to the Freedom of Information Act, 5 U.S.C. § 552, and the implementing regulations under 21 CFR Part 20, I hereby request a copy of all documents regarding the food recall classification completed by the U.S. Food and Drug Administration Office of Regulatory Affairs (ORA) for Recall Enterprise System (RES) event number 93631."
2024-3547,2024-04-16,Investigative Reporting Program,"Form 483s sent for inspections for clinical trials conducted in Australia where the intervention was a gene therapy from the following sponsors: BioMarin Pharmaceutical, Bluebird Bio, Spark Therapeutics, Sangamo Therapeutics, Arrowhead Therapeutics, Prevail Therapeutics, Encoded Therapeutics and Krystal Biotech.  "
2024-3548,2024-04-16,Womble Bond Dickinson (US) LLP,All accepted for filing letters issued for PMTAs filed in May 2022
2024-3549,2024-04-16,Womble Bond Dickinson (US) LLP,All accepted for filing letters issued for any PMTAs for myBlu ENDS products.
2024-3550,2024-04-16,BLOOMBERG NEWS,"All adverse event reports for compounded semaglutide or for compounded tirzepatide_x000D_
received by FDA between January 1, 2020 and the date that this request is processed._x000D_
For reference, the FDA acknowledged receiving “adverse event reports after patients_x000D_
used compounded semaglutide” on this website:_x000D_
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-andproviders/_x000D_
medications-containing-semaglutide-marketed-type-2-diabetes-or-weightloss"
2024-3552,2024-04-16,Womble Bond Dickinson (US) LLP,"All “accepted for filing” letters for PMTAs that remain under or are pending scientific review. Exclude_x000D_
records related to tobacco-derived nicotine products filed after September 2020 as well as records related_x000D_
to synthetic nicotine products filed after May 2022"
2024-3553,2024-04-16,"camelio, michael a","I hereby request, as part of my FOIA request, access to any and all documents, research, correspondence, and records pertaining to Thera Bionics' frequency treatments and their approval process. Moreover, I seek clarification and formal documentation regarding any connection or similarities between Thera Bionics' treatments and the frequencies originally researched by Royal Raymond Rife. In light of this inquiry, I also wish to invoke a patient challenge law, if applicable, to further assess the legitimacy and origins of Thera Bionics' treatments under FOIA."
2024-3554,2024-04-16,Boston Scientific Inc,K182408. I would like the full 510(k) K182408 filed by Olympus.
2024-3555,2024-04-16,THE NEW YORK TIMES,"Hello, I am a New York Times reporter requesting the 483 for an inspection of Bloodworks Northwest (FEI: 3071347) located at 921 Terry Ave, Seattle, WA, 98104. This is inspection number 1146276 dated July 17, 2021. Thank you. "
2024-3556,2024-04-16,THE NEW YORK TIMES,"Hello, I am a reporter with the New York Times seeking the following documents related to Cord for Life (FEI: 1000525281) located at 270 Northlake Blvd Ste 1012, Altamonte Springs, FL 32701: 1) The 483 for Inspection #1149863 dated 8/26/2021 2) The 483 for Inspection $1073266 dated 11/30/2018 3) The warning letter dated 3/29/2019 related to case #572770  Thank you."
2024-3557,2024-04-16,Kasey Hughes,I am seeking a copy of the bond posted by Flow Tobacco LLC. 
2024-3558,2024-04-16,SI-Bone,Copy of K230857 and K240720 (Referral 2024-00048-FOPA-OS)
2024-3559,2024-04-17,Sovish,"Please share the Form 483 for Eurofins Amatsi Analytics Inspection ended on Nov 03, 2023 for the site Fontenilles, France and fei id 3006118993. The inspection was related to Human Drugs"
2024-3560,2024-04-17,Nomura,Form 483 issued to Sun Pharma post the USFDA inspection of Dadra site in Dec 2023
2024-3561,2024-04-17,"Sonoma Pharmaceuticals, Inc.","I am requesting the dossier that was submitted to the FDA by Oculus Innovative Sciences, Inc. in its 510(k) application for K152055 (Ceramax Skin Barrier Cream).  "
2024-3562,2024-04-17,Harrington Films,"Pursuant to the Freedom of Information Act (5 U.S.C. § 552), I hereby request access to and copies of records from the years 2017 and 2018 specifically related to cases concerning raw pet food companies or pet food (feed) products that the U.S. Food and Drug Administration's Center for Veterinary Medicine (FDA-CVM) referred to the Department of Justice (DOJ) for prosecution.   "
2024-3563,2024-04-17,Harrington Films,I am requesting the receipts for all purchases of the AAFCO O.P. (American Association Of Feed Control Officials Official Publication) purchased by FDA-CVM
2024-3564,2024-04-17,Harrington Films,All email records for FDA CVM employee Charlotte Conway containing the key search term: AAFCO. (Date range for records search is:  01.01.2024-03.31.2024)
2024-3565,2024-04-17,"Han, Harry ",Please provide the instructions-for-use/user manual for Caption Interpretation Automated Ejection Fraction Software submitted under De Novo Number: DEN220063.   The details of the device is as follows: Device Classification Name: Radiological Machine Learning Based Quantitative Imaging Software With Change Control Plan Regulation Number: 892.2055 Classification Product Code: QVD Classification Advisory Committee: Radiology 
2024-3566,2024-04-17,GMP Trends,"Please provide the FDA-483 documents pertaining to Human DRUG Inspection for the following 3 firms: Abraxis Bioscience, LLC, 620 N 51st Ave, Phoenix, AZ, 85043-2702, United States, dated: 9/25/2023 - 10/6/2023; Adonis Inc., 475 N Sheridan St, Corona, CA, 92878-4021, United States, dated: 10/30/2023 - 11/3/2023; Aerosol and Liquid Packaging, Inc., 3701a Southwestern Blvd Ste 100, Baltimore, MD, 21229-5030, United States, dated: 12/4/2023 - 12/18/2023. Please send the documents as separate email attachment pdf.  "
2024-3567,2024-04-17,"Orca1 Digital Intelligence, LLC","2020-2599, 2022-7573, 2023-10331, 2023-10623, 2023-10933 "
2024-3568,2024-04-17,"Orca1 Digital Intelligence, LLC","2023-11418, 2023-8022, 2023-9313, 2023-9430, 2023-9431 "
2024-3569,2024-04-17,"Orca1 Digital Intelligence, LLC","2023-9432, 2023-9508, 2023-9510, 2024-1281, 2024-783 "
2024-3570,2024-04-17,"Orca1 Digital Intelligence, LLC","2024-784, 2020-5742, 2021-6857, 2022-7046, 2022-7169 "
2024-3571,2024-04-17,"Orca1 Digital Intelligence, LLC","2022-7662, 2022-8323, 2023-10213, 2023-10372, 2023-10480 "
2024-3572,2024-04-17,DiaPharma,"Hello, I would like the 510(k) summary for K912061, Sigma Heparin Adsorbent. This is a class II device under 21CFR 864.5425-Multipurpose system for in vitro coagulation studies. If possible please send the summary and all applicable documentation for this 510(k). Thank you!"
2024-3573,2024-04-17,GMP Trends,"Please provide the FDA-483 documents pertaining to Human DRUG Inspection for the following 4 firms: Alkermes Inc, 265 Olinger Cir, Wilmington, OH 45177-2484, United States, dated 9/25/2023 - 10/19/2023; Alpha Aromatics, 294 Alpha Dr, Pittsburgh, PA 15238-2906, United States, dated 11/28/2023 - 12/12/2023;  Apothecus Pharmaceutical Corp., 485 S Broadway Ste 27, Hicksville, NY 11801-5071, United States, dated 9/13/2023 - 10/6/2023; Aura Cacia, 5398 31st Ave, Urbana, IA 52345-9025, United States, dated 11/27/2023 - 12/1/2023. P "
2024-3574,2024-04-17,GMP Trends,"Please provide the FDA-483 documents pertaining to Human DRUG Inspection for the following 4 firms: Blaine Labs Inc, 11037 Lockport Pl, Santa Fe Springs, CA 90670-4634, United States, dated 12/1/2023 - 12/15/2023; Bolger & O'Hearn Inc, 47 Slade St, Fall River, MA 02724-1347, United States, dated 12/4/2023 - 12/19/2023; DSP Skin Care LLC, 1930 Wilshire Blvd Ste 507, Los Angeles, CA 90057-3649,  etc"
2024-3575,2024-04-17,GMP Trends,"Please provide the FDA-483 documents pertaining to Human DRUG Inspection for the following 3 firms: SOFTAP INC, 550 N Canyons Pkwy, Livermore, CA 94551-9472, United States, dated 12/7/2023 - 12/11/2023; Spirit Pharmaceuticals, 2004 Orville Dr N Ste 2, Ronkonkoma, NY 11779-7645, United States, dated 10/23/2023 - 11/1/2023; Tri Tech Laboratories LLC dba KDC/One Columbus, 8825 Smiths Mill Rd, New Albany, OH 43054-6649, United States, dated 12/6/2023 - 12/19/2023;  Please send the attachments as separate emails in pdf format.      "
2024-3576,2024-04-17,GMP Trends,"Please provide the FDA-483 documents pertaining to Human DRUG Inspection for the following 3 firms: Ultrum Labs LLC, 6013 Benjamin Rd Ste 201, Tampa, FL 33634-5100, United States, dated 10/10/2023 - 10/16/2023; University Instrumentation Center at UNH, 105 Main St, Durham, NH 03824-2512, United States, dated 11/27/2023 - 12/5/2023; Westwood Laboratories, LLC., 710 S Ayon Ave, Azusa, CA 91702-5123, United States, dated 10/30/2023 - 11/20/2023; Please send the attachments as separate emails in pdf format."
2024-3577,2024-04-17,GMP Trends,"Please provide the FDA-483 documents pertaining to Medical Device Inspection, for the following 4 firms:  Advantage Dental Products, Inc., 4498 Klais Dr, Clarkston, MI 48348-2372, United States, dated 11/6/2023 - 11/16/2023; Allied Medical LLC, 1720 Sublette Ave, Saint Louis, MO 63110-1927, United States, dated 10/30/2023 - 11/8/2023; American Medical Endoscopy, Inc., 3020 NW 82nd Ave, Doral, FL 33122-1042, United States, dated 10/10/2023 - 10/11/2023; Biocore9 LLC, 9 Whippany Rd Bldg A1 Unit 12, Whippany, NJ 07981-1525, United States, dated 10/10/2023 - 11/6/2023; Please send the attachments as separate emails in pdf format."
2024-3578,2024-04-17,GMP Trends,"Please provide the FDA-483 documents pertaining to Medical Device Inspection, for the following 4 firms: Howmedica Osteonics Corp., 325 Corporate Dr, Mahwah, NJ 07430-2006, United States, dated 11/15/2023 - 12/1/2023; IncludeHealth, 495 Metro Pl S Ste 320, Dublin, OH 43017-5399, United States, dated 10/24/2023 - 11/1/2023; Oxygen Therapy Institute, 5971 Powers Ave # 8, Jacksonville, FL 32217-1209, United States, dated 11/13/2023 - 11/17/2023; Stoner Incorporated, 1070 Robert Fulton Hwy, Quarryville, PA 17566-9617, United States, dated 11/7/2023 - 11/15/2023; Please send the attachments as separate emails in pdf format."
2024-3579,2024-04-17,GMP Trends,"Please provide the FDA-483 documents pertaining to Medical Device Inspection, for the following 2 firms: Synovo Production, 1501 N Harbor Blvd Ste 209, Fullerton, CA 92835-3803, United States, dated 9/8/2023 - 10/2/2023; TMJ Services LLC, 8119 Isabella Ln Ste 108, Brentwood, TN 37027-8780, United States, dated 10/17/2023 - 12/12/2023; Please send the attachments as separate emails in pdf format."
2024-3580,2024-04-17,"Khan, Kiran ","The orphan drug designation application for ""recombinant human alkaline phosphatase"" for the treatment of hypophosphatasia which was designated on 05/13/2015. The sponsor is Bunnik, Netherlands."
2024-3581,2024-04-17,"Lath, Sanjeev ",I am requesting authentication  and/or certified copies of the following documents attached 21 CFR 20.3 (b)- A request for certified copies of records or for authentication of records shall be sent in writing to the Division of Freedom of Information at the address located on the agency's web site at http://www.fda.gov. 
2024-3582,2024-04-17,SMP Nutra," Establishment Inspection Report For the inspection Conducted by Ms. Meredith Soehl._x000D_
Company name: SMP Nutra, Address of facility inspected: 1 Rodeo Drive, Brentwood, NY 11717. Also warehouse at 250 Executive Drive, Brentwood, NY 11717."
2024-3583,2024-04-17,Keller and Heckman LLP,FOIA Request for Unredacted FDA Review Memoranda for No Objection Letter (NOL) 327.
2024-3584,2024-04-17,Redica Systems,CBER/Biologics 483 Request (US-based inspection)
2024-3585,2024-04-17,Christopher Alston," Additional request for number of investigations opened and number of arrests for the timeframe 1/1/2011 to 12/31/2023 broken down by month and year for the following OCI MFCC codes: 732.000, 732.100, 732.200, 732.300, 732.400, 732.500, and 732.600. "
2024-3587,2024-04-17,Luis Tanon Reyes,"GlaxoSmithKline Conshohocken, Pennsylvania. Form 483s and Established Inspection Reports for the following inspection IDs: 1043309, 927643, and 730716.     "
2024-3588,2024-04-17,"Ascher, Amy ","Nucleus Network Level 5, 300 Herston Road,  Herston, QLD 4006 Australia   Form 483 and/or EIRs"
2024-3589,2024-04-17,Rudra rao,EIR of Daicel chiral technologies Pvt Ltd for the audit conducted on February 12th to February 14th 2024
2024-3590,2024-04-17,Lewis Brisbois Bisgaard & Smith LLP,"Any memoranda or other documents reflecting FDA's determinations with respect to the eligibility, disposition, or forfeiture of 180-day exclusivity in relation to Topiramate Extended-release Capsules (RLD Qudexy XR), 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg. Such documents may be contained in the records for approved ANDA 208949 and approved ANDA 210278.     "
2024-3591,2024-04-17,All Natural Iroducts Inc,"ALL NATURAL PRODUCTS EIR  727 Drake Street, Bronx, NY 101474 "
2024-3592,2024-04-17,Womble Bond Dickinson (US) LLP,"Freedom of Information Act Request – Any Policy Regarding the_x000D_
Review of Premarket Tobacco Product Applications (PMTAs) for_x000D_
Tobacco-Flavored ENDS Products"
2024-3593,2024-04-17,Womble Bond Dickinson (US) LLP,"All Memoranda or_x000D_
Communications Between or Among Center for Tobacco Products,_x000D_
Office of the Center Director Leadership, and Office of Science_x000D_
Leadership and the Divisions’ Employees Related to the Criteria for_x000D_
Granting or Denying Marketing Orders for Tobacco-Flavored ENDS_x000D_
Products"
2024-3594,2024-04-17,"DIGESTIVE CARE, INC.","During review of the 2023 4th quarter FAERS files, case reports were identified that were not sent to Digestive Care, Inc. As the manufacturer of Pertzye (pancrelipase) drug product, we would like to request the following case reports that list Pertzye as the primary/secondary suspect. Case ID 23049414, 23074026, 23111528, 23126537"
2024-3595,2024-04-17,FIS North America,"requesting a copy of the form 483 issued to Gland Pharma Limited during their inspection. They are a manufacturer of drug products and located at: Survey No. 143 - 148, 150 & 151,  Near Gandimaisamma Cross Roads,  D. P. Pally, Dundigal Post, Dundigal - Gandimaisamma Mandal,  Medchal - Malkajgiri District,  Hyderabad, Telangana 500043, India (IND)"
2024-3596,2024-04-17,Zoetis,"Company: Midwest Veterinary Services, Inc., Address: 12890 County Road M, Oakland, NE  68045 REQUEST Info: FDA 482, FDA 483, FDA GLP Inspections, EIR, All inspections and notices. Clinical Investigator: Dr. Lechtenberg and Dr. Cull"
2024-3597,2024-04-17,Zoetis,"Company: Charles River  Address: 1407 George Road, Ashland, OH  44805 Request Info: FDA 482; FDA 483; FDA GLP Inspections; EIR; All Inspections and notices"
2024-3598,2024-04-17,Meitheal Pharmaceuticals,"Requesting the most current labeling files (container, carton, and PI) for NDA 050731, Daunorubicin Hydrochloride, HIKMA to evaluate whether our approved ANDA aligns with the referenced listed drug for this product.  Best Regards,"
2024-3599,2024-04-17,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Syfovre (branded name / marketed by Apellis Pharmaceutical) or pegcetacoplan (generic name) between April 11, 2024 and April 17, 2024.  Please provide the documents electronically if possible."
2024-3600,2024-04-17,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for ELEVIDYS (branded name / marketed by Sarepta Therapeutics, Inc.) or delandistrogene moxeparvovec-rokl (generic name) between April 11, 2024 and April 17, 2024.   Please provide the documents electronically if possible."
2024-3601,2024-04-17,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Wegovy (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between April 11, 2024 and April 17, 2024  Please provide the documents electronically if possible."
2024-3602,2024-04-17,Kelley Drye and Warren,"FDA FAERS reports on the drug SYFOVRE (pegcetacoplan), from 8/1/23 to 4/17/24 (or the latest date available). Please look for events under both the brand and generic names. Where possible, please include full narrative of events, and email the results in a PDF or Excel file"
2024-3603,2024-04-17,Kelley Drye and Warren,"FDA FAERS reports on the drug IZERVAY (avacincaptad pegol), from 9/1/23 to 4/17/24 (or the latest date available). Please look for events under both the brand and generic names. Where possible, please include full narrative of events, and email the results in a PDF or Excel file"
2024-3604,2024-04-17,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Ozempic  (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between April 11, 2024 and April 17, 2024.  Please provide the documents electronically if possile."
2024-3605,2024-04-17,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Zepbound (branded name / marketed by Lilly) or tirzepatide (generic name) between April 11, 2024 and April 17, 2024.  Please provide the documents electronically if possible."
2024-3606,2024-04-17,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Mounjaro (branded name / marketed by Lilly) or tirzepatide (generic name) between April 11, 2024 and April 17, 2024.  Please provide the documents electronically if possible."
2024-3607,2024-04-17,CBS NEWS,"FDA's after action report for the applesauce lead poisonings outbreak response, reference #1198 on the CORE table."
2024-3608,2024-04-17,Center for Science in the Public Interest,Qualitative research results from the two front of package focus groups (listed on the website https://www.fda.gov/food/food-labeling-nutrition/front-package-nutrition-labeling  as “Front of Package Focus Groups-2022” and “Front of Package Focus Groups-2 -2023”) conducted as part of FDA’s consumer research to explore the development of a front-of-package nutrition labeling scheme.
2024-3609,2024-04-17,Jessica O'Brien,Manufacturing guideline used to assure the effectiveness of an antiperspirant as mentioned in the Over-the-Counter Monograph M019: Antiperspirant Drug Products for Over-the-Counter Human Use Section M019.60 Guidelines for effectiveness testing of antiperspirant drug products
2024-3610,2024-04-17,Pomonva Valley Hospital Medical Center,We would like to obtain a copy of the original Warning Letter associated to the closeout letter that is attached.  The letter was issued by Center for Devices and Radiological Health.  According to the closeout letter the Warning Letter was dated on 06/30/2014.
2024-3611,2024-04-17,Aryeh Gold,"I am an investment professional requesting this information under the Freedom of Information Act.  Can we please have FDA FAERS reports on the drug Ogsiveo (nirogacestat), from 11/27/23 to 4/17/24 (or the latest date available). Please look for events under both the brand and generic names. Where possible, please include full narrative of events, and email the results in a PDF or Excel file._x000D_
_x000D_
Thank you!"
2024-3612,2024-04-17,Andrew Sheinfeld,"I am an investment professional requesting this information under the freedom of information act.  Can we please have FDA FAERS reports on the drug Veozah (fezolinetant), from 5/1/23 to 4/17/24 (or the latest date available). Please look for events under both the brand and generic names. Where possible, please include full narrative of events, and email the results in a PDF or Excel file._x000D_
_x000D_
Thank you!"
2024-3613,2024-04-18,Millennium,"would like all adverse events reports submitted for Izervay since Jan 1,2024 "
2024-3614,2024-04-18,TechPharm Inc.,"Bioequivalence data on which Oxybutynin Chloride Tablet, Extended Release oral tablets 15 mg from Accord Healthcare Inc. (Reference Standard) was approved for ANDA 207138, whether this bioequivalence data was submitted directly in this ANDA or in another application and cross referenced."
2024-3615,2024-04-18,"Xpro associates, LLC","483 issued to "" Otsuka Pharmaceutical , Second Tokushima Factory (FEI:3002807834)"" Tokushima Japan on FDA drug inspection. (240320)"
2024-3616,2024-04-18,"Sheehan & Associates, PC","All documents, comments, submissions, associated with Docket No. 95N–0245, RIN 0910–AA59.  The subject of this docket is Food Labeling; Statement of Identity, Nutrition Labeling and Ingredient Labeling of Dietary Supplements.  I attempted to locate this on regulations.gov but could not find it thanks"
2024-3617,2024-04-18,"Francis, Susan M",K073504   
2024-3618,2024-04-18,Patrick Curry,FAERS reports for Izervay and (avacincaptad pegol) from 3/01/24-3/31/2024. We would like to request electronic versions of the reports. Thank you.
2024-3619,2024-04-18,Patrick Curry,FAERS report for SYFOVRE/Pegcetacoplan in Ophthalmology 3/01/24-3/31/2024. We would like to request electronic versions of the reports. Thank you.
2024-3620,2024-04-18,"Nalco Water, An Ecolab Company",  CAS# 1643-20-5 or C-12 DIMETHYL AMINE OXIDE SUBMISSION AND APPROVAL
2024-3621,2024-04-18,Harrington Films,All email records for FDA CVM employee Charlotte Conway containing the key search term: AAFCO. (Date range for records search is: 11.01.2020-11.30.2020
2024-3622,2024-04-18,Harrington Films,"calendar records for FDA-CVM employee William T. Flynn, dates 03.01.24-03.31.24 "
2024-3623,2024-04-18,Harrington Films,"Inspection Reports and documents of Lystn, LLC (Answer Pet Food), Address 356 Maidencreek Road, Fleetwood, PA 19522 (01.01.24-03.31.24)"
2024-3624,2024-04-18,Protect the Public's Trust,"RECS RE NATASHA PHELPS - CALIFF, KING, MITAL ETC_x000D_
  "
2024-3625,2024-04-18,Protect the Public's Trust,"NATASHA PHELPS - CALENDAR, ETHICS GUIDANCE, SG-50, WAIVERS, COMMUNICATIONS WITH OCC ETC_x000D_
 "
2024-3626,2024-04-18,"Richardson, Holly ",I am looking for a list of all consent decrees/injunctions issued from January 2000 - end of March 2024. I would like the date in which the injunction was entered and when the consent decree was cleared along with the name of the company it was filed against.  Thank you so much. 
2024-3627,2024-04-18,PUBLIC CITIZEN'S HEALTH RESEARCH GROUP,"On behalf of Public Citizen’s Health Research Group (HRG), and pursuant to the Freedom of Information Act, 5 U.S.C. 522 as amended, we hereby request all MedWatch reports for the following 12 serious botulism reaction case reports associated with the use of onabotulinumtoxinA (BOTOX, BOTOX COSMETIC), abobotulinumtoxinA (DYSPORT), and incobotulinumtoxinA (XEOMIN) from the FAERS database: Case ID	Suspect drug brand name 6447854	        botox 17028091	xeomin 15701315	botox 7509851	        botox 11045908	botox cosmetic 9837888	        botox 15025509	botox 7824048	        botox cosmetic 6446455	        botox 6085889	        botox 5874243	        dysport 7508438	        botox"
2024-3628,2024-04-18,OLSSON FRANK WEEDA TERMAN MATZ PC,"All documents, comments, submissions, etc., and the petition itself and any attachments, related to a citizen petition for a New RACC for Certain Candies Weighing 20 g or Less per Piece filed by the Chocolate Manufacturers Association (CMA) and the National Confectioners Association (NCA) (Docket No. FDA–1996–P–0246, formerly Docket No. 96P–0179).  "
2024-3629,2024-04-18,PUBLIC CITIZEN'S HEALTH RESEARCH GROUP," MedWatch reports for the following 12 case reports associated with repeated use of onabotulinumtoxinA (Botox, Botox Cosmetic) and abobotulinumtoxinA (Dysport) from the FAERS database.  Case ID	Suspect drug brand name  4044336	botox cosmetic 4046066	botox 4108260	botox cosmetic 4113159	botox cosmetic 4129424	botox 4160648	botox 4176048	botox 4177332	botox cosmetic 5793268	botox 5799757	botox cosmetic 5861268	botox 6259316	dysport"
2024-3630,2024-04-18,Andrew Shienfeld,"I am an investment professional requesting this information under the freedom of information act.  Can we please have  copies of any form 483s, warning letters, import alerts issued to Cipla ltd. From 3/1/2024 to 4/17/24 (or the latest date available). _x000D_
_x000D_
Thank you!"
2024-3631,2024-04-18,airis PHARMA Inc.,SBOA of Guanfacine Tablets
2024-3632,2024-04-18,SIRI & GLIMSTAD LLP,"All records concerning “Empirical Bayesian data mining” and “Empirical Bayesian Geometric Means” pursuant to Section 2.3 (2.3.2) of the VAERS Standard Operating Procedures for COVID-19. This should include, but not be limited to, any communications between FDA and CDC “shar[ing] and discuss[ing] results of data mining analyses and signals.” (See Section 2.3.2)._x000D_
_x000D_
Information helpful to fulfilling the request: The FDA’s Center for Biologics Evaluation and Research is the likely custodian of responsive records."
2024-3633,2024-04-18,Athyna Pharma LLC,"All documents related to drug approval package for Aloprim (Allopurinol Sodium) Injection/Injectable EQ 500MG BASE/VIAL, NDA 020298 "
2024-3634,2024-04-18,FOIA Professional Services,"Please provide all documentation (including correspondence and memos) related to FDA’s review of Novartis manufacturing in relation to Kisqali, including any correspondence related to the nitrosamines in the drug, required manufacturing or supply chain adjustments, and pausing of early breast cancer trials.  Please provide the documents electronically if possible."
2024-3635,2024-04-18,"Xttrium Laboratories, Inc.",Request a copy of NDA 19-127 Original (ORIG-1) Approval Letter dated 12/24/1984.
2024-3636,2024-04-18,FOIA Professional Services,"I would like to submit a FOIA request for all inspection materials issued between 2/15/24 - 4/15/24, for the following manufacturing site:  Woodstock Sterile Solutions (Woodstock, IL) - FEI: 1419377   Please provide the documents electronically if possible. The category for these two requests is ""Drug Substance"" or ""Drug Product: Blow/Fill/Seal."
2024-3637,2024-04-18,Malis | Law,"All documentation concerning the Might Bliss Heating Pad subject to recall, including all documentation concerning the defect and corrective measures taken by the company, including but not limited to how which lots were determined to be defective and which to be safe or not subject to recall.  "
2024-3638,2024-04-18,Kleinfeld Kaplan & Becker LLP,"•	Copies of the Technical Project Lead Review(s) associated with the Center for Tobacco Products’ (“CTPs”) issuance of a marketing denial order to Shenzhen Yibo Technology Co. Ltd. dated April 15, 2024, related to CTP’s review of the company’s Premarket Tobacco Product Application(s). "
2024-3639,2024-04-18,"Pritzker Hageman, P.A.","E. coli O157:H7 Infections Associated with Romaine Lettuce Served at a Restaurant in_x000D_
Ramsey County June 2023"
2024-3640,2024-04-18,Harrow Health,"Any and all unredacted Health Hazard Evaluation(s) and related documentation prepared by FDA related to FDA’s requests that Imprimis NJOF (FEI 3013024146): (1) recall certain distributed lots of drug products within their expiry period; specifically, Epinephrine (0.25 mg/mL), Lidocaine (7.5 mg/mL) Sterile injectable Prednisolone (1%), Moxifloxacin (0.5%) ETC"
2024-3641,2024-04-18,COZEN O'CONNOR,RECS RE SALMONELLA 
2024-3642,2024-04-18,FOIA Professional Services,"I would like to submit a FOIA request for all inspection materials issued between 2/15/24 - 4/15/24, for the following manufacturing site:  Nephron Pharma (West Columbia, SC) - FEI: 3011158388  Please provide the documents electronically if possible. The category for these two requests is ""Drug Substance"" or ""Drug Product: Blow/Fill/Seal."
2024-3643,2024-04-18,Lightning Crashes Research,"This is a request under the Freedom of Information Act. I would like to request any adverse events reported for Vyjuvek (branded name / marketed by Krystal Biotech) or beremagene geperpavec-svdt (generic name) between May 1, 2023 and April 17, 2024"
2024-3644,2024-04-18,Medisca Inc.,"Hello, I would like to request the firm's response to the observations of the inspection that took place at Zhejiang Peptites Biotech Co. located at No.8,Hengyizhi Road, Sanjie Town, Shengzhou City, Shaoxing City, Zhejiang 312452. China.  Thank you, Akeisha"
2024-3645,2024-04-18,Medisca Inc.,"Hello, I would like to request the Establishment Inspection reports(EIR) as well as the observations received for the inspection that took place at Chengdu Shengnuo Biopharm Section 1, Gongye Avenue, Dayi County, Chengdu 611330, China. Thank you, Akeisha "
2024-3646,2024-04-18,Medisca Inc.,"Hello, I would like to request the Establishment Inspection reports(EIR) as well as the observations received for the inspection that took place at Sinopep-Allsino Biopharmaceutical No.28, Linpu Road, Economic & Technological Development Zone,, Lianyungang, Jiangsu 222000, China Thank you, Akeisha "
2024-3647,2024-04-18,Medisca Inc.,"Hello, I would like to request the most recent FOIA log for Establishment Inspection reports(EIR) requests made by other manufacturers for Medisca Inc. Thank you, Akeisha"
2024-3648,2024-04-18,"Wallace and Graham, PA","Seeking (1) records of reports and all adverse events reported to FDA related to use of LivaNova 3T heating cooling device at Piedmont Atlanta Hospital located in Atlanta, GA; (2) all communications to and from/between FDA and Piedmont Atlanta Hospital pertaining to the LivaNova 3T heating cooling device; (3) any warnings published or recalls issued to Piedmont Atlanta Hospital pertaining to the LivaNova 3T heating cooling device"
2024-3649,2024-04-18,"Wallace and Graham, PA","All Reports to MAUDE database for any and all problems related to use of LivaNova (Sorin) 3T heater cooler device at Piedmont Atlanta Hospital in Atlanta, GA. This request includes the serial numbers of any such devices included in any reports."
2024-3650,2024-04-18,CALIFORNIA DEPARTMENT OF FOOD AND AGRICULTURE,"California-specific cecal and HACCP FSIS NARMS isolates tested data from 1/1/2013 through 12/31/2023 for livestock, poultry, and aquaculture species. Please include the following items within this dataset:  o	Slaughter Class (e.g., beef, dairy, veal) or Product Type o	Collection Date o	Genus, species, and serotype (where applicable) for Isolates o	NARMS Interpretations o	AST AMR Profile      etc"
2024-3651,2024-04-18,HARMONI INTERNATIONAL SPICE INC.,"Hi,_x000D_
Please help provide the FDA exam result for AYD-0565319-9. Thank you._x000D_
_x000D_
Best regards,_x000D_
_x000D_
Miki"
2024-3652,2024-04-18,Yale University,I am looking for all cases of patients who took Mexican Tejocote Root and suffered any injury; or patients who believed they were taking Mexican Tejocote Root (Crataegus mexicana) and were actually taking Yellow Oleander (Cascabela thevetia). I am interested in any medical problems that arose from either during the specified time period. 
2024-3653,2024-04-18,Matthew Zorn,"All e-mails between Janssen Pharmaceuticals and/or Johnson & Johnson and FDA from January 1, 2020 to the present containing the word “ketamine.” To collect responsive records for this search, please search for all e-mails to or from the domain *@its.jnj.com or *@janssen.com including the word ""ketamine."""
2024-3654,2024-04-18,Yetter Coleman LLP,All meeting/calendar invites involving Janssen Pharmaceuticals and/or Johnson & Johnson that contain the word “ketamine”
2024-3655,2024-04-18,WASHINGTON POST,"Under the Freedom of Information Act, the Washington Post seeks any and all email communications (including attachments) between Joseph Briggs and representatives of Curative, including but not limited to Matt Michelsen.  "
2024-3656,2024-04-18,Longeviti Neuro Solutions,Please provide any releasable information from medical device master file MAF-300 Polycast medical grade PMMA
2024-3657,2024-04-19,Industry Dive,"I am looking for copies of two warning letters issued to Philips Respironics: - A warning letter dated Oct. 11, 2011 from findings of a June 2011 of its Murrysville, PA facility - A warning letter dated June 30, 2014 from findings of an April 2014 inspection of the Murrysville facility. "
2024-3658,2024-04-19,Industry Dive,"I am looking for a copy of the Recall Remediation Plan that Philips submitted to the FDA on March 28, 2024, including any modifications made to the plan"
2024-3659,2024-04-19,WIS News 10,"•	Complaints made about the “Omnicell” and “Omnicell Automated Dispensing Cabinet” (type of device: system/device, pharmacy compounding). Please include the FDA’s investigation into the complaint and the FDA’s conclusion to the complaint. •	Inspection records from the following facilities from Jan. 1, 2019 to April 18, 2024: Prisma Health Baptist Hospital (Columbia, SC 29220), Prisma Health Richland Hospital (Columbia SC 29203),  etc"
2024-3660,2024-04-19,Verified Credentials,Verified Credentials is conducting a background check  
2024-3661,2024-04-19,Sovish,"PLease share  the Form 483 for Southern Tier Pet Nutrition, LLC Inspection ended on Apr 15, 2022 for the site Sherburne, United States and fei id 1317428. The inspection was related to Animal Drugs & Feeds."
2024-3662,2024-04-19,POINT72,"I am an investment professional and this is a request under the Freedom of Information Act. We would like to request Daybue (ACAD) AERS in PDF and Excel. If possible, please email the materials to quinn.lin@point72.com. Thank you!  "
2024-3663,2024-04-19,POINT72,"I am an investment professional and this is a request under the Freedom of Information Act. We would like to request Syfovre AERS in PDF and Excel. If possible, please email the materials to quinn.lin@point72.com. Thank you!"
2024-3664,2024-04-19,POINT72,"I am an investment professional and this is a request under the Freedom of Information Act. We would like to request Izervay AERS in PDF and Excel. If possible, please email the materials to quinn.lin@point72.com. Thank you!"
2024-3665,2024-04-19,POINT72,"I am an investment professional and this is a request under the Freedom of Information Act. We would like to request Rezdiffra AERS in PDF and Excel. If possible, please email the materials to quinn.lin@point72.com. Thank you!"
2024-3666,2024-04-19,POINT72,"I am an investment professional and this is a request under the Freedom of Information Act. We would like to request Zurzuvae AERS in PDF and Excel. If possible, please email the materials to quinn.lin@point72.com. Thank you!  "
2024-3667,2024-04-19,"J.O. Alvarez, Inc","Records related to our FDA Food Facility registration at 1 Andy Ramos Rd, Laredo, Texas 78043. To include any record of persons associated with our account, contact information, dates filed and dates terminated."
2024-3668,2024-04-19,THE NEW YORK TIMES,"Hello, I am a New York Times reporter seeking the 483 for the inspection of University of Texas MD Cancer Center (FEI: 3010547404) dated March 24, 2022. This is Inspection #1165594. Thank you."
2024-3669,2024-04-19,THE NEW YORK TIMES,"Hello, I am a New York Times reporter requesting the 483 for the most recent inspection of Genecell International LLC (FEI 3008369088) dated 9/19/2018. This is inspection #1066756. Thank you. "
2024-3670,2024-04-19,Keller and Heckman LLP,FOIA Request for Company Documents Related to SE0016736.PD2 - company request. 
2024-3671,2024-04-19,Keller and Heckman LLP,FOIA Request for Company Documents Related to SE0016741 - company request. 
2024-3672,2024-04-19,Redica Systems,CDRH/Medical Devices & Rad Health 483 Request (US-based inspection)
2024-3673,2024-04-19,Redica Systems,CDER/Human Drugs 483 Request (US-based inspection)
2024-3674,2024-04-19,Keller and Heckman LLP,FOIA Request for FDA Documents Related to SE0016741 - FDA request. 
2024-3675,2024-04-19,Keller and Heckman LLP,FOIA Request for Company Documents Related to SE0017690 - company request. 
2024-3676,2024-04-19,Keller and Heckman LLP,FOIA Request for FDA Documents Related to SE0017690 - FDA request. 
2024-3677,2024-04-19,IPD Analytics,Please consider this a request for a copy of the 4/5/2024 Effective Approval letter for ANDA No. 218047 for Eribulin mesylate (generic drug). This document is not currently available on the Drugs@FDA website. 
2024-3678,2024-04-19,Besmed Health Business Corp.,Request for the complete medical device approval records for the 510k Clearance of Acapella Choice Blue Vibratory PEP Device  (K181660)
2024-3679,2024-04-19,"Payne & Fears, LLP","Records from the U.S. Food & Drug Administration Office of Regulatory Affairs including: 1.	Any request by Sri Trang Gloves (Thailand) Co. Ltd. (Suratthani Branch), 189 Moo 7, Playwas, Kanchanadit, Suratthani, Thailand (FEI: 3014768817) to unmerge its name from any other firm, made from January 1, 2021, through June 1, 2022; 2.	Records pertaining to Import Alert # 80-04, published 10/26/21, (attached) including any detainment or seizures of gloves from any entity using the “Sri Trang” name, from June 1, 2021, through June 1, 2022.  "
2024-3680,2024-04-19,Solve Consulting International Pty Ltd,NDA 060613 product registration documentation and supplements
2024-3681,2024-04-19,UNIVERSITY OF CALIFORNIA SAN DIEGO,Please provide copies of FDA 483s sent to the list of IRBs from inspections during the above review period.  The copy of FDA inspections is attached. 
2024-3682,2024-04-22,ABC News,"Records that the FDA has received, and databases compiled, regarding adverse event reports on necrotizing enterocolitis (NEC) caused by preterm infant formula manufactured by either Abbott (including Liquid Protein Fortifier, Similac NeoSure, Similac Human Milk Fortifiers, Similac Special Care 20, Similac Special Care 24, Similac Special Care 24 High Protein, and Similac Special Care 30) or Mead Johnson (including but not limited to Enfamil24) etc"
2024-3683,2024-04-22,Andrew Sheinfeld,"I am an investment professional, and this is a request under the Freedom of Information Act. I would like to request a summary inspection record (form 483) for Establishment Lab's manufacturing facility in Sulayom, Costa Rica from January 2023 until current.   Thank you."
2024-3684,2024-04-22,Arla Foods Ingredients Group P/S,"Please kindly share GRAS Petition No. 1G0371 upon which GRN 37 is based. Please further share any correspondence between FDA and the submitter of the GRAS Petition No. 1G0371. To support the FOIA request, GRN 37 states that GRAS Petition No. 1G0371 was accepted for filing by the FDA in 1995. See 60 FR 6731."
2024-3685,2024-04-22,Ayush Dalia,"I see several Bacteriophage containing dietary supplements in the marketplace. However, I am also aware that FDA has taken a position that bacteriophage are biologics and several INDs for it are made public. Can bacteriophage still be marketed as a dietary supplement if they make allowable sturtcure function claims ? "
2024-3686,2024-04-22,Christopher Stewart,2021-3087  
2024-3687,2024-04-22,FOIA Professional Services,"I would like to submit a FOIA request for all inspection materials issued between 2/15/24 - 4/15/24, for the following manufacturing site:  Rommelag (sites in Germany and Switzerland) - FEI: 3002808845  The product category is Drug Substance or Drug Product: Blow/Fill/Seal.   Please provide the documents electronically if possible. "
2024-3688,2024-04-22,"FOIA Request Services, LLC",all releasable portions of Food Contact Notification (FCN) No. 183
2024-3689,2024-04-22,Relate XR,"We hereby request detailed records for the following classifications and specific submission:  1) We request all submissions including 510(k)s, IDEs, PMAs, and related documents for products classified under 882.5801 — Computerized Behavioral Therapy Device for Psychiatric Disorders.  2) We request all submissions including 510(k)s, IDEs, PMAs, and related documents for products classified under 890.5800 — ETC"
2024-3690,2024-04-22,SIRI & GLIMSTAD LLP,"The full transcripts for all Vaccines and Related Biological Products Advisory Committee (“VRBPAC”) meetings held between January 1, 2020 and December 31, 2021."
2024-3691,2024-04-22,REGENXBIO Inc.,"Request for the Establishment Inspection Report (EIR) from the manufacturing facility Pre-License Inspection (PLI) for Spark (now Roche) located in Philadelphia, PA. The inspection occurred approximately August 21-25, 2017.  "
2024-3692,2024-04-22,REGENXBIO Inc.,"Request for the Establishment Inspection Report (EIR) from the manufacturing facility Pre-License Inspection (PLI) for Krystal Biotech in Pittsburgh, PA. The inspection took place in the November, 2022 timeframe, possibly November 11 to 16, 2022.  "
2024-3693,2024-04-22,REGENXBIO,"Request for the Establishment Inspection Report (EIR) from the manufacturing facility Pre-License Inspection (PLI) for BioMarin located in Novato, CA. The inspection concluded in December, 2022. "
2024-3694,2024-04-22,Redica Systems,CDER/Human Drugs EIR Request (International inspection)
2024-3695,2024-04-22,Redica Systems,CVM/Animal Drugs & Feed 483 Request (US-based inspection)
2024-3696,2024-04-22,Redica Systems,CFSAN/Food & Cosmetics 483 Request (US-based inspection)
2024-3697,2024-04-22,RBC CAPITAL MARKETS,We were hoping to study the review documents that led to recent givinostat approval in DMD. We would love to learn more about your latest views on study endpoints in balance with the drug's overall efficayc/safety profile. Hope you find this request acceptable. Thank you.  
2024-3698,2024-04-22,Penn Chemicals Inc,"21 CFR Part 173  [Docket No. 90F-0344]   I am looking for the petiton which has the procedure below referenced:   “Determination of Molecular Weight Distribution of Poly(Maleic) Acid,” March 17, 1992, produced by Ciba-Geigy, Inc., Seven Skyline Dr., Hawthorne, NY 10532-2188, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51.   "
2024-3699,2024-04-22,"Paul, Weiss, Rifkind, Wharton & Garrison LLP","All documents, including all communications, related to any inspection, investigation, inquiry, or enforcement or compliance action or proceeding concerning or relating to Catalent, Inc.’s manufacturing facilities in the following locations:   •	Bloomington, Indiana (USA) •	Harmans/BWI, Maryland (USA) •	Brussels, Belgium •	Anagni, Italy  Catalent, Inc. develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide.  "
2024-3700,2024-04-22,"Leucine, Inc.","Request for Warning Letter/Form 483 received by: Company name: NATCO Pharma Limited FEI Number: 3004540906 Location: Pharma Division, Kothur Village, Rangareddy, India Date : April 2024"
2024-3701,2024-04-22,Nathan Olinger,"This is a request under the Freedom of Information Act. I request that a copy of the following documents be provided to me: All correspondence and documents regarding the approval process of the drug ZEPBOUND™ (tirzepatide) Injection owned by Eli Lilly and Company which was approved by the FDA in 2022. Including all communications with the pharmaceutical company, clinical trial data, and quality reports."
2024-3703,2024-04-22,Marler Clark Law Firm,"• summary reports of any investigation done for this outbreak, including information regarding the suspected source; • any laboratory analyses conducted on samples collected and tested in the outbreak (phylogenetic trees, lab reports, and/or linelists; and • any traceback information regarding the sources associated with this outbreak."
2024-3704,2024-04-22,KFF Health News,"Any and all documents related to complaints, adverse reactions, citations, inspections, and investigations since 2008 pertaining to the Rocky Mountain Lions Eye Bank (FEI# 3011694463 and 1000517466) in Aurora, Colorado, including but not limited to Forms 483 and Forms 3500, 3500A, and 3500B."
2024-3705,2024-04-22,Vincent Ang,"I would like all records related to Application # AYE2D-GZKW for position Criminal Investigator (GS-1811-11), Vacancy # 12222951.  This includes all formal and informal communication regarding the determination for employment.  Including, but not limited to, the persons involved in making the decision, correspondence, meeting notes, discussion notes, formal and informal."
2024-3706,2024-04-22,Sovish," Please share the Form 483 for ANTHEM BIOSCIENCES PRIVATE LIMITED - Phase II Inspection ended on Dec 08, 2022 for the site Ramnagar, India and fei id 3013884349. This was a Human Drug related inspection."
2024-3707,2024-04-22,Harrington Films,"I am requesting the FEI # for Lystn LLC in relation to what can be looked up in FDA's OSAR. Additionally, I'm requesting all records relating to Lystn LLC that exist in OSAR Facility addresses are 260 Washington Ave, West Hazleton, PA 18202 and 38 S Franklin St Elizabethville, PA 17023 356 Maidencreek RoadFleetwood, PA 19522"
2024-3708,2024-04-22,Gland Pharma Limited,"Labetalol Hydrochloride injection (ANDA # A076051) held by BAXTER HEALTHCARE CORP is approved on Jul 5, 2002. Please provide the ANDA approval letter.    "
2024-3709,2024-04-22,"Vetoquinol USA, Inc.",FOIA for NADA 116-087 Phenylzone (phenylbutazone) paste.
2024-3710,2024-04-22,Pender & Strickland,"All records of incidents in New Jersey, concerning the product ""Neptune's Fix"" "
2024-3711,2024-04-22,Functional Government Initiative,"Records as described below related to the House Committee on Oversight and_x000D_
Accountability’s hearing, “Oversight of the U.S. Food and Drug Administration,” held on April 11,_x000D_
2024: • Copies of all final preparatory materials provided for the hearing to Commissioner Califf. • Any emails, text message, or other communications with anyone outside the federal government related to the hearing. • Any communications with congressional offices related to the hearing. etc_x000D_
"
2024-3714,2024-04-22,"University of Technology,Jamaica",LIST OF RECALLS 
2024-3715,2024-04-22,POINT72,"I am an investment professional and this is a request under the Freedom of Information Act. We would like to request for Eylea (aflibercept 2mg) and Eylea HD (aflibercept 8mg) AERS in PDF and Excel. If possible, please email the materials to quinn.lin@point72.com. Thank you!"
2024-3716,2024-04-22,POINT72," I am an investment professional and this is a request under the Freedom of Information Act. We would like to request Vabysmo (faricimab) AERS in PDF and Excel. If possible, please email the materials to quinn.lin@point72.com. Thank you!  "
2024-3717,2024-04-23,"OFT Law, PLLC","We recently received the FDA Core Report Salmonella Thompson/Seafood/Aug 2021 Cara 1025 Incident Summary Report 11/30/21 and mentioned on page 6 is ""The Traceback timeline, summary and diagram are available in CARA 1025."" We would like to request these documents. Thank you!"
2024-3718,2024-04-23,CSL BEHRING,"Orphan Drug Designation application and any correspondences associated with the application for Balfaxar, prothrombin complex concentrate, human-lans."
2024-3719,2024-04-23,Registrar Corp," We request a spreadsheet which includes the 23 publicly available data points for all entries that led to the inclusion of all TJX Brands - HomeGoods, HomeSense, Marshalls, Sierra, TJ Maxx, on FDA's list. If possible, please include the FEI number for each of the entities above as a column in the spreadsheet. In previous similar requests (FOI 2019-10489 for example), FDA included the FEI numbers in a separate tab in the resulting spreadsheet."
2024-3720,2024-04-23,"Curemark, LLC","eCTD Submissions for IND 73,059 - Treatment of Autism in Children"
2024-3721,2024-04-23,Harrington Films,"Inspection Reports and documents of Lystn, LLC (Answer Pet Food), Address 356 Maidencreek Road, Fleetwood, PA 19522 (01.01.24-03.31.24)"
2024-3722,2024-04-23,THE NEW YORK TIMES,"Full adverse event case files for the following case IDs: 23231603, 23084987, 23172947, 23172842, 23135654, 22829404, 22168734, 22918397, 22265327, 22302803, 22193265.  Please note this is the other half of my previous request (2024-2655).  "
2024-3723,2024-04-23,Bioventus LLC,"On behalf of regulatory affairs department at Bioventus I am requesting for the following PMA supplement(s) for EXOGEN Ultrasound Bond Healing System: 1. PMA 90009/S003:Normal 180 day track, Supplement reason: Change Design/Components/Specifications/Material Approval order statement: APPROVAL FORTHE SONIC ACCELERATED FRACTURE HEALING SYSTEM (SAFHS) MODEL 2000(TM). _x000D_
_x000D_
Note: this is a first party request for one of the PMA supplements owned by Bioventus."
2024-3724,2024-04-23,FOIA Professional Services," I would like to request FDA FAERS reports on the drug Amtagvi (lifileucel), from 2/16/24 to 4/22/24 (or the latest date available). Please look for events under both the brand and generic names. Where possible, please include full narrative of events, and email the results in a PDF or Excel file.  "
2024-3725,2024-04-23,"Skywood Biosciences, Inc","Dear FDA: I am submitting this FOIA request regarding FDA De Novo #BR220737, SeCore CDx HLA Sequencing System.   "
2024-3726,2024-04-23,WilmerHale LLP,"Request No. 1:  Any and all proposals submitted to the U.S. Food and Drug Administration (“FDA”) under Section 804 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 384, to import eligible prescription drugs from Canada.  This request encompasses copies of all initial, amended, supplemented, or otherwise modified Section 804 importation program (“SIP”) proposals submitted to FDA for approval whether pending, withdrawn, or approved.  _x000D_
_x000D_
•	Request No. 2:  All communications between FDA and any entity that submitted a proposal as described in Request No. 1 regarding the contents or substance of that proposal._x000D_
_x000D_
In accordance with 5 U.S.C. § 522(a)(6), please reply to this request within 20 business days.  Any charges authorized by statute up to $500 are pre-authorized and will be paid by us.  Please contact me if the service charges will exceed that amount and, if so, provide an estimate for the total cost.  All electronic records should be produced in native format; if that is not possible, please provide them in usable electronic format with file and system metadata intact._x000D_
_x000D_
If you contend that any part of the requested information is exempt from disclosure, please state in writing the basis of such exemption including a description of the allegedly exempt information and the specific statutory citation of the exemption(s) at issue.  If you rely upon a previous exception determination, please identify the applicable court decision or Attorney General’s opinion._x000D_
If you have any questions, or if you need additional information or clarification to respond to this request, please let me know as soon as possible."
2024-3727,2024-04-23,Union Agener Inc,"The EIR (in electronic format) for Animal Drug inspection of Union Agener Inc for inspection dates 12/11/2023 - 12/15/2023 at the location in Augusta, Georgia.  "
2024-3728,2024-04-23,Keller and Heckman LLP,FOIA Request for Documents Relating to FCN 2326.
2024-3729,2024-04-23,"Pyros Pharmaceuticals, Inc.",FAERS Individual Case Reports Suspect Drug Vigabatrin Case Number Source: FAERS Public Dashboard Case IDs: 10847373; 10794566; 10770067; 10759195; 10753198; 10753092; 10753000; 10746169; 10716514; 10711707; 10705267; 10696144 
2024-3730,2024-04-23,Ocular Therapeutix,"I am requesting the Establishment Inspection Report (EIR) and Form 483 issued by the FDA with regard to the two inspections that occurred between 01 April - 30 June, 2013, at Ocular Therapeutix, located at 36 Crosby Drive, Bedford, MA - 01730.   "
2024-3731,2024-04-23,WORMINGTON AND BOLLINGER,"In support of New Drug Application 22-58 (Zymaxid), FDA employee Constantine Markos sent an email on 4/14/2010 to Allergan. I seek a copy of the email sent by Constantine Markos to Allergen on 4/14/10. This involves litigation and a protective order is in place that I can provide you so that you may provide me the letter. I also have correspondence from Allergan referencing Constantine Markos' email but not the actual email."
2024-3732,2024-04-23,"Sun Phamaceutical Industries, Inc.","Bioequivalence Review  [Reviewed By - Division of Bioequivalence III (DBIII), Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research]"
2024-3733,2024-04-23,"Celltrion, Inc.",A copy of complete response letter (CRL) issued to Xbrane Biopharma AB regarding biologics license application (BLA) for its ranibizumab biosimilar candidate (development name Xlucane) for treatment of retinal disorders.
2024-3734,2024-04-23,Novick Biosciences Pvt. Ltd.,"We are looking for HYDROXYUREA (application# 075734) approval/review summary i.e. Recent Printed Labeling, Summary Review, Medical Review(s), Chemistry Review(s), Pharmacology Review(s), and Clinical Pharmacology Biopharmaceutics Review(s). "
2024-3735,2024-04-23,ManaMed,"The entire FDA submission file for product code JOW, applicant name JKH Health Co. Ltd, and the 510K number is K202839.  We would like all sections of the 510K. "
2024-3736,2024-04-23,ManaMed,"We would like to receive all sections submitted to the FDA for the 510K number K240011.  Applicant is JKH Health Co. Ltd., device name is Lymphedema compression. "
2024-3737,2024-04-23,"Xpro associates, LLC","483 issued to ""Fujimoto Chemicals, Amagasaki Japan"" (FEI: 3002806358) on FDA Drug Inspection. (240207)"
2024-3738,2024-04-23,BioCytics," 1-	The number of cell and gene therapy  IND applications received by the FDA since 2014 (past 10 years), year-by-year. 2-	 The number of cell and gene therapy  IND applications approved by the FDA since 2014 (past 10 years), year-by-year. 3-	The number of active cell and gene therapy  IND since 2014 (past 10 years), year-by-year. "
2024-3739,2024-04-23,Shehadeh Giannamore PLLC,"All documents and communications to or from the FDA with the name ""Relaxium"" "
2024-3740,2024-04-23,Womble Bond Dickinson (US) LLP,2024-3162
2024-3741,2024-04-23,Womble Bond Dickinson (US) LLP,2023-3163
2024-3742,2024-04-23,Womble Bond Dickinson (US) LLP,2023-3164
2024-3743,2024-04-23,Womble Bond Dickinson (US) LLP,2023-3219
2024-3744,2024-04-23,Womble Bond Dickinson (US) LLP,2023-6818
2024-3745,2024-04-23,Womble Bond Dickinson (US) LLP,2023-6819
2024-3746,2024-04-23,Womble Bond Dickinson (US) LLP,2023-6820
2024-3747,2024-04-23,Womble Bond Dickinson (US) LLP,2023-6821
2024-3748,2024-04-23,Womble Bond Dickinson (US) LLP,2023-5934
2024-3749,2024-04-23,Womble Bond Dickinson (US) LLP,2023-7774
2024-3750,2024-04-23,Womble Bond Dickinson (US) LLP,2023-8156
2024-3751,2024-04-23,Womble Bond Dickinson (US) LLP,2023-8157
2024-3752,2024-04-23,Womble Bond Dickinson (US) LLP,2023-8158
2024-3753,2024-04-23,Womble Bond Dickinson (US) LLP,"Scientific Review Documents_x000D_
Pertaining to MNGO Disposable Stick E-Cigarettes PMTAs"
2024-3754,2024-04-23,FOIA Professional Services,Please provide the disclosable portions of the entire fulfillment for File number: 2022-5691  Please provide the documents electronically if possible.
2024-3755,2024-04-23,FOIA Professional Services,Please provide the disclosable portions of the entire fulfillment for File number: 2022-6418  Please provide the documents electronically if possible.
2024-3756,2024-04-23,COGENCY GLOBAL INC.,2020-3090
2024-3757,2024-04-23,COGENCY GLOBAL INC.,2020-4085
2024-3758,2024-04-23,COGENCY GLOBAL INC.,2020-4091
2024-3759,2024-04-24,"Duty, Harry ","calendar records for FDA-CVM employee William T. Flynn, dates 01.01.24-02.29.24"
2024-3760,2024-04-24,"Duty, Harry ","Inspection Reports and documents of Lystn, LLC (Answer Pet Food), Address 356 Maidencreek Road, Fleetwood, PA 19522 (01.01.23-12.31.23)"
2024-3761,2024-04-24,Law Office of L. DeWayne Layfield,All files and records regarding Complaint 185534 and Complaint 185542
2024-3762,2024-04-24,FOIA Professional Services,"I would like to submit a FOIA request for all inspection materials issued between 2/15/24 - 4/15/24, for the following manufacturing site:  Rommelag  FEI Number: 3004079469  Please provide the documents electronically if possible. "
2024-3763,2024-04-24,FOIA Professional Services,"I would like to submit a FOIA request for all inspection materials issued between 2/15/24 - 4/15/24, for the following manufacturing site:  Rommelag  FEI Number: 3002807230  Please provide the documents electronically if possible. "
2024-3764,2024-04-24,PharmaLogic Holdings Corp," This letter is a Freedom of Information Action (FOIA) request for all 483 citations, 483 citation responses including attachments if applicable, and Establishment Inspection Reports (EIRs) issued for 3D Imaging Drug Design and Development (FEI 3009143510) from April 19, 2016 to April 23, 2024 (Present).  The address of this establishment is:  P.O. Box 3457 Little Rock, AR 72203  "
2024-3765,2024-04-24,FOIA Professional Services,"I would like to submit a FOIA request for all inspection materials issued between 2/15/24 - 4/15/24, for the following manufacturing site:  Unither Pharma (France)- FEI: 3006974616  Please provide the documents electronically if possible. "
2024-3766,2024-04-24,FOIA Professional Services,"I would like to submit a FOIA request for all inspection materials issued between 2/15/24 - 4/15/24, for the following manufacturing site:  Recipharm (Kaysersberg, France) - FEI: 3002806288  Please provide the documents electronically if possible. "
2024-3767,2024-04-24,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Syfovre (branded name / marketed by Apellis Pharmaceutical) or pegcetacoplan (generic name) between April 18, 2024 and April 23, 2024.  Please provide the documents electronically if possible. "
2024-3768,2024-04-24,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for ELEVIDYS (branded name / marketed by Sarepta Therapeutics, Inc.) or delandistrogene moxeparvovec-rokl (generic name) between April 18, 2024 and April 23, 2024.   Please provide the documents electronically if possible."
2024-3769,2024-04-24,Registrar Corp,"We are the agent for Plastube Inc.  Plastube Inc. does not have a copy of Drug Master File (DMF) 21501 that it has submitted in paper format. Please provide a copy of the files for Drug Master File (DMF) 21501 in paper, or eCTD Format if applicable, submitted to FDA. Your assistance on this matter is greatly appreciated. Thank you in advance."
2024-3770,2024-04-24,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Wegovy (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between April 18, 2024 and April 23, 2024.  Please provide the documents electronically if possible."
2024-3771,2024-04-24,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Ozempic  (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between April 18, 2024 and April 23, 2024.  Please provide the documents electronically if possible."
2024-3772,2024-04-24,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Zepbound (branded name / marketed by Lilly) or tirzepatide (generic name) between April 18, 2024 and April 23, 2024.  Please provide the documents electronically if possible."
2024-3773,2024-04-24,Registrar Corp,"We are the agent for Plastube Inc.  Plastube Inc. does not have a copy of Drug Master File (DMF) 21502 that it has submitted in paper format. Please provide a copy of the files for Drug Master File (DMF) 21502 in paper, or eCTD Format if applicable, submitted to FDA. Your assistance on this matter is greatly appreciated. Thank you in advance."
2024-3774,2024-04-24,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Mounjaro (branded name / marketed by Lilly) or tirzepatide (generic name) between April 18, 2024 and April 23, 2024.  Please provide the documents electronically if possible."
2024-3775,2024-04-24,Registrar Corp,"We are the agent for Plastube Inc.  Plastube Inc. does not have a copy of Drug Master File (DMF) 21503 that it has submitted in paper format. Please provide a copy of the files for Drug Master File (DMF) 21503 in paper, or eCTD Format if applicable, submitted to FDA. Your assistance on this matter is greatly appreciated. Thank you in advance."
2024-3776,2024-04-24,KFF Health News,"The documents provided in response to three previously completed requests with the following control numbers: 2023-3179, 2020-8428, 2020-999."
2024-3777,2024-04-24,Trader Joe's Company,"This is a request under the Freedom of Information Act. I am requesting copies of public records that contain information from the FDA’s Foreign Supplier Verification Programs - List of Participants (FSVP Importer List) for the time period of January 1, 2023 – February 29, 2024 for the following listed importers:_x000D_
_x000D_
•	Trader Joe’s Company_x000D_
•	Trader Joe’s_x000D_
•	Trader Joes_x000D_
•	Trader Hoes Company_x000D_
•	Trader Joees Company_x000D_
•	Trader Joe San Bernardino_x000D_
•	Trader Joe’s Company 5053-WCD ST_x000D_
•	Trader Joe’s Company – Chino_x000D_
•	Trader Joe’s(East)_x000D_
•	Trader Joes Fontana_x000D_
•	Trader Joes West_x000D_
_x000D_
I am requesting data associated with the above listed FSVP importers, specifically identification of the filer, the filer’s contact information, the port of entry, and any other information that can be used to follow up with the filer(s) to address the improper naming of the above-referenced companies as FSVP importers. _x000D_
_x000D_
If there are any fees for searching or copying these records, please inform me if the cost will exceed $200.00. The records should be sent to the email indicated below. In order to help determine my status to assess fees, I am affiliated with a private corporation and am seeking the information for use in the company’s business. _x000D_
_x000D_
Please contact me with information about when I might expect copies of the requested records or if you require further information to complete this request. The records should be sent to the address or email address below. _x000D_
_x000D_
Thank you for your assistance on this matter._x000D_
_x000D_
Elizabeth Skulavik _x000D_
Trader Joe’s Company_x000D_
foodsafety@traderjoes.com"
2024-3778,2024-04-24,Riley Trachtenberg,"•	All traceback documentation (especially invoice documents and inspection records) for all leafy green products (iceberg, romaine, spinach, spring mix, green leaf, red leaf) associated with the 2309MLEXH-1 outbreak from July – September 2023."
2024-3779,2024-04-24,Pharmavite LLC,"Dear FDA,  This is a request under the Freedom of Information Act. I kindly request the following documents:  • Pharmavite LLC 483 Response, dated September 2021 • Pharmavite LLC 483 Ninety (90) Business Day Update, dated January 2022 • Pharmavite LLC Final 483 Update, dated July 2022  In addition, I am requesting Establishment Inspection Reports (EIR), FDA-483, FDA-482, and Warning Letters filed since January 1, 2016 for each of the below facilities:   • Pharmavite LLC 4701 Northpark Dr Opelika, AL 36801  etc"
2024-3780,2024-04-24,"SI-TECHNOLOGY, LLC","Please provide all 510(k) submission related information, media, citations, attendee lists, meeting minutes, notes, memos, transcripts, communications, attachments and correspondences specific to the following 510(k): K232149 (Decision Date: 04/20/2024)"
2024-3781,2024-04-24,Redica Systems,CDER/Human Drugs 483 Request (US-based inspection)
2024-3782,2024-04-24,Redica Systems,CDER/Human Drugs EIR Request (US-based inspection)
2024-3783,2024-04-24,"Zymergi, Inc.",Please provide the pdfs of Drug & Device 483s previously released to FDA News for the above 2 month time period 09.01.2023 thru 10.31.2023.
2024-3784,2024-04-24,Keller and Heckman LLP,FOIA Request for Documents Relating to FCN 2221.
2024-3785,2024-04-24,Steve Campbell,"Hello - I am looking to obtain a copy of the EIR published for the audit conducted April 3rd - April 5th 2023 of PPD Development, L.P., FEI # 2129896"
2024-3786,2024-04-24,CNBC,"Please share form 483 for Zydus Lifesciences india Jarod unit, near Vadodara.  USFDA conducted an inspection at the Injectable Manufacturing site situated at Jarod, near Vadodara. The inspection was conducted from April 15 to April 23, 2024.  The inspection closed with 10 observations"
2024-3787,2024-04-24,Pranav Chawla,"requesting a copy of Form 483 issued to Zyduslife sciences for the inspection conducted at the Injectable Manufacturing site situated at Jarod, near Vadodara. The USFDA issued 10 observations upon closure of inspection.  "
2024-3788,2024-04-24,Avendus,"Please provide the Form 483 issued by USFDA at Zydus Lifesciences' Injectable Manufacturing site situated at Jarod, near Vadodara, India (FEI #: 3013712903) after an inspection ending 23rd April 2024."
2024-3789,2024-04-24,Morgan Stanley,"Please send form 483 for Zydus, April 2024 inspection at Jarod, Vadodara injectable facility, India. "
2024-3790,2024-04-24,"Agarwal, Bhavish ","Please share the copy of the Form483 for the inspection that  happened at the Zydus Lifesciences injectables manufacturing unit in situated at Jarod, near Vadodara Gujarat. The FDA inspected the facility from April 15 to April 23. The inspection was related to Human Drugs."
2024-3791,2024-04-24,"Agarwal, Bhavish ","The United States Food and Drug Administration (US FDA) has inspected the formulations (oncology) manufacturing facility of its subsidiary, Pinnacle Life Science at Baddi, Himachal Pradesh from 16 April 2024 to 22 April 2024. The inspection was related to Human Drugs. Request you to please share the copy of the Form 483."
2024-3792,2024-04-24,Element Materials Technology,Seeking redacted 510(k) record for the following submission:  K234073
2024-3793,2024-04-24,CeBIL: Center for Advanced Studies in Biomedical Research (Copenhagen),"Remarks by FDA Commissioner Margaret A. Hamburg on ""Effective Enforcement and Benefits to Public Health"" at Food and Drug Law Institute, August 6, 2009. [previously available at: http://www.fda.gov/NewsEvents/Speeches/ucm175983.htm]"
2024-3794,2024-04-25,"Melton, Donavan ","calendar records for FDA-CVM employee William T. Flynn, dates 01.01.24-02.29.24"
2024-3795,2024-04-25,"Melton, Donavan ","Inspection Reports and documents of Lystn, LLC (Answer Pet Food), Address 356 Maidencreek Road, Fleetwood, PA 19522 (01.01.23-12.31.23)"
2024-3796,2024-04-25,Sundaram Mutual Fund,"Human Drug - Form 483 of Zydus Lifescience Ltd site located at Survey Nos. 434/6/B and 434/1/K, Vadodara - Halol Highway, Village - Jarod, Taluka - Waghodia, District - Vadodara, Vadodara, Gujarat 391510, India (IND) which was inspected from April 15 to April 23, 2024. "
2024-3797,2024-04-25,FDA NEWS,"A listing of all FDA Form 483 Notices of Inspectional Observations for:   •	Pharmaceutical, biologics and medical device manufacturing facilities, including premarket approval inspections, •	Clinical research sites, investigators, and IRBs AND •	Bioresearch Monitoring (BIMO)  both in the United States and outside the United States that received such notices dated from March 1 to 31, 2024. etc"
2024-3798,2024-04-25,"FOIA Request Services, LLC","Requesting a copy of Food Contact Notification (FCN) No. 285, including all releasable FDA chemistry and toxicology review memoranda and all correspondence. This FCN clears the use of 2- oxepanone, polymer with 1,4-butanediol (CAS Reg. No. 31831-53-5) as a processing aid in all polyolefins for single and repeat use food-contact applications. "
2024-3799,2024-04-25,Emily Marshall,"We are looking for the two reports FDA has sent to Congress, as indicated in its FY2022 and FY 2023 OMUFA Performance Reports:  ""The congressionally required Pediatrics Cough/Cold Letter, describing the FDA’s progress in evaluating and revising, as appropriate, the cough and cold monograph with respect to children under age 6, was sent to Congress on March 15, 2022.""  ""The congressionally required Pediatrics Cough/Cold Letter, describing the FDA’s progress in evaluating and revising, as appropriate, the cough and cold monograph with respect to children under age 6, was sent to Congress on March 23, 2023.""   "
2024-3800,2024-04-25,FOIA Professional Services,"I would like to request the medical review and cross-discipline team reviews for the following approval:  ENHERTU (fam-trastuzumab deruxtecan-nxki, Daiichi Sankyo, Inc.) SUPPL-28, approval dated April 5, 2024, for adult patients with unresectable or metastatic HER2-positive (ICH3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options (approval press release here)  Please provide the documents electronically if possible.      "
2024-3801,2024-04-25,FOIA Professional Services," I would like the medical review and cross-discipline team reviews for the following approval:  TUKYSA (tucatinib, Seagen Inc.) SUPPL-4, approval dated January 19, 2023, in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (approval press release here)  Please provide the documents electronically if possible."
2024-3802,2024-04-25,CLARK & BRODY,"Seeking information relating to Gras Notice GRN 000607 for glucosylated steviol glycosides (minimum purity 80%) The GRAS Notice GRN No. 607 as found on the FDA web page for GRAS Notices indicates a date of filing of November 24, 2015.  Requester is seeking information filed with the FDA on the date of November 24, 2015 or thereabout that date. "
2024-3803,2024-04-25,"Hyman Phelps & McNamara, P.C.","Request for any and all Exclusivity Determination documentation concerning Eohilia (generic name budesonide), designation date December 20, 2006. Additional information on the product can be found at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=227406.  "
2024-3804,2024-04-25,Pender & Strickland,"This office requests files from the criminal investigation by the FDA into the case of United States v. Stabile (3:19-cr-30041). Specifically, any information acquired through investigation, regarding the buyers of Tianeptine Sodium from Ryan M Stabile, and any companies or incorporations associated with the buyers and dates the purchases were made."
2024-3805,2024-04-25,FOIA Request Services,   BPA 75F40123A00018 awarded to Research Triangle Institute for Tobacco Control Policy Evaluation Support Services by FDA in May 2023 BPA 75F40118A10042 awarded to Research Triangle Institute for Tobacco Control Policy Evaluation Support Services for FDA in Sept 2018    
2024-3806,2024-04-25,ASSOCIATED PRESS,Please send all materials the FDA provided in response to the following FOIA control numbers: 2020-5038 2021-5314 2021-5654 2022-2320
2024-3807,2024-04-25,Washington University in St. Louis School of Medicine,"My laboratory at Washington University in St Louis is looking for anonymized medical records of patients participating in the study ""Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis"" published in the the NEJM in 2002  (https://www.nejm.org/doi/full/10.1056/NEJMoa020191). "
2024-3808,2024-04-25,Center for Science in the Public Interest,All written records of data collected during the Front of Package Focus Groups in 2022 and 2023 (listed on the website https://www.fda.gov/food/food-labeling-nutrition/front-package-nutrition-labeling  as “Front of Package Focus Groups-2022” and “Front of Package Focus Groups-2 -2023”) conducted as part of FDA’s consumer research to explore the development of a front-of-package nutrition labeling scheme
2024-3809,2024-04-25,FOIA Professional Services,"I am requesting copies of the complete detailed reports for the following individual case reports listed on the FAERS Public Dashboard: 23231472, 23231471, 23231468, 23231466, 23231465, 23231463, 23231462, 23231460, 23231458, 23231457, 23231456, 23231455.  Please provid ethe documents electronically if possible."
2024-3810,2024-04-25,HAGENS BERMAN SOBOL SHAPIRO LLP,"This request under the Freedom of Information Act seeks certified copies of the Office of Generic Drugs Approval Routing Summary—for both tentative and/or final approval—for any Abbreviated New Drug Application referencing Celgene’s Pomalyst (pomalidomide) New Drug Application (NDA 204026) held by or associated with Teva Pharmaceutical Industries Ltd. or its affiliates, including ANDA 209956."
2024-3811,2024-04-25,K&L GATES,"The “Recall Remediation Plan” that was submitted to FDA, and amended on or about March 28, 2024, by Philips RS North America LLC, Respironics California LLC, or Philips Holding USA Inc. (collectively “Philips”) and was referenced in the Consent Decree entered into by Philips and FDA on April 9, 2024."
2024-3812,2024-04-25,K&L GATES,"Copies of any meeting minutes generated between January 1, 2023 and February 6, 2024 relevant to Supplement number SUPPL-5312, dated February 6, 2024, to Biologic License Application (BLA) 103979, held by GENZYME."
2024-3813,2024-04-25,K&L GATES,"All available review documents related to Supplement SUPPL-5312, dated 2/6/2024 with regard to Biologic License Application (BLA) 103979, for the company GENZYME."
2024-3814,2024-04-25,K&L GATES,Any safety labeling change notifications sent to the Applicant/Sponsor/owner of BLA 103979 regarding 103979 within the last 2 years.
2024-3815,2024-04-25,Keller and Heckman LLP,Freedom of Information Act (FOIA) Request for Unredacted Associated Review Memoranda for FCN 2325. 
2024-3816,2024-04-25,Redica Systems,"Please provide the following inspection-related documents in electronic PDF format:  - 483 (in electronic format) for the Biologics inspection of Grand River Aseptic Manufacturing, Inc., located in Grand Rapids MI, United States, inspection ending 2/21/2024 (FEI 3008716173). - 483 (in electronic format) for the Biologics inspection of Center for Reproductive Medicine & Robotic Surgery LLC, located in Saint Louis, MO, United States, inspection ending 3/11/2024 (FEI 3008945619). - 483 (in electronic format) for the Biologics inspection of Octapharma Plasma, Inc., located in Dallas, TX, United States, inspection ending 3/22/2024 (FEI 3012288516).  etc"
2024-3817,2024-04-25,The Epoch Times,"Hello,  Please provide all documents showing the results of testing for H5N1 on samples of pasteurized milk from grocery stores.  Thank you"
2024-3818,2024-04-25,Redica Systems,"Please provide the following inspection-related documents in electronic PDF format: - EIR (in electronic format) for the Medical Devices & Rad Health inspection of Mesa Laboratories, Inc., Bozeman Manufacturing Facility, located in Bozeman, MT, United States, inspection ending 6/14/2019 (FEI 3013667284)."
2024-3819,2024-04-25,REUTERS,"I would like to request electronic copies over email of the summary narratives for the following 12 adverse event records related to semaglutide, the earliest of which was initially received by the FDA January 2 2024: (Case ID): 23675472, 23589564, 23556600, 23447747, 23434895, 23413203, 23407280, 23407249, 23407242, 23407234, 23389975, 23355684 "
2024-3820,2024-04-25,VIVEK MANE,Request to send Form-483 issued to Jubilant Pharmova (Jubilant Draximage Inc) for its facility at Montreal Canada.
2024-3821,2024-04-25,CNBC TV18,FORM 483 for  Zydus Life's Vadodara Injectable facility  10 observations 
2024-3822,2024-04-25,Jefferies LLC,"I would like to request complete detailed reports of any and all adverse events reported to the FAERS database for Syfovre (branded name / marketed by Apellis) or pegcetacoplan (generic name) and Izervay (branded name / marketed by Astellas) or avacincaptad pegol (generic name) between January 1, 2024 and April 24, 2024"
2024-3823,2024-04-25,"Radice Law Firm, P.C.","This request under the Freedom of Information Act seeks certified copies of the Office of Generic Drugs Approval Routing Summary—for both tentative and/or final approval—for any Abbreviated New Drug Application referencing Celgene’s Pomalyst (pomalidomide) New Drug Application (NDA 204026) held by or associated with Aurobindo Pharma or its affiliates, including ANDA 210249. "
2024-3824,2024-04-25,"TLC Biopharmaceuticals, Inc.",Drug Name: Exparel NDA No.: 022469 Company: PACIRA PHARMS INC Document Requested: FDA's ClinicalPharmacology/Biopharmaceutical Review(s) on SUPPL-37 or 38 for the approval of new Manufacuring process.
2024-3825,2024-04-25,"Nichols, Kevin ","FDA occasionally issues ""It Has Come to Our Attention"" (IHCTOA) letters to manufacturers when the agency identifies potential issues that need to be addressed. FDA no longer publishes these online, but states they are subject to FOIA. I am seeking any IHCTOA letters that reference ""over-the-counter"" devices, also sometimes referred to as ""OTC"" devices that have been the subject of an IHCTOA letter since FDA stopped publicly posting these. The last publically posted IHCTOA posted as a ""Letters to Industry"" communication was posted on 8/1/18."
2024-3826,2024-04-25,The Sidebar (blog),Recs re FDA choking response statement
2024-3827,2024-04-26,Harrington Films,"I am requesting all email records from Edward Potter [/DHHS/FDA/OC/OPLIA/OGPS/OGO---CONSUMER SAFETY OFFICER---Baltimore MD 21215---Edward.Potter@fda.hhs.gov] pertaining to key terms: Aunt Jeni's, Aunt Jeni, Jennifer Boniface 01.01.20-06.17.20"
2024-3828,2024-04-26,Harrington Films,"Requesting records for:  1. All reports of adverse events and/or reactions dog and/or cats have had to dog and cat food and dog and cat treats from 03.05.2024-03.31.2024 a. Please include the type of animal, the reaction, the brand name and the product name of the food item to which the dog or cat reacted, the symptoms displayed and the outcome, if available. etc"
2024-3829,2024-04-26,"CD Diagnostics, INC","Any and all documents, attachments, communications, publications related to De Novo # DEN200052, KidneyIntelX.Dkd, summited to FDA. "
2024-3830,2024-04-26,"FOIA Request Services, LLC",Please note that we would like to be contacted if there are ANY costs for this request.  Requesting a copy of Food Contact Notification (FCN) No. 1454.
2024-3831,2024-04-26,PLEXUS CORP,"EIR for FDA Inspection of Nalu Medical, Inc 2320 Faraday Ave Ste 100, Carlsbad CA 92008; Date of Inspection conclusion: April 28, 2021 "
2024-3832,2024-04-26,Labtest International Inc. dba Intertek,"Chemistry and Toxicology Memo's for FCN No. 798 Food Contact Substance: 12H-Phthaloperin-12-one, 8,9,10, 11-tetrachloro- (CAS Reg. No. 20749-68-2). Intended Use: As a colorant for use in polyethylene terephthalate polymers complying with 21 CFR 177.1630."
2024-3833,2024-04-26,Matcher-True Crime Media,"1. Please provide all interrogation video of Raynaldo Rivera Ortiz Jr. arrested in Plano, Texas, by your agency and the Dallas  Police Department for injecting nerve blocking and bronchodilation drugs into patient IV bags. ETC"
2024-3834,2024-04-26,KFF Health News,"The Report of Correction filed by Thoratec Corp. for the Urgent Medical Device Correction initiated in February 2024 for HeartMate 3 LVAS Kits & HeartMate 3 Outflow Grafts, HeartMate II LVAS Kits & HEARTMATE II Outflow Grafts, and which led to a Class 1 Recall of HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS) due to Long-term Buildup Causing an Obstruction, announced by FDA on April 15, 2024.  ETC"
2024-3835,2024-04-26,Al Jazeera,"- All memos, briefings, reports and correspondence sent and/or received by Celia Gabrel, Acting Director, China Office, between July 1, 2023 and December 31, 2023 that address, or relate to, China's revised anti-espionage law."
2024-3836,2024-04-26,Besmed Health Business Corp.,Request for the complete medical device approval records for the 510kClearance of Acapella Choice Blue Vibratory PEP Device (K181660)
2024-3837,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                            Active Intelligence LLC Cherryville, North Carolina End Dates of inspection: 08 Mar 2024  Project Area: Drug Quality Assurance FEI: 3014556381 Classification: VAI   "
2024-3838,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                            Aeye Health Inc. New York, United States End Dates of inspection: 15 Mar 2024  Project Area: Postmarket Assurance: Devices FEI: 3025301728 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3839,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                               Amphastar Pharmaceuticals, Inc. Rancho Cucamonga, California United States End Dates of inspection: 01 Mar 2024  Project Area: Drug Quality Assurance FEI: 3002936358 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200.  "
2024-3840,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                               Arc Precision Acquisitions, LLC. Isanti, Minnesota United States End Dates of inspection: 20 Mar 2024  Project Area: Compliance: Devices FEI: 3011567699 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3841,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                           BioTissue Holdings Inc Miami, Florida United States End Dates of inspection: 06 Mar 2024  Project Area: Compliance: Devices FEI: 3003415347 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200.  "
2024-3842,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                   Center for Reproductive Medicine & Robotic Surgery LLC Saint Louis, Missouri United States End Dates of inspection: 11 Mar 2024  Project Area: Human Cellular, Tissue, and Gene Therapies FEI: 3008945619 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3843,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                              Cerapedics, Inc. Westminster, Colorado United States End Dates of inspection: 13 Mar 2024  Project Area: Postmarket Assurance: Devices FEI: 3007155473 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3844,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                          Charity Helpers Foundation Salt Flat, Texas United States End Dates of inspection: 01 Mar 2024  Project Area: Human Cellular, Tissue, and Gene Therapies FEI: 3026792122 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200.  "
2024-3845,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                          Cryos International USA LLC Raleigh, North Carolina United States End Dates of inspection: 22 Mar 2024  Project Area: Human Cellular, Tissue, and Gene Therapies FEI: 3021830708 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3846,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                              Dallas IVF Frisco, Texas United States End Dates of inspection: 28 Mar 2024  Project Area:  Blood and Blood Products FEI: 3006631826 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200.  "
2024-3847,2024-04-26,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                              Distron Corporation Attleboro Falls, Massachusetts United States End Dates of inspection: 20 Mar 2024  Project Area:  Compliance: Devices FEI: 3006621944 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3848,2024-04-26,David Margolick,Transcript of hearing before FDA advisory committee on application by Immune Response Corporation to conduct human clinical tests of AIDS vaccine.
2024-3849,2024-04-26,Eye Bank Association of America (EBAA),"EBAA / FDA Executive Liaison Meeting Summary Report for the meeting on April 18, 2024 with the Office of the Center Director, the Super Office of Therapeutic Products, and the Office of Compliance & Biologics Quality."
2024-3850,2024-04-26,"McCarter & English, LLP","The disclosable portions of any and all documents and records concerning the Cath-Tech Port Implantable Vascular Access System (K880571), including but not limited to memoranda, reports, summaries, briefing documents, presentations, slide decks, reviews, analyses, meeting minutes, notes, letters, emails, facsimiles, telephone logs, etc., from January 1, 1986 to present."
2024-3851,2024-04-26,"McCarter & English, LLP","The disclosable portions of any and all documents and records concerning the PowerPort Implanted Port with Groshong Catheter (K081311), including but not limited to memoranda, reports, summaries, briefing documents, presentations, slide decks, reviews, analyses, meeting minutes, notes, letters, emails, facsimiles, telephone logs, etc., from January 1, 2006 to present."
2024-3852,2024-04-26,"McCarter & English, LLP","The disclosable portions of any and all documents and records concerning the GamCath® High Flow Dolphin® Catheter, MS-GDHC-1315 A, MS-GDHC-1315J A, MS-GDHC-1320 A, and MS-GDHC-132 (K100451), including but not limited to memoranda, reports, summaries, briefing documents, presentations, slide decks, reviews, analyses, meeting minutes, notes, letters, emails, facsimiles, telephone logs, etc., from January 1, 2008 to present."
2024-3853,2024-04-26,Redica Systems,"Please provide the following inspection-related documents in electronic PDF format: - 483 for the Medical Devices & Rad Health inspection of Milford Regional Franklin Diagnostic Imaging, located in Franklin, MA, United States, inspection ending 3/28/2024 (FEI 3015282476). - 483 for the Medical Devices & Rad Health inspection of Premier Radiology Mequon, located in Mequon, WI, United States, inspection ending 3/28/2024 (FEI 3021820470). - 483 for the Medical Devices & Rad Health inspection of St. Marys Short Pump Emergency Center, located in Richmond, VA,  etc"
2024-3854,2024-04-26,STAT,"All FDA memorandum, internal letters and correspondence between Wilson W. Bryan M.D., Office of Therapeutic Products in the FDA’s Center for Biologics Evaluation and Research, and Dr. Namandjé N. Bumpus, principal deputy commissioner and FDA chief scientist. "
2024-3855,2024-04-26,, All emails sent from or received by Grade A Milk Safety Branch chief Gregory Gharst concerning the FDA's discovery of viral particles from H5N1 (Highly Pathogenic Avian Influenza) in samples of pasteurizes milk in the commercial supply chain.
2024-3856,2024-04-29,," All outbreak investigation reports; laboratory reports; milk testing sample reports; copies of test samples or reports from the Grade A program; memos; white papers and/or any other documentation that informed the FDA's announcement on April 23, 2024 that it had found viral particles from Highly Pathogenic Avian Influenza in samples of pasteurized milk in the commercial supply chain. "
2024-3857,2024-04-29,Shane Wanninger,"Documents related to the activities and operations of TATRC (The Telemedicine and Advanced Technology Research Center) and the divisions under TATRC, including the BHSAI Data Sciences Division, Digital Health Innovation Center, Medical Modeling Simulation, Information and Visualization, and Medical Robotics and Autonomous Systems divisions, or departments, etc"
2024-3858,2024-04-29,"Center for Regulatory Services, Inc",Please provide a copy of the request and full response to FOI 2018-9433.
2024-3859,2024-04-29,Lieberman PLLC,"On March 3, 2021, FDA issued a press release announcing that it had sent letters to 25 firms that produce and issue “FDA registration certificates” to medical device companies (including manufacturers, distributors and sellers) to stop producing and issuing these certificates. I am seeking copies of the 25 letters to the firms."
2024-3860,2024-04-29,Sovish,2023-10649
2024-3861,2024-04-29,United Safety Agents,"Dear Division of Freedom of Information Team,  We respectfully request all entry-line records that contain any of the following data points in reference to any entry-line’s FSVP Importer, Importer of Record, or Consignee; for entry-lines with submission or arrival dates from April 01 to April 30, 2024:   1) DUNS Number / Unique Facility Identifier (UFI) of  080801169  2) Name of  United Safety Agents, United Safety Agents LLC,etc"
2024-3862,2024-04-29,Monogram Orthopedics,"Dear FOIA Officer, I am writing on behalf of Monogram Orthopaedics to request records under the Freedom of Information Act (FOIA), regarding the FDA submission for following:   1) 510(k) # K220459  Device Name - MAKO Total Knee Application Decision Date - April 15, 2022 Company Name - MAKO Surgical Corp  etc"
2024-3863,2024-04-29,Monogram Orthopedics,"Dear FOIA Officer, I am writing on behalf of Monogram Orthopaedics to request records under the Freedom of Information Act (FOIA), regarding the FDA submission for following:   1) 510(k) # K233227 Device Name - VELYS? Robotic-Assisted Solution Decision Date - December 14, 2023 Company Name - Depuy Ireland   2) 510(k) # - K202769 Device Name - VELYS? Robotic-Assisted Solution Decision Date - January 14, 2021 etc"
2024-3864,2024-04-29,PHYSICIANS COMMITTEE FOR RESPONSIBLE MEDICINE,"  On April 23, 2023, the Washington Post reported that the ""the agency was testing milk on grocery store shelves for H5N1. On Tuesday, the agency confirmed that viral particles had been found 'in some of the samples,'"" and on ""Wednesday, an FDA official confirmed fragments were found in milk on shelves[.]""  Please provide all records documenting the finding of viral particles in samples of milk from store shelves."
2024-3865,2024-04-29,Globizz Corp.,"510(k) Number: K221683_x000D_
"
2024-3866,2024-04-29,GMP Trends,"Please provide the FDA-483 documents pertaining to Human DRUG Inspection, for the following 4 firms: Madcar A Division of Century Direct Solutions, 130 Hoffman Ln, Islandia, NY 11749-5008, United States, dated 12/15/2023 - 12/20/2023; Phoenix Wipes Inc, 100 Dale St Unit A, West Babylon, NY 11704-1120, United States, dated 12/4/2023 - 12/19/2023; Products By O2, Inc, 3020 High Ridge Rd Ste 300, Boynton Beach, FL 33426-8731, United States, dated 10/17/2023 - 10/23/2023; Seatex LLC, 445 Highway 36 N, Rosenberg, TX 77471-8756, United States, dated 10/16/2023 - 10/20/2023.  "
2024-3868,2024-04-29,"ARTHREX, INC.","We request the following 510(k). K211202 Trade/Device Name: 1688 4K Camera System, L11 LED Light Source with AIM, AIM SafeLight Cable, Precision S 4K Sinuscopes Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope and Accessories Company: Stryker"
2024-3869,2024-04-29,"ARTHREX, INC.",We request the following 510(k).  K210088 Trade/Device Name: AIM (Advanced Imaging Modality) System Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope and Accessories Company: Stryker
2024-3870,2024-04-29,"ARTHREX, INC.",We request the following 510(k). K191102 Trade/Device Name: Precision S 4K Sinuscope Regulation Number: 21 CFR 874.4760 Regulation Name: Nasopharyngoscope (flexible or rigid) and accessories Company: Stryker
2024-3871,2024-04-29,Schnuck Markets Inc," Request for records that have led to Schnuck Markets, Inc to be listed on page 386 of the FDA Importer List on 4 lines between January 1, 2024 - March 31, 2024 as SCHNUCK MARKETS INC MO; SCHNUCK MARKETS, INC. MO; SCHNUCKS MARKETS, INC. MO; SCHNUCKS MARKETS INC-ST LOUIS -NORTH PARK DRY. "
2024-3872,2024-04-29,"Ryan Alexander, Chtd.",FDA complaint number CC#184582 
2024-3873,2024-04-29,Vicente LLP,"complaints, testing results, interview notes, records of product nonconformance, case files, inspection and investigation reports (including summaries and conclusory notes of such reports), and correspondence (email, memo, etc.) both internal to the FDA and external, related to DRINK BREZ LLC, a Florida limited liability company (“Brez”),  etc"
2024-3874,2024-04-29,B. Braun / Aesculap,Requesting a copy of K233445 - Bactiseal Catheters; Bactiseal Barium Striped Catheters; Bactiseal Endoscopic Ventricular Catheter.  Including all correspondence.  
2024-3875,2024-04-30,"C.H. Robinson Worldwide, Inc. DBA Robinson Fresh","C.H. Robinson Worldwide, Inc. DBA Robinson Fresh requests a spreadsheet that includes the 23 publicly available data points for all FSVP importer declarations.  "
2024-3876,2024-04-30,SIDLEY AUSTIN LLP,"All correspondence to FDA by or on behalf of Agena Bioscience, Inc. relating to the subject matter of the Warning Letter issued to that company on March 21, 2024 (CMS # 665159), including the Agena response to the Warning Letter and any communications between FDA and Agena identified in the Warning Letter or agency records that memorialize such communications, to the extent disclosable."
2024-3877,2024-04-30,Redica Systems,"Please provide the following inspection-related documents in electronic PDF format: - The 483 (in electronic format) for the Biologics inspection of Community Fertility Specialty Care, located in Indianapolis, IN, United States, inspection ending 1/11/2024 (FEI 3004417184). - The 483 (in electronic format) for the Biologics inspection of Janssen Pharmaceuticals Inc., located in Raritan, NJ, United States, inspection ending 12/14/2023 (FEI 2211100). - The 483 (in electronic format) for the Biologics inspection of BioTek America LLC, located in Paducah, KY ETC"
2024-3878,2024-04-30,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/media/119312/download, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs. We request a spreadsheet which includes the 23 publicly available data points for all entries that led to 1189405 Tigusta, LLC's inclusion in this list for the last 2 years (March 1, 2022 - March 31, 2024). See attached Waiver. "
2024-3879,2024-04-30,Registrar Corp,"On the publicly available FDA site: https://www.fda.gov/media/119312/download, FDA provides a list of companies participating in the FDA Foreign Supplier Verification Programs. We request a spreadsheet which includes the 23 publicly available data points for all entries that led to Coca Cola Puerto Rico Bottler's inclusion in this list for the last 2 years (March 1, 2022 - March 31, 2024). See attached Waiver. "
2024-3880,2024-04-30,Hunterbrook Media,"I'd like your records about Safety Shot, a drink that claims it can reduce blood alcohol content by 50% in 30 minutes. Specifically any consumer complaints and if it has violated any FDA rules."
2024-3881,2024-04-30,"Figus, Allison ",What is involved in the medical procedure of Euthanasia? What are the chemicals and drugs used for Euthanasia? What is involved throughout the in-patient hospital process of Euthanasia?  How long does Euthanasia take before a person is dead?  Is Euthanasia painful?
2024-3882,2024-04-30,NSF,"We are seeking a copy of the redacted hypochlorous acid FCNs numbers 2316, 2297.  This will be used to file an FCN for a similar use and material and thus there is interest to file data in a similar manner to expedite the FCN review for FDA."
2024-3883,2024-04-30,WSB-TV,WSB-TV is requesting all complaints about all brands of Purina dog and cat food.
2024-3884,2024-04-30,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                              Happy Farm Botanicals Hyattsville, Maryland United States End Dates of inspection: 15 Mar 2024  Project Area:  Drug Quality Assurance FEI: 3011407349 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3885,2024-04-30,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                       Electro Cap International Inc Eaton, Ohio United States End Dates of inspection: 01 Mar 2024  Project Area:  Compliance: Devices FEI: 1000119368 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3886,2024-04-30,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                          Midwest Sperm Bank, LLC Downers Grove, Illinois United States End Dates of inspection: 20 Mar 2024  Project Area: Blood and Blood Products FEI: 3004743932 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3887,2024-04-30,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483:  NanoEnTek America Inc                                                         Waltham, Massachusetts United States End Dates of inspection: 01 Mar 2024  Project Area: Compliance: Devices FEI: 3007113174 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3888,2024-04-30,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483:  Octapharma Plasma, Inc.  Dallas, Texas United States End Dates of inspection: 22 Mar 2024  Project Area: Blood and Blood Products Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3889,2024-04-30,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483:  Ophthalmic Labs, Inc.                                                         Milton, Massachusetts United States End Dates of inspection: 09 Apr 2024  Project Area: Compliance: Devices FEI: 3014655548 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200 "
2024-3890,2024-04-30,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483:  New York Cryo                                                         Great Neck, New York United States End Dates of inspection: 21 Mar 2024  Project Area: Human Cellular, Tissue, and Gene Therapies FEI: 3003422359 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200.  "
2024-3891,2024-05-01,REUTERS,"I would like to request electronic copies over email of the summary narratives for the following 2 adverse event records related to tirzepatide, the earliest of which was initially received by the FDA January 5 2024: (Case ID) 23429767, 23369961 "
2024-3892,2024-05-01,Patrick Curry,"We would like to request detailed FAERS report for the following case IDs: 23055875, 22647784, 22334031, 22839700, 23239141, 23420683, 23409450, 22686691, 23580113, 23580108, 23580139, 23580090, 23550523, 23547621"
2024-3893,2024-05-01,"Leading Pharma, LLC","In view of distribution of the approved drug product, please provide us the ANDA Approval Letter for the following generic drug product-  Active Ingredient: OXCARBAZEPINE Proprietary Name: OXCARBAZEPINE Dosage Form; Route of Administration: SUSPENSION; ORAL Strength: 300MG/5ML Reference Listed Drug: No Reference Standard: No TE Code: AB Application Number: A217782 Product Number: 001 Approval Date: Feb 14, 2024 Applicant Holder Full Name: MEDLEY PHARMACEUTICALS LTD Marketing Status:  Prescription Patent and Exclusivity Information"
2024-3894,2024-05-01,"Leading Pharma, LLC","In view of distribution of the approved drug product, please provide us the ANDA Approval Letter for the following generic drug product-  Active Ingredient: LACOSAMIDE Proprietary Name: LACOSAMIDE Dosage Form; Route of Administration: TABLET; ORAL Strength: 50MG Reference Listed Drug: No Reference Standard: No TE Code: AB Application Number: A218014 Product Number: 001 Approval Date: Apr 2, 2024 Applicant Holder Full Name: MEDLEY PHARMACEUTICALS LTD Marketing Status:  Prescription Patent and Exclusivity Information"
2024-3895,2024-05-01,Hach Rose Schirripa & Cheverie LLP,"This request under the Freedom of Information Act seeks certified copies of the Office of Generic Drugs Approval Routing Summary—for both tentative and/or final approval—for any Abbreviated New Drug Application referencing Celgene’s Pomalyst (pomalidomide) New Drug Application (NDA 204026) held by or associated with Mylan Pharmaceuticals or its affiliates, including ANDA 210275. "
2024-3896,2024-05-01,Meitheal Pharmaceuticals,"We request the most recent labels (package insert, container, and carton labels) for NDA 020449 Taxotere, Docetaxel Injection. Due to the product being the RLD, we would like to confirm our labels are up to date."
2024-3897,2024-05-01,Pharmalex,CASE ID's 22928472 22899118 22984339 22313001 22934536 22852019 
2024-3898,2024-05-01,Atrogi AB,"Dear Sir/Madam,   I hope this request finds you well.   We would like to file a request for study documentation related to the FDA report on Levalbuterol HCI (NDA number 020837). "
2024-3899,2024-05-01,QYOBO GmbH,"Please provide the following 2 form 483s in electronic PDF format: FEI: 3004540906; Inspection date: October 9 to 18, 2023; Firm Name: Natco Pharma Limited FEI: 3013712903; Inspection date: April 15 to April 23, 2024; Firm Name: ZYDUS LIFESCIENCES LIMITED"
2024-3900,2024-05-01,Patrick Curry,We would like to FOIA  case numbers 23058256 and 23055875
2024-3901,2024-05-01,ALK Abello INC,Individual Case Safety Report Request  Primary Suspect Drug: HYDROCORTISONE BUTYRATE /ODACTRA / CERTOLIZUMAB PEGOL Secondary Suspect Drug: MITICURE/ None/ Histamine Source: FAERS Q4 2023 Quarterly Data File Case Number: 21979955/ 23166926/ 21166268
2024-3902,2024-05-01,The Epoch Times,"Hello,  Please provide all FDA attendees of the CEPI-WHO meeting that took place on Aug. 17, 2023.  Thank you"
2024-3903,2024-05-01,The Epoch Times,"Hello,  Please provide all FDA attendees of the EMA-FDA-Health Canada meeting that took place on August 24, 2023.  Thank you"
2024-3904,2024-05-01,Erin Maxwell,Requesting a copy of the FDA multidiscipline review and/or integrated review documents for Voydeya (danicopan). Voydeya was approved on 03/29/2024. 
2024-3905,2024-05-01,PHARMALEX US CORP,"I would like to request the following 4 Illucix cases: 23322776, 23422924, 23435520, 23438392 "
2024-3906,2024-05-01,Athyna Pharma LLC,"All available Drug approval package sections for Zyloprim tablets, 100, 200 & 300 mg including chemistry, quality, clinical pharmacology and biopharmaceutical sections. "
2024-3907,2024-05-01,COGENCY GLOBAL INC.,"Under the Freedom of Information Act, as amended, 5 U.S.C. §§ 552, et seq., COGENCY GLOBAL INC. hereby requests the documents associated with each event reported in the FAERs database listed below by manufacturing control number. We can also provide an Excel spreadsheet of the case list if required.   Case ID	Suspect Product Names	Manufacturer Control Number 13519474 13766927 13810460 13817102 ETC"
2024-3908,2024-05-01,"Winthrop & Weinstine, P.A.","New Drug Application for Rezdiffra (Resmetirom), submitted by Madrigal Pharmaceuticals and/or its affiliates. In particular, the Human Pharmacokinetics & Bioavailability section and the Clinical and Statistical section. "
2024-3909,2024-05-01,Samantha French,"I'd like any records pertaining to the evaluation of Apomorphine hydrochloride for treatment of patients in a persistent vegetative state (NOT as indicated for effects of Parkinson's).  Designated orphan status on 5/23/2006 for the treatment of PVS, but it was not approved for orphan indication._x000D_
Thank you."
2024-3910,2024-05-01,"Genentech, Inc.",FDA Case ID: 21886726
2024-3911,2024-05-01,Eximis Surgical, K221365 510K Submission for Lapbox
2024-3912,2024-05-01,Redica Systems,"Please provide the following inspection-related documents in electronic PDF format: - The 483 (in electronic format) for the Medical Devices & Rad Health inspection of Macromedics BV, located in Oostbaan 670, Moordrecht, Netherlands, inspection ending 1/18/2024 (FEI 3010701021)."
2024-3913,2024-05-01,Redica Systems,"Please provide the following inspection-related documents in electronic PDF format: - The 483 (in electronic format) for the Medical Devices & Rad Health inspection of Medtronic Navigation, Inc., located in Medtronic Drive, CO, 80026, United States, inspection ending 2/9/2024 (FEI 1000517638). - The 483 (in electronic format) for the Medical Devices & Rad Health inspection of Premier Radiology Greenfield, located in Greenfield, WI, ETC"
2024-3914,2024-05-01,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Mounjaro (branded name / marketed by Lilly) or tirzepatide (generic name) between April 24, 2024 and April 30, 2024.  Please provide the documents electronically if possible."
2024-3915,2024-05-01,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Zepbound (branded name / marketed by Lilly) or tirzepatide (generic name) between April 24, 2024 and April 30, 2024.  Please provide the documents electronically if possible."
2024-3916,2024-05-01,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Ozempic  (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between April 24, 2024 and April 30, 2024.  Please provide the documents electronically if possible."
2024-3917,2024-05-01,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Wegovy (branded name / marketed by Novo Nordisk Inc.) or semaglutide (generic name) between April 24, 2024 and April 30, 2024.  Please provide the documents electronically if possible. "
2024-3918,2024-05-01,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for ELEVIDYS (branded name / marketed by Sarepta Therapeutics, Inc.) or delandistrogene moxeparvovec-rokl (generic name) between April 24, 2024 and April 30, 2024.   Please provide the documents electronically if possible."
2024-3919,2024-05-01,FOIA Professional Services,"I would like to request full reports of any and all adverse events reported to the FAERS database for Syfovre (branded name / marketed by Apellis Pharmaceutical) or pegcetacoplan (generic name) between April 24, 2024 and April 30, 2024.  Please provide the documents electronically if possible."
2024-3920,2024-05-01,Patrick Curry,"We would like to request case information for Case ID: _x000D_
23058256_x000D_
23055875"
2024-3921,2024-05-01,"West Pharmaceutical Services, Inc.",1.  Coherus BioSciences' combination product filing for UDENYCA ONBODY™ for UDENYCA® (pegfilgrastim-cbqv) 2. Amgen's combination product filing for Neulasta® Onpro® for Neulasta® (pegfilgrastim) 
2024-3922,2024-05-01,Sovish,2023-10889
2024-3923,2024-05-01,Ben-Zvi & Associates,"	All documents constituting, concerning, or relating to the FDA’s determination to place Compania Nacional de Chocolates on Import Alert 99/42.  	All documents that constitute, concern, or relate to any determination of what concentration of cadmium in food products containing cocoa as an ingredient render such products adulterated and/or injurious to health."
2024-3924,2024-05-01,Evan Alexander,"Dear FDA, _x000D_
I would like to receive copies of FDA correspondence with Eli Lilly regarding changes to Prozac labeling involving persistent sexual dysfunction."
2024-3925,2024-05-01,Ben-Zvi & Associates,"	With respect to the Notice of FDA Action concerning Entry Number TXC-6503607-0 dated March 4, 2024, all documents constituting, concerning, or relating to the FDA’s determination that the products that were detained without examination “appear to be adulterated, misbranded or otherwise in violation.”  	 "
2024-3926,2024-05-01,Ben-Zvi & Associates,"	With respect to the Notice of FDA Action concerning Entry Number M92-3183891-0 dated January 19, 2024 and the FDA’s email dated March 12, 2024 concerning such Entry Number, all documents constituting, concerning, or relating to the FDA’s determination that the products that were detained “appear[] to bear a poisonous or deleterious substance which may render the article injurious to health.”  	With respect to the Notice of FDA Action concerning Entry Number M92-3183891-0 dated January 19, 2024 and the FDA’s email dated March 12, 2024 concerning such Entry Number, all documents constituting, concerning, or relating to the FDA’s assessment of such product.  	 "
2024-3927,2024-05-01,English Capital,"We are requesting the database of FAERS adverse events reports relating to the drug Daybue (trofinetide) from Jan 1, 2024 to the latest date available at the time of request. Please provide all reports mating the keywords ""Daybue"" and ""trofinetide"" .  "
2024-3928,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	  Zizion Group, LLC Boca Raton, Florida United States End Dates of inspection: 12 Mar 2024  Project Area: Compliance: Devices FEI: 3009435759 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3929,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	  Washington University School of Medicine Saint Louis, Missouri United States End Dates of inspection: 21 Mar 2024  Project Area: Drug Quality Assurance FEI: 3009930596 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3930,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	  Unified Spine, Llc Westerville, Ohio United States End Dates of inspection: 01 Mar 2024  Project Area: Compliance: Devices FEI: 3006215390 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3931,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	  Texas Injection Molding, LLC Houston, Texas United States End Dates of inspection: 21 Mar 2024  Project Area: Compliance: Devices FEI: 3021887565 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3932,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	  Taiji Medical Supplies Inc. Lincolnton, North Carolina United States End Dates of inspection: 15 Mar 2024  Project Area: Compliance: Devices FEI: 3017168761 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3933,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	  Sacks Holdings, Inc. San Diego, California United States End Dates of inspection: 29 Mar 2024  Project Area: Compliance: Devices FEI: 3010119775 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3934,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	       RNA Coporation Blue Island, Illinois United States End Dates of inspection: 08 Mar 2024  Project Area: Drug Quality Assurance FEI: 3017156960 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200.  "
2024-3935,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                                Radialogica LLC Saint Louis, Missouri United States End Dates of inspection: 06 Mar 2024  Project Area: Compliance: Devices FEI: 3009140718 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3936,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                                Purisys LLC Athens, Georgia United States End Dates of inspection: 13 Mar 2024  Project Area: Drug Quality Assurance FEI: 3012286613 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3937,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                          Precision Diabetes Inc. Raleigh, North Carolina United States End Dates of inspection: 08 Mar 2024  Project Area: Compliance: Devices FEI: 3016698405 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3938,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern:  As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document:  Form FDA 483: 	                                                       MSN Laboratories Private Limited, Unit-II Isnapur India End Dates of inspection: 22 Mar 2024  Project Area:  Drug Quality Assurance FEI: 3008656542 Classification: VAI  I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200. "
2024-3939,2024-05-01,Clarivate Analytics (France) SAS,"To Whom it May Concern: As permitted by the Freedom of Information Act (FOIA), I am hereby requesting the following document: Form FDA 483: Kekule Pharma Limited Jinnaram India End Dates of inspection: 15 Mar 2024 Project Area: Drug Quality Assurance FEI: 3009261338 Classification: VAI I confirm that Clarivate Analytics will be charged accordingly by FOI for this request, however please contact me if the charges exceed $ 200."
2024-3940,2024-05-01,"Kahn, Ryan ","This request is for any letters sent by the FDA to doctors involved in the clinical trials for pelabresib, regarding imbalances in severe cancer progressions.  I am requesting to view any such letters.  Thank you"
2024-3941,2024-05-01,"OneBlood, Inc.",Requesting EIRs from several OneBlood locations 1044671 OneBlood Brandon - 6-27-2023 3009572488 OneBlood Crestview - 5-29-2023 1000132464 OneBlood Ft. Walton Beach - 6-7-2023 3005150725 OneBlood Lantana - 4-27-2023 1000143757 OneBlood Melbourne - 2-15-2024 3002866388 OneBlood Pensacola 9th Ave - 3-20-2023 1000307568 OneBlood Pompano Beach - 7-15-2021 1070202 OneBlood Pensacola 9 Mile - 3-22-2023 3003452356 OneBlood Royal Palm Beach - 9-28-2021 3007786894 OneBlood Tallahassee Memorial Hospital - 4-25-2023
2024-3942,2024-05-01,"Mazie Slater Katz & Freeman, LLC",RECS RE NOVO NORDISK RYBELSUS
2024-3943,2024-05-01,"Mazie Slater Katz & Freeman, LLC",RECS RE NOVO NORDISK AND WEGOVY
2024-3944,2024-05-01,"MAZIE, SLATER, KATZ & FREEMAN, LLC",RECS RE NOVO NORDISK AND OZEMPIC
2024-3945,2024-05-01,BLOOMBERG NEWS,I am requesting the letter the FDA sent to doctors involved in a late-stage trial of the drug pelabresib from MorphoSys on patients progressing from myelofibrosis to acute myeloid leukemia. Thank you 
2024-3946,2024-05-01,bofa securities,"Form 483 for Zydus Lifesciences plant inspection at the Injectable Manufacturing site situated at Jarod, near Vadodara"
2024-3947,2024-05-01,"Fahmi, Saiyara ","  I am requesting FAERS data for Syfovre (pegcetacoplan) from January 1 2023 to present. Please provide both detailed and summary format, and if possible share in electronic format CSV/excel."
2024-3948,2024-05-01,FOIA Professional Services,"I am requesting to receive copies of any minutes of, memoranda and reports generated by, each of the “subsequent meetings … held between DAAP, the OSE team, and experts from the Division of Dermatology and Dental Products (DDD) referenced in the first paragraph of the “Executive Summary” of the Postmarketing Safety Review, SS-10019999 (Reference ID: 4917842), performed by Mark A Liberatore, PharmD, RAC Deputy Director for Safety, DAAP.  Please provide the documents electronically if possible."
2024-3949,2024-05-01,FOIA Professional Services,"I am requesting to receive copies of any minutes of, memoranda and reports generated by, the September 14, 2018 meeting between OSE/DPV II, the Division of Dermatology and Dental Products (DDD), and the Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP), referenced in the second paragraph of the “Background” section of the Postmarketing Safety Review, SS-10019999 (Reference ID: 4917842), performed by Mark A Liberatore, PharmD, RAC Deputy Director for Safety, DAAP.  Please provide the documents electronically if possible."
2024-3950,2024-05-01,FOIA Professional Services,"I am requesting to receive copies of the following two “data sources” referenced in the Postmarketing Safety Review, SS-10019999 (Reference ID: 4917842), performed by Mark A Liberatore, PharmD, RAC Deputy Director for Safety, DAAP.  Office of Surveillance and Epidemiology (OSE) Pharmacovigilance and Drug Utilization Review:   o   Joint review performed by Dr. Samantha Cotter (Division of Pharmacovigilance II) and LCDR Jennie Wong (Division of Epidemiology II). Signed final: March 3, 2020   Office of Immunology and Inflammation: Memorandum of Consultation:   o   Response to Inter-Division Consult Request From DAAP to the Division of Dermatology and Dentistry (DDD). Performed by Drs. Natalia Chalmers and David Kettl. Signed Final: August 3, 2021.   Please provide the documents electronically if possible."
2024-3951,2024-05-01,FOIA Professional Services,"Please provide electronic copies of the following:  1) all correspondence – including reports, emails or memo – between FDA agency staff and Eisai/Biogen/Eli Lilly regarding the drug Lecanemab and Donanemab that contain any of the following keywords: “brain atrophy”, brain shrinkage”, “brain volume” and “demand generation”  Please provide the documents electronically if possible."
2024-3952,2024-05-01,Kelley Drye and Warren,May I please request the FDA FAERS Individual Case reports for Case IDs: 23291067; 23103910; 22525551; 22691801; 23162398; 23256261; 23105144; 23457074; 19754806; 23506037; 22861132; 23271566; 23148221; 23153509; 23509561; 23456754; and 23269940
2024-3953,2024-05-01,Kathleen Pimental,"I would like to get the data on how many people have died by fentanyl overdose in the United States and by each individual state for the years of 2020, 2021, 2022, 2023, and 2024"
2024-3954,2024-05-01,Nomura,"Form 483 issued by USFDA following the inspection of Jarod facility of Zydus Healthcare. The USFDA had conducted the inspection of the facility from April 15 to April 23, 2024 and concluded it with 10 observations. "
2024-3955,2024-05-01,Vena Medical," Device Classification Name	angioscope 510(k) Number	K923996 Device Name	DISPOSABLE VASCULAR ANGIOSCOPE Applicant	 ENDOVASCULAR, INC.  Could we please get either the 510k summary or if available, the redacted 510k?  Thank you for your time,  - Michael"
2024-3956,2024-05-01,University of California College of the Law at San Francisco,"I would like any and all records on the the criteria for determining marketing exclusivity use-codes for the FDA's ""Approved Drug Products with Therapeutic Equivalence Evaluations"" (Orange Book). Specifically, I would like records that outline which use-codes indicate a New Clinical Investigation (NCI) Exclusivity. "
2024-3957,2024-05-01,Pharmalex,CASE ID'S  23011475 22689953 22809619 22691751 22969302 17938520 
2024-3958,2024-05-01,PROPHARMA GROUP,Human Adverse Drug MedWatch Reports for the following case IDs:  23430062 23469382 23479111 23507094 23548399 23613209 23613500 23650797 23685202 
2024-3959,2024-05-01,RBC CAPITAL MARKETS,"Hi FDA FOIA Team,  Can we please have the detailed case information packets for the following FAERS case IDs? These events occurred with Skyclarys (Omaveloxolone).  23650450 23656134 23646624 23450154 23608335 23472137 23439804 23422732 23250045 "
2024-3960,2024-05-01,Regunalys LLC,PREVIOUSLY RELEASED INSPECTION RECS
2024-3961,2024-05-01,POINT72,"Hello,   I am an investment professional and this is a request under the Freedom of Information Act.   I request copies of any agency documentation or communication regarding the Form 483 (FEI 3001451441) issued to Lonza Biologics, Inc. at 101 International Drive, Portsmouth, NH 03801-2846 from February 1st - Present.   "
